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Summary
In chapter one the aim was to establish and extend the characterization of murine models 
o f thyroiditis and Graves' ophthalmopathy (GO), induced by transfer of TSH receptor 
(TSHR) primed T cells. In the first experiment, genetic immunization or TSHR fusion 
protein induced TSHR antibodies in all nine mice. Some of the antibodies functioned as 
thyroid-stimulating antibodies and/or TSH binding inhibiting Igs with 2/7 mice having 
elevated T4. Splenocyte transfer induced no immune response in naive BALB/cbyJico 
recipients. Subsequently genetic immunization or fusion protein-treated mice were 
maintained in either local or Brussels conditions (water, chow, and bedding). TSHR 
antibodies were induced in 9/9 Brussels (with decreased T4 in 1/9) but 5/9 local mice. No 
thyroiditis or orbital changes were induced, but misleading fixation artefacts in extraocular 
muscles were noted. Thyroids from many TSHR-treated and control mice contained 
ectopic thymus. Ectopic thymus can masquerade as thyroiditis, and care is required to 
avoid muscle artefacts.
In chapter 2 the biological effects of TSHR activation in vitro, in adipose tissue - the site of 
orbital TSHR expression was examined. Activating mutant TSHR (TSHR*) or wild type 
(WT), were introduced into human orbital preadipocytes using retroviral vectors. Their 
proliferation, basal cAMP accumulation, spontaneous and PPARy induced adipogenesis 
were assessed and compared with non-modified cells. Expression of TSHR* significantly 
inhibited the proliferation o f preadipocytes and produced an increase in unstimulated 
cAMP. PPARy induced adipogenesis in non-modified cells produced morphological 
changes, but not in TSHR* expressing cells. TSHR activation renders preadipocytes 
refractory to PPARy induced adipogenesis. The failure to develop lipid-containing 
vacuoles suggested the terminal stages of differentiation have been inhibited.
In chapter 3 tears from patients with Graves' disease (GD), GO and smokers were 
examined for TSHR activation and protein changes. Reflex tears were collected from 37 
normal non-smokers (NNS), 33 normal smokers (NS), 51 GD and 85 GO patients. Specific 
thyrotropin receptor stimulating activity (TSHRSA) was measured and also serum thyroid 
stimulating antibodies (TSAB). Pooled NNS, NS and GO tears were separated by SDS- 
PAGE and silver stained. Proteins expressed in the NS and GO pools but not NNS, were 
excised and analysed by MALDI-TOF mass spectrometry. Specific TSHRA was detected 
in 25% NS, 32% GD and 41% GO. A thyroid blocking antibody did not inhibit TSHRA. 
Clinical activity score correlated with serum TSAB but not tear TSHRSA. SDS-PAGE 
analysis revealed a higher vol/vol protein concentration in GO tears and additional proteins 
of 30 to 41 kD, in GO and NS compared with NNS. These were identified as zinc-alpha-2- 
glycoprotein (ZAG) and lactoferrin (LF). ZAG (also known as lipid mobilising factor) and 
LF do not have TSHRSA. Therefore, similar changes in tear composition are present in 
GO and NS compared with NNS. We postulate that TSHRSA is a protease enzyme. ZAG 
and LF expression is increased and their molecular weights are modified, suggesting 
degradation and/or changes in glycosy.lation, which may affect their bioactivities.
In chapter 4, transgenic adiponectin elevation in FVB mice produced profound changes in 
interscapular and orbital fat depots. No previous models have demonstrated orbital fat 
proliferation and these changes could be followed by orbital MRI. TSHR expression 
increases with adipogenesis but does not in this case lead to autoimmunity directed 
towards the TSHR. A wide range of circulating adiponectin levels are present GO patients 
and no clinical correlations were evident.
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1 Introduction 
1.1 Graves’ ophthalmopathy
1.1.1 Introduction to Graves’ ophthalmopathy
Graves’ disease is a common autoimmune condition in which thyroid stimulating 
antibodies (TSAB) mimic the action of thyrotropin (T SH )1. Since both the growth and 
function of the thyroid are controlled by TSH, TSAB lead to hyperthyroidism and diffuse 
goitre 2. The target of the autoimmune response in Graves’ disease is the thyrotropin 
receptor (TSHR)3. The majority of patients with Graves’ disease have some degree of 
ocular involvment that is self limiting, but 3 to 5% of patients develop Graves’ 
ophthalmopathy, an autoimmune condition that requires intervention 4. Graves’ 
ophthalmopathy is also known as thyroid eye disease and thyroid associated 
ophthalmopathy, but as they share a common clinical and histological spectrum the use of 
the term Graves’ ophthalmopathy is used throughout this work.
The main clinical features of Graves’ ophthalmopathy present with varying degrees of 
severity are; proptosis, conjunctival injection, chemosis, diplopia and, in extreme cases, 
loss of sight due to compression of the optic nerve or in years gone by, corneal ulceration 
and globe perforation. These signs and symptoms can be explained by the increase in 
volume of the orbital contents by three mechanisms; oedema, production of hydrophilic 
glycosaminoglycans (GAG) and hypertrophy of the adipose tissue by adipogenesis 5. The 
mechanism by which orbital fat proliferates in Graves’ ophthalmopathy is not well 
characterised. Performing biopsies on actively inflamed tissue can exacerbate the situation 
and is therefore unethical. Models offer surrogate opportunities to investigate such a 
condition. There are four experimental chapters in this thesis; each comprises an 
introduction, methods, results and discussion section. As a background to this some 
general introductions are given on Graves’ ophthalmopathy, thyroid biology, thyroid 
autoimmunity and lipid metabolism. We have used in vivo and in vitro models to examine:
1. TSHR induced thyroiditis and ophthalmopathy.
2. Effects of TSHR activation during adipogenesis.
3. TSHR stimulation by tears and protein changes therein.
4. Orbital adipogenesis induced by transgenic adiponectin expression and its
possible relationship to Graves’ ophthalmopathy.
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1.1.2 Historical aspects of Graves’ ophthalmopathy
This thesis has at its core a clinical spectrum of thyroid and eye disease reported by a 
respected physician in Bath, Caleb Parry in a posthumous publication6. The first patient in 
his series o f 8 with thyrotoxicosis also had proptosis and was seen in 1786. Graves went 
on to describe patients more in terms of their thyrotoxicosis while Basedow focussed on 
the ophthalmopathy 7’8. For many years the presence of a diffuse toxic goitre and raised 
basal metabolic rate, had proptosis as an accepted feature but anomalies in this contented 
description soon emerged. Duke-Elder’s 1952 ‘Text-book of Ophthalmology’ gives a 
historical perspective to the considered wisdom half a century ago 9. The anomalies 
included; persistence of proptosis after normalising metabolic rate and goitre, worsening 
proptosis after apparent spontaneous remission or thyroidectomy, proptosis that developed 
when basal metabolic rate was low and in the presence of myxoedema and most 
confounding, proptosis that developed preceding hyperthyroidism. The main cause of 
proptosis, that of Graves’ disease, was soon labelled as “thyrotoxic exophthalmos” and the 
hypothyroid causes called “thyrotropic” or “exophthalmic ophthalmoplegia”. Some 
authors thought that the manifestations o f eye disease were completely removed from the 
thyroid and were dependent on pituitary activity. So as to not lose track of those who 
originally described various features of the ophthalmopathy Table 1-1 records some rarely 
used medical eponyms.
Table 1-1 Historical medical eponyms relating to Graves’ ophthalmopathy
Sign Description
Enroth’s Puffy, oedematous, upper and lower lid swelling
Jellinek’s Abnormal upper lid pigmentation
Dalrymple’s The frightened appearance of upper lid retraction
Kocher’s Increased upper lid retraction on holding fixation
Von Graefe’s Lid lag on downgaze
Boston’s Jerky irregular upper lid descent in down gaze
Joffroy’s Absence of forehead creases on upgaze
Rosenbach’s Trembling eyelids on gentle closure
Stellwag’s Infrequent and incomplete blinking reflex
Gifford’s Difficulty inverting the upper lids
Moebius’ Convergence weakness
Suker’s Inability to maintain extreme lateral gaze
Ballet’s Partial or complete immobility of one or all the ocular muscles
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Early observations were that thyrotoxic exophthalmos occurred in early adult life and had 
a male to female ratio of 1:9 and most cases had a relatively benign course resolving 
without much disfigurement9. In contrast cases of exophthalmic ophthalmoplegia were a 
disorder of middle age and roughly equal sex incidence. The severity of exophthalmic 
ophthalmoplegia was such that it was not uncommon to exenterate an eye on the suspicion 
of tumour only to find nothing and then have the condition develop in the remaining eye. 
An ocular muscle traction test was advocated to assist in such diagnostic dilemmas; 
ophthalmoplegia due to neurological causes would still allow free movement of the 
anaesthetised globe when pulled on with forceps, in exophthalmic ophthalmoplegia no 
such movement would be possible due to fibrosis. The number of patients dying with 
complications of the disease was greater and there was ready access to whole orbit 
pathological specimens. Histological descriptions of thyrotoxic exophthalmos commented 
on the near normal appearance of most cases apart from fat proliferation within the orbit, 
ocular muscles and other skeletal muscles. More severe cases had lymphocytic infiltrates 
in connective tissue, fat and muscle, oedema and nerve fibre degeneration. In 
exophthalmic ophthalmoplegia all the orbital tissues were involved with oedema, patchy 
lymphocytic infiltrates and fibrosis of muscles and lacrimal gland. Severely affected 
muscles would take on a cartilaginous appearance. The changes were largely due to 
degeneration rather than inflammation, the oedema accentuated by strangulation of the
Q 0circulation in the closed orbital space . The changes seen are not dissimilar to those
described in an unrelated set of experiments examining Volkman’s ischaemic paralysis,
whereby venous return from the forearm is impeded and arterial supply initially continues.
Lymphocytic infiltration, oedema and progressive fibrosis develop followed by contracture 
10
Attempts to explain the proptosis revolved around four main theories. The first, “muscular 
activity”, specifically the contraction of smooth muscle within the orbit was severely 
hamstrung by the minimal presence of such a tissue within the orbit, the only real 
candidate for this would be Muller’s muscle beneath the levator which could account for 
lid retraction but none of the other signs. The second, “vascular congestion”, smooth 
muscle fibres crossing the inferior orbital fissure obstruct orbital venous drainage when 
stimulated sypmpathetically, but again no such structure exists. The third, “muscular 
weakness”, proposed that weakness and elongation of the recti had a permissive effect on 
proptosis. Lastly, “increased orbital tissue bulk”, clear histological demonstration of fat, 
oedema and hydrophillic hyaluronic acid was thought by most to be the cause of proptosis.
Therefore, explaining the cause of proptosis in mechanical terms had some consensus 50 
years ago but how this accumulated or was related to thyroid or pituitary function was 
unclear and without adequate explanation. In terms of treatment, iodine or thyroidectomy 
for thyrotoxicosis, crude thyroid extract for hypothyroidism, relying on basal metabolic 
rate to titrate dosage, tarsorrhaphy for corneal exposure, orbital decompressions were 
crude and used as a last resort and once burnt out the proptosis could be reduced by 
shortening the recti.
Before continuing on with more current work one individual case report by Stallard is 
noteworthy 11. He reports a hypothesis of Russell Brain who suggested that exophthalmic 
ophthalmoplegia with thyrotoxicosis is due to an excessive production of an X-factor, 
believed to by thyrotropic hormone of the pituitary and hyperthyroidism was a subordinate 
part o f the process. A 31 year old man with mild signs of thyrotoxicosis, bilateral proptosis 
worse on the left, had a slightly reduced basal metabolic rate and was treated with 
thyrotropic hormone injection on three consecutive days. Over the next month his left 
sided proptosis dramatically worsened to the point where corneal exposure and ulceration 
ultimately lead to perforation and enucleation. While the TSH preparation may be crude 
and the worsening of the ophthalmopathy put down as coincidence it is suggestive that a 
TSH like factor is involved in the mechanism of proptosis. Early evidence of the role of 
TSH in animal models is reviewed in chapter 2.
1.1.3 Autoantigens in Graves’ ophthalmopathy
Oedema and glycosaminoglycans induce expansion of the extra-ocular muscles (EOM) 
which are greatly enlarged and have been the focus of investigations to identify the 
autoantigen in Graves’ ophthalmopathy and the link with the thyroid gland. A variety of 
methods, including screening EOM expression libraries 12 and western blotting 13, have 
identified a number of potential antigens e.g. flavoprotein subunit of mitochondrial 
succinate dehydrogenase 14 and extracellular matrix proteins l5. A 64kD protein ‘D l’ or 
tropomodulin, which is expressed in thyroid and EOM but not skeletal muscle, was 
isolated from a thyroid expression library 16. Other investigators have studied the orbital 
connective tissue and adipose compartments and identified a 23 kD protein present in 
orbital fibroblasts as a potential Graves’ ophthalmopathy autoantigen 17. Ocular muscle 
biopsies from normal and Graves’ ophthalmopathy patients show fibroblasts expressing
12
HLA class II antigens, no expression was present on muscle cells which all had a normal 
morphology, this lead the authors to question the likelihood of clinically significant 
reaction to muscle antigen l8. In fact fibroblasts are a prime suspect for the target of the 
autoimmune response, not only in Graves’ ophthalmopathy but also in another extra- 
thyroidal manifestation, pretibial myxoedema (PM). In this context, it has been reported 
that immunoglobulins from Graves’ disease patients stimulate the production of ICAM-1 
from Graves’ disease fibroblasts but not normal fibroblasts 19. This highlights the presence 
of fibroblast antibodies in the circulation of patients and also a difference in the response 
to these antibodies between normal and Graves’ disease fibroblasts. Finally the similarity 
between thyroglobulin (TG), an autoantigen in Hashimoto’s thyroiditis, and 
acetylcholinesterase (ACHE) led to the proposal that a TG/ACHE shared epitope could 
provide the link between the thyroid and the orbit . Graves’ ophthalmopathy sera were
91shown to bind to the neuromuscular junction in vitro but, as in all of the preceding
examples, even though a proportion of Graves’ ophthalmopathy patients’ sera were found 
to contain antibodies, their presence did not correlate with disease activity. In contrast, 
disease severity, as measured by the clinical activity score (CAS)22, correlates with TSAB 
23. The role of the target antigen, TSHR is introduced in chapter 3
1.1.4 Graves’ ophthalmopathy; a TH2 disorder?
Graves’ disease and ophthalmopathy have an underlying autoimmune pathogenesis 24. 
Adequate immunoregulation depends on a range of mechanisms that maintain 
discrimination between self and non self. These include elimination of auto reactive T cells 
in the thymus, peripheral tolerance and anergy (the requirement of a second signal in the 
immune synapse). The T cell has a central control role in these processes, with CD4+ cells 
having “helper” and CD8 + “cytotoxic” phenotypes. CD4+ (and CD8+) cells are further 
classified into TH1 (TCI) or TH2 (TC2) on the basis of the cytokines they secrete; IL-2 
and IFN-y from TH1 and IL-4,5,6,9,10,13 from TH2. TH1 are associated with cell 
mediated responses and TH2 with humoral immunity. Organ specific autoimmune diseases 
are considered to result from an imbalance between TH1 and TH2. This is elegantly 
demonstrated in a human model of Graves’ disease and ophthalmopathy happened on by 
chance. In patients with multiple sclerosis (MS) treated in vivo with a monoclonal 
antibody to CD52, greater than 95% of their circulating T lymphocytes were eliminated 
and there was considerable amelioration of their disease. Five to twenty-one months after
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this treatment, T cell numbers had returned to 35% and B cells to 180% of pre-treatment 
values but 14/47 patients had developed Graves’ disease with TSAB, with 5 also having 
Graves’ ophthalmopathy symptoms 25 (and personal communication). The deviation from 
TH1 to TH2, although beneficial for MS, was permissive for Graves’ disease and stresses 
the importance of balance in maintaining appropriate immune responsiveness.
Additional support for the Th2 skew of Graves’ ophthalmopathy comes from the positive 
correlation of levels o f soluble CD30 with TBII activity and it is suggested that it could be 
used as a marker as to when to complete anti-thyroid drug therapy 26. Part of the 
TNF/nerve growth factor superfamily, sCD30 is preferentially expressed and secreted 
from TH2 cells. Cross-linking has expansion and effector functions particularly on B cells
97while blocking promotes TH1 phenotype cells developing . In contrast, studies of T cell 
clones derived from Graves’ ophthalmopathy patients indicate a predominance of TH1
9 8 ' 90type autoreactivity in early stages of the disease and TH2 as the condition develops 
The culture conditions could influence the clonal phenotype and ex vivo analysis of
i r v
cytokines in orbital tissues by RT-PCR has found a TH2 spectrum .
One feature of TH2 reactivity, the participation of mast cells, has been shown to induce 
prostaglandin synthesis and GAG production in human orbital fibroblasts, at least in vitro 
31. Mast cells have been reported in Graves’ ophthalmopathy biopsies 30 but their precise 
role warrants further investigation. Furthermore increases in circulating IgE, which could
79  77activate mast cells and stem cell factor, a mast cell growth factor , have been reported 
in Graves’ disease. It has been demonstrated by flow cytometry that IgE antibodies bind 
directly to the TSHR in a small number of patients with Graves’ ophthalmopathy34. 
Interestingly IgE production by B cells requires T-cells, however mast cells are capable of 
this via their expression of CD 154 (CD40 ligand) that activates CD40 on B cells and is 
dependent on 11-4 35. 11-4 production by mast cells has also been demonstrated to augment 
fibroblast proliferation via cell-cell adhesion .
As will be discussed further in chapter 4, smoking is a major risk factor for Graves’ 
ophthalmopathy and when cells from the mast cell lineage were exposed to cigarette 
smoke in vitro, the release of several cytokines including IL-4, 5, 10 and 13 and TNFa 
was induced. IL-4 and 13 induce class switching to IgE whilst TNFa is a major Graves’ 
ophthalmopathy cytokine implicated in several aspects of pathogenesis . Smoking and 
other possible environmental factors appear to have a greater contribution to Graves’
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ophthalmopathy than genetic susceptibility and would seem unrelated to TSHR, CTLA-4, 
HLA and TNF-P genes38.
1.1.5 Cellular mechanisms producing Graves’ ophthalmopathy
The activity o f cytokines marshals the recruitment of inflammatory cells to the orbit and 
their subsequent responses. A wide range of techniques has been used in the examination 
of the limited number of surgical specimens that are available for research investigation. 
The cellular protagonists are lymphocytes, macrophages, mast cells and 
fibroblasts/preadipocytes. From an initial standpoint that IFNy, TNFa and IL-1 are the 
primary effectors , have evolved the following mechanisms.
Facilitating entry to the orbit of lymphocytes and monocytes requires activation of 
adhesion molecules. In situ demonstration of ICAM-1, ELAM-1, VCAM-1 and LFA-3 on 
blood vessels and vascular endothelium from TED orbits has been linked with in vitro 
fibroblast production of ICAM-1 and LFA-1 stimulated by IFNy, TNFa and IL-1 39. The 
expression of ICAM-1, ELAM-1, VCAM-1 and leucocyte integrins CD1 la-c is greater in 
early disease in perimysial connective tissue and vascular endothelium in Graves’ 
ophthalmopathy 40.
Chemoattractants implicated include IL-6 , 8 and 16, RANTES and monocyte chemotactic 
protein (MCP)-l. IL-16 is important in T-cell trafficking as a ligand for CD4+ cells that is 
believed to follow RANTES production in orbital and thyroid fibroblasts 41. This activity 
is induced by IL-1 p simulating a pathological state. The IL-16 promolecule is cleaved by 
caspase 3 and is basally expressed by lymphocytes and stored preformed in mast cells. The 
production of these chemoattractants has recently been shown to be due to a specific 
interaction between IgG from Graves’ disease patients and Graves’ disease fibroblasts 
insulin-like growth factor 1 receptor (IGF-1R) 42. This is a new concept and adds IGF-1R 
to the list of possible autoantigens mentioned previously. Similarly IL-6 , 8 and MCP-1 
chemokine production is induced by proinflammatory cytokines from orbital fibroblasts 43; 
44. The CD40/CD154 costimulatory pathway has been demonstrated to have a potential 
role in IL-6 , 8 expression. T-cells and mast cells express CD154 that activates the TNFa 
related CD40 receptor on orbital fibroblasts and is upregulated by IFNy 43. CD 154 triggers
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nuclear mobilization of NF-kB that in turn has binding sites within the promoter regions of 
IL-6, 8.
Once in the orbit, specific antigen presentation to T-cells is suggested to occur via major 
histocompatibility complex (MHC) class II HLA-DR antigen 45. IFNy can induce orbital 
fibroblasts expression of HLA-DR 43; 46. Antigen intracellular processing and presentation 
may also be facilitated by expression of heat shock proteins (HSP) present in Graves’ 
ophthalmopathy orbital and pretibial fibroblasts 45,47.
Fibroblastic activation follows one of two divergent routes, denoting a heterogeneous 
population. One engages in prostanoid synthesis and GAG production 48 49 the other, the 
preadipocyte undergoes an inflammatory mediated program of adipogenesis 50. Both 
production o f hyaluronan and prostaglandin E2 (PGE2), via prostaglandin endoperoxidase 
H synthase-2 (PGHS2), in the former can be stimulated by CD40/154 activation 51. PGE2 
is a determinant for B cell maturation, mast cell activation and the phenotypic bias of THO 
lymphocytes to become TH2. Orbital fibroblasts from Graves’ ophthalmopathy have 
recently been demonstrated to proliferate in the presence of autologous T cells 52. 
Proliferation required cell contact, MHC II and CD40/154 signaling. The interruption of 
CD40 activation may represent a specific site for therapeutic intervention .
Just as orbital fibroblasts appear heterogeneous in their adipogenic potential so too is their 
expression of Thy-1 (CD90) 54. Two major sub-populations of lung fibroblast can be 
defined, one expresses Thy-1 and accumulates lipid, and the non-expressing population 
does not express lipid but does express MHC II when stimulated 55. Thy-1 expression is 
associated with a distinct pattern of cellular events regarding cytokine, collagen and 
fibronectin production 55,56,57. Approximately 65% of orbital fibroblasts express Thy-1 54. 
Curiously opposite to lung fibroblasts, it has subsequently been shown that orbital and 
myometrial fibroblasts expressing Thy-1 have TGF-p driven myofibroblastic potential 
whereas fibroblasts not expressing Thy-1 had a PPAR-y driven lipoblastic potential58. The 
ligands for Thy-1 are not well characterized but endothelial cells expressing Thy-1 have 
been shown to interact specifically with the leukocyte integrin Mac-1 (CD1 lb/CD 18) and 
be important in leukocyte extravasation 59. This perhaps further suggests orbital fibroblasts 
fall into two subsets, those interacting with leukocytes express Thy-1 and those
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participating in adipogenesis do not (or simply lose expression as initial commitment to 
differentiation occurs).
The process described in sections 1.3-5 are summarised in Figure 1.1 and have in part been
published in this format in a review article by us previously60. Additional recent
information is reported in a recent review of the pathogenesis of Graves’ ophthalmopathy 
61
Figure 1.1 Summary of the steps involved in the initiation of Graves’ 
ophthalmopathy
(1) T cells recognize TSHR on orbital fibroblasts. (2) Activated mast cells aid fibroblast 
activation, stimulate a TH2 response and (3) stimulate TSAB production. (4) Fibroblast 
activation results in the production of proinflammatory mediators and adhesion molecules 
with the preadipocyte fraction undergoing differentiation and increasing TSHR expression 
that heightens TSH/TSAB sensitivity. The resultant inflammation and adipogenesis 
produce the clinical manifestations of TED.
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Figure. 1.1
1.2 The thyroid axis and disease
1.2.1 Thyroid structure and function
This section is a basic review of thyroid structure and function 62. The thyroid gland is a 
highly vascular, bilobed structure anterior to the trachea and its basic unit of structure is 
the follicle that produces thyroid hormones. Follicles are roughly spheres of polarised cells 
encasing a protein rich colloid. Development starts around day 24 from an outgrowth of 
pharyngeal endoderm, this descends into the neck and assumes its final position around 
week 7. Closely associated are the parathyroid glands and thymus, their development is 
discussed in chapter 2 .
Follicular cells produce thyroglobulin and actively transport iodide using the sodium 
iodide symporter (NIS), an ATPase dependent transporter that allows concentration of 
iodide to 30-50 times that of plasma. Adjacent follicles are often at different levels of 
activity, those less active have a more cuboidal epithelium, those more active have 
columnar appearances and hence the normal follicular heterogeneity. Iodide in the 
follicular cell is oxidised to iodine by hydrogen peroxide catalysed by thyroid peroxidase 
(TPO) and then actively transported into the lumen. At the apical colloid interface, 
iodination of tyrosyl residues o f thyroglobulin produces monoiodotyrosine (MIT) and 
diiodotyrosine (DIT). The coupling of DIT produces tetra-iodothyronine (thyroxine, T4) or 
coupling DIT with MIT to produce tri-iodothyronine (T 3), both are catalysed by TPO. The 
follicle stores the thyroid hormones in this state, until the thyroglobulin is taken back up 
into the follicular cell by active pinocytosis under stimulation by TSH. Lysosomal fusion 
hydrolyses the thyroglobulin molecules to release T3 and T4 On average lOOpg of 
hormone is secreted daily, 1 0% of which is the more active T3, 80% of the T4 then 
undergoes peripheral conversion mainly in liver and kidneys by deiodinase type 1, to T3 or 
inactive reverse T3. The hormones are transported bound to thyroxine binding globulin, 
thyroxine binding prealbumen or albumen.
Cellular signaling of thyroid hormone is via nuclear receptors that remain bound to DNA 
apart from in the presence of hormone. On ligand binding the receptors either dimerise or 
couple with other nuclear receptors such as retinoid X receptor. “Zinc finger” binding of 
hormone response elements (HRE) on the nuclear receptors ultimately controls gene
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transcription. Thyroid hormone also has non transcriptional effects on glucose, calcium 
and sodium transport by unknown mechanisms 62.
Thyroid hormone raises cellular metabolic rates by transcription of respiratory chain 
enzymes, sodium and potassium ATPase and increasing mitochondria in most tissues. Up 
to 40% of a cells energy requirement can be in maintaining its electrochemical gradient so 
increasing its sodium and potassium ATPase can alone increase expenditure greatly. From 
this we understand patients with excess hormone (thyrotoxic) have a high metabolic rate, 
weight loss, fatigue, palpitations, atrial fibrillation and heat intolerance. Patients deficient 
in hormone (hypothyroid) conversely have a low metabolic rate, weight gain, lethargy and 
cold intolerance
Normal secretion of thyroid hormone is under control by the hypothalamic-pituitary axis 
. Hypothalamic secretion of thyrotropin releasing hormone (TRH) to pituitary 
thyrotrophs is via the hypothalamo-hypophyseal capillaries and stimulates secretion of 
TSH. Thyroid hormone negatively feeds back on pituitary thyrotrophs not on TRH 
secretion. When thyroxine is low the thyrotrophs increase TRH receptor expression and 
vice versa. Inhibition can also occur at the pituitary by hormonal (dopamine/somatostatin) 
or cytokine (IL-ip & 6 / TNF-a) effects. Cold exposure increases TRH secretion raising 
metabolic rate.
TSH is a glycoprotein composed of a generic a  unit (identical to that of lutenising 
hormone and follicle stimulating hormone) and a specific p unit and its circulation half life 
is 30 minutes (reviewed 64). Secretion follows a diurnal pattern with a midnight peak and is 
pulsatile.
The TSH receptor (TSHR) is an archetypal G-protein linked structure with 3 external and 
internal loops, 7 transmembrane helices, an external amino terminus and an internalized 
carboxyl terminus (reviewed 65). Ligand binding activates the aPy G protein trimer by 
GTP displacing bound GDP on the G a subunit. This unit (Ga) dissociates and activates 
adenylate cyclase to produce cAMP (Gsa  pathway) until GTP is hydrolysed back to GDP. 
cAMP activates protein kinase A (PKA) which in turn phosphorylates cAMP response 
element binding protein (CREB). CREB translocates to the nucleus and stimulates 
transcription by binding cAMP responsive elements (CRE). This results in follicle cells
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increasing iodine and colloid uptake and producing hydrogen peroxide and TPO to elevate 
circulating thyroxine. Another pathway is also stimulated, Gqa  stimulates phospholipase C 
to hydrolyse phosphoinositides to inositol triphosphate (IP 3 ) and diacylglycerol. IP3
• • • 6 9 ' 66elevates intracellular calcium and diacylglycerol activates protein kinase C 
1.2.2 Thyroid Autoimmunity
1.2.2.1 Central and peripheral tolerance
Graves’ disease is the commonest cause of thyrotoxicosis and is a well characterized 
autoimmune condition (reviewed 3’24,67). It evolves from abnormal immune surveillance 
that allows T and B lymphocytes to circulate that recognize autoantigens in the thyroid,
most importantly, the TSHR. This represents a loss of tolerance of self antigens and a brief
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background to tolerance is described here (reviewed ). T and B cells have a common 
lymphoid progenitor; T cells are matured in the thymus while B cells remain in the bone 
marrow before relocating to the spleen.
Thymic T cell maturation is stepwise, early thymocytes have dual expression of CD4 and 
8, those unable to recognize major histocompatibility antigens (MHC) are deleted. The 
remaining cells expressing CD4 recognize class II MHC and those expressing CD8, class 
I. Further selection deletes cells recognizing auto antigens associated with MHC and 
therefore most auto-reactive T cells are removed due to central tolerance by clonal 
deletion. Clonal anergy can induce peripheral tolerance whereby T cells exposed to 
prolonged antigen are forced into apoptosis by Fas ligand binding, known as activation 
induced cell death. B cell maturation is initially in the bone marrow, auto-reactive surface 
IgM can be rearranged. Once rearranged, if auto-reactivity resolves, further maturation 
follows in the spleen otherwise apoptosis removes auto-reactive B cells 69.
1.2.2.2 Lymphocytes in autoimmunity
As mentioned previously, circulating T cells can be divided into cytotoxic (CD8) and 
helper (CD4) roles and are further divided into TH1 and TH2 cells that have different 
cytokine profiles. These distinct cytokine profiles are less rigid in humans but the diseases
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they produce are contrasting; TH1, the inflammatory autoimmune diseases and TH2, 
allergy and antibody mediated diseases.
Activation of T and B cells is via surface receptors (T/BCR) that recognize antigens with 
appropriate co-stimulation (reviewed 24). Antigen presenting cells (APC) digest antigen 
and present peptide fragments and human leucocyte antigen (HLA) that binds to TCRs. 
CD4 TCR interaction is restricted to HLA class II molecules (usually presenting 
exogenous proteins), while CD8 are restricted to class I (endogenous proteins). Additional 
co-stimulation between APC and T cells occur via B7-CD28 and CD40-CD40L, without 
this second signal anergy can be induced and no further stimulation develops. BCRs are 
membrane bound immunoglobulins identical to those they secrete. Bound antigen requires 
co-stimulation with either cytokines or via direct antigen, class 2 and T cell binding to 
activate antibody production.
Matured CD4+ thymocytes contain a high frequency of cells capable of becoming 
regulatory T cells once in the periphery, that if present in sufficient numbers, can prevent 
disease 70. A radiation and thymectomy-induced thyroiditis model provides clear evidence 
for regulatory T cells by demonstrating disease prevention when animals were 
reconstituted with peripheral CD4+ cells from syngeneic donors 71. Cells with such a 
phenotype, CD45RC-, are described as “memory” cells and imply the initial recognition of 
antigen in the periphery is an important event. In utero radio-iodide ablation of rat thyroids 
lead to depletion of peripheral regulatory T cells capable of preventing thyroiditis, despite
I')the capacity of the thymus maintain their production . A process of antigen-specific
• 7Timmuno-suppression in autoimmune thyroid disease is suggested by such experiments .
1.2.2.3 Mechanisms of loss of tolerance and susceptibility in Graves’ disease
The highly ordered process of immunity breaks down in Graves’ disease and tolerance is 
lost leading to production of antibodies that stimulate the TSHR relentlessly, producing 
thyrotoxicosis and goitre. Viral infections have been suggested to cause unmasking of 
proteins not seen by the adult immune system and have been sequestered away from 
immune surveillance, similar to the lens protein induced uveitis seen after traumatic 
rupture of a lens 74. No similar model has been proposed for the thyroid. Coincident 
similarity between infectious agents and host proteins, “molecular mimicry” has been
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postulated between Yersinia enterocolitica and the TSHR 75, but direct evidence that such 
infection leads to Graves’ disease is not present. “Bystander activation” is a hypothesis 
suggesting a viral infection within the thyroid results in production of IFN-y or other 
cytokines that induces MHC II expression on thyrocytes. The thyrocytes act as APCs to 
circulating or resident CD4 cells, however no evidence of concordant co-stimulatory 
signals and HLA expression are present (reviewed ]' 24' 76).
The lack of genetic susceptibility in Graves’ ophthalmopathy contrasts with Graves’ 
disease in which familial links are evident, numerous genes have been identified; HLA- 
DR3, HLA-DR fll, CTLA4, protein tyrosine phosphatase non-receptor type 22 and 
thyroglobulin (reviewed in 77). Concordance rates between monozygotic twins is 25-30% 
and drops to 2-7% in dizygotic twins 78. The fact that it is at best 30% in monozygotes and 
not much higher suggests other factors are important. As discussed in relation to Graves’ 
ophthalmopathy smoking is an important risk factor in Graves’ disease along with stress, 
pregnancy and radiation exposure 76,79.
Models of Graves’ disease and ophthalmopathy are discussed in chapter 2.
1.2.2.4 The TSHR and its antibodies
The TSHR as discussed briefly before has some homology with LH and FSH receptors but 
differs in having two subunits. This was deduced before cloning the gene and confirmed
fin* si • so t tsubsequently ’ ’ . The a  subunit is the ectodomain and the p unit is smaller, comprising 
the membrane spanning and carboxyl terminus. The 9 leucine rich repeats of the 
ectodomain binds TSH, while the transmembrane loops interact with the G proteins. 
Cysteine bonding in the ectodomain is important for ligand binding . The creation of the 
two subunits requires cleavage of a 50 amino acid segment in the ectodomain possibly by 
a matrix metalloprotease, then disulphide bonds link the subunits and breaking these bonds 
leads to shedding of the a  subunit (reviewed in 65). TSHR exists in multimeric forms until
a a
bound by TSH . On ligand binding, the ectodomian changes confirmation from a tethered 
inverse agonist (closed) to a full agonist (open) of the transmembrane domain that allows
* SSdisinhibition of the natural constitutive activity of the receptor (reviewed in ).
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Germline mutations in the TSHR can lead to inactivation and activation of the receptor. 
Some inactivating mutations cause partial resistance to TSH (normal thyroid hormone
oz
levels, normal sized thyroid with raised TSH) . Complete resistance is seen in congenital
07
hypothyroidism but can be due to defects in genes other than the TSHR . Congenital 
hyperthyroidism due to activating mutations is rare and similar somatic mutations can 
cause benign and malignant nodular thyroid disease . A large number of mutations have 
been identified (www.uni-leipzig.de/innere/tshr) most are present within exon 10 and code
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for amino acids in the transmembrane domain . Retroviral transduction of a panel of 
activating mutations into human thyrocytes, a rat thyrocyte cell line and COS-7 cells 
showed the mutations result in varying levels of adenylate cyclase and phosphoinositide-3 
kinase activation with roughly similar responses in the thyrocytes but differing in the 
COS-7, suggesting the cellular context influences the mutations activities 89. It was also 
shown that the highest levels of cAMP did not necessarily induce the greatest proliferation. 
This may be due to differing mechanisms of phosphodiesterases and cAMP regulatory 
elements.
The autoimmune process in Graves’ disease produces antibodies to the TSHR that can take 
several forms and are generically called thyrotropin receptor antibodies (TRAb). 
Stimulating antibodies were originally identified as IgG and called long acting thyroid 
stimulator (LATS) 90, they are currently referred to as thyrotropin receptor stimulating 
antibodies or immunoglobulin (TSAB/TSI). TSAB can be detected in up to 95% of 
untreated Graves’ disease patients 91. Immunoglobulin from Graves’ disease patients can 
also compete for binding with both TSH and TSAB, blocking signal transduction, these 
antibodies have been called thyrotropin receptor binding inhibiting immunoglobulins 
(TBII) 2. TSHR antibodies can also bind the receptor without blocking or stimulating i t 34. 
These thyrotropin receptor blocking antibodies (TBAB) occur in some cases of idiopathic 
myxoedema and are seen less commonly in Hashimoto’s thyroiditis. The hypothyroidism 
of Hashimoto’s is mainly due to a destructive process. It has a higher incidence in areas 
with adequate dietary iodine 92.
The TSHR has proved difficult to purify and therefore investigators have used a number of 
non thyroidal cells to express recombinant TSHR; prokaryotic bacteria, eukaryotic insect 
cells and mammalian cells 65. Expression in Chinese hamster ovary (CHO) cells 
demonstrated a fully functional TSHR 93. The use of recombinant TSHR was largely to
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generate elusive antibodies mimicking TSAB, this was ultimately achieved using animal 
models similar to the plasmid DNA driven model investigated in chapter 2 94.
Work 30 years ago showed the existence of adipocyte TSH receptor antibodies detected by 
immunoprecipitation of radiolabelled TSH, guinea pig fat tissue and Graves’ patients sera 
95. The immunoprecipitation values did not correlate with antimicro somal, 
antithyroglobulin, TBII and TSAB acitivities were weak. It was concluded they were 
antibodies that recognized different determinants to TBII and TSAB, research has not 
followed to study epitopes that may be involved. However the presence of a functional 
TSHR in adipose tissue has been the subject of recent attention and TSHR expression is 
upregulated during adipogenesis as described in chapter 3.
1.3 Adipocyte Biology and Differentiation
In the past 25 years the view of fat as a simple storage depot of triacylglycerol during 
times of plenty has undergone major revision. Obesity is increasing in prevalence, 
associated with NIDDM, Hypertension, Atherosclerosis, gallbladder disease, all with 
associated morbidity and mortality. Through the production of adipocytokines (adipsin, 
leptin, plasminogen activator inhibitor-1, TNF-a) the central role fat has to play in 
metabolism and diseases such as obesity and diabetes has become apparent96. Adipose 
tissue expansion is composed of both increased volume and increased cell number 
(hypertrophy and hyperplasia). Adipocytes can be differentiated from preadipocytes, 
adipocyte decrease occurs mainly by apoptosis (to a lesser extent dedifferentiation) both of 
which occur throughout life, although preadipocyte differentiation capacity may decrease 
with age 91. Control o f this system is a mixture of endocrine, paracrine and autocrine
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feedback . Understanding the development and biology of fat pads is relevant to this 
thesis as the mechanism of orbital fat proliferation in Graves’ ophthalmopathy is not well 
characterised.
1.3.1 White fat biochemistry
Fatty acids are important structurally in membranes, as hormones, second messengers and 
as a fuel source in white adipose tissue " .  Fatty acids are esterified in the liver to glycerol
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phosphate to form triacylglycerol (triglyceride) and then transported to adipose tissue as 
very low density lipoproteins. An extracellular lipoprotein lipase (stimulated by insulin) 
hydrolyses the triacylglycerol before uptake. The adipocyte then activates the fatty acids 
and transfers the resulting CoA derivatives to glycerol 3-phosphate. Glucagon and 
adrenaline stimulate reversible phosphorylation of hormone sensitive lipase (HSL) via 
cAMP activation of a protein kinase. HSL breaks down triacylglycerol while in contrast 
insulin inhibits lipolysis. The released fatty acids are then broken down to acetyl CoA and 
are transported to the inner mitochondrial membrane and degraded in the matrix to 
produce ATP. Insulin stimulates acetyl CoA carbxylase to promote fatty acid synthesis.
1.3.2 Adipocytokines
Adipose tissue as an organ is a relatively new concept, the proteins secreted have been 
called adipocytokines or adipokines. Leptin acting via its receptor (Ob-R) in the 
hypothalamus controls energy intake and expenditure 10°. The leptin deficient mouse is
obese, diabetic, infertile and hyperphagic 101. Human genetic mutations in the leptin gene
10 '}result in a very similar phenotype . However, in normal and obese individuals body fat
correlates positively with leptin, suggesting obesity is associated with leptin insensitivity
100 jN p_a  js present in human adipose tissue and increased in obesity, it correlates
inversely with lipoprotein lipase and is thought to cause insulin resistance l03. When
adipose TNF-a production is reversed in models o f obesity and diabetes it leads to
improved insulin sensitivity 104. TNF-a while being secreted from fat pads might not
enter the circulation and may have local autocrine or paracrine actions 105. IL-6 plasma
levels correlate positively with obesity and insulin resistance 106 and weight loss reduces
IL-6 in plasma 107. IL-6 is secreted into plasma (unlike TNF-a) and therefore could
increase insulin resistance systemically 105. Resistin is expressed during differentiation and
secreted from 3T3-L1 cells, it appears to inhibit adipogenesis and may function as a 
1 08negative regulator , however its role is not fully characterised and it may simply be a 
bystander product109. Other adipokines include angiotensin, acylation stimulation protein, 
plasminogen activator type-1 and TGF-p. Adiponectin is discussed in chapter 5.
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1.3.3 Adipocyte differentiation and transcriptional control
Adipose tissue forms in loose connective tissue that is abundant subcutaneously and tends 
to cluster, suggesting autocrine or paracrine factors are acting. Human preadipocytes are 
harvested from stromal vascular sites and the close physical association of preadipocytes 
and endothelial cells is extended by them sharing surface markers, suggesting a possible 
common lineage 110. It is likely they represent stem cells that have recently diverged, cells 
with pluripotent capacity to differentiate into cartilage, muscle and fat have been identified 
for many years m . The immortalisation of murine preadipocytes (3T3-L1 and 3T3-F442A) 
112 committed to adipocyte differentiation expanded infinitely the experimental 
possibilities due to a defined differentiation cocktail of insulin, glucocorticoids and cAMP, 
which produces adipocytes over 4-6 days. T4 has been shown to aid fetal adipocyte
1 1 Tdevelopment by inducing IGF-1 and IGF binding proteins
The pathway of preadipocyte differentiation is well described commencing with growth 
arrest, usually at confluence, when the differentiation cocktail is added. Up to two more 
rounds o f cell division occur (clonal expansion) and finishes with expression of the key 
adipogenic transcription factors; peroxisome proliferator-activated receptor y (PPARy) and 
CCAAT/enhancer binding protein a  (C/EBPa), after which permanent growth arrest is 
followed by the full mature phenotype. Blockage o f DNA binding by the E2F/DP 
transcription factor correlates with PPARy expression 114, E2F binding can also be 
decreased by the retinoblastoma gene 115. Early morphological changes are loss of the 
slender fibroblastic appearance with rounding. Early changes in mRNA expression are; 
increased lipoprotein lipase, transient elevation of C/EBPp and C/EBP5, before PPARy 
and C/EBPa. Terminal differentiation is characterised by increased gene expression of 
aP2, Glut 4, malic enzyme, glycerophosphate dehydrogenase, fatty acid synthase and 
acetyl CoA carboxylase, amongst others 96. With these proteins comes the lipid laden 
morphology of mature adipocytes.
Currently the key transcription factors are PPARy, C/EBP’s and adipocyte determination 
and differentiation factor-1/ sterol regulatory element binding protein-lc 
(ADDl/SREBPlc). PPARy2 is the predominant isoform in adipose tissue 116 and like all 
nuclear hormone receptors are ligand activated. One clinically important set of ligands are 
the thiazolidinediones (TZD) that bind with moderately high affinity and are 
proadipogenic and reverse hyperglycaemia ll7. In terms of naturally occurring ligands the 
list is continually growing and include: 15 deoxy-A12 14 prostaglandin U (15dPGJ2)
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polyunsaturated fatty acids, but these have low affinity, binding well below that o f TZD’s 
ii8; 119 ppARy activation is so profoundly adipogenic that vector driven expression can 
lead to myoblasts trans-differentiating to adipocytes 120.
The role of C/EBPs (basic leucine zipper transcription factors) were demonstrated by 
ectopic expression in 3T3-L1 cells, C/EBPp alone can induce differentiation while 
C/EBP5 still requires a differentiation cocktail121. C/EBPa expression can similarly 
induce differentiation and antisense C/EBPa mRNA can reciprocally block adipogenesis 
122; ,23. ADDl/SREBPlc is a basic helix-loop-helix transcription factor and binds E-box 
sequences (CANNTG) and sterol regulatory elements on DNA124' l25. It is expressed early 
in adipogenesis and when over-expressed assists adipogenesis but cannot drive it
1 9 f iindependently of differentiation cocktails . ADDl/SREBPlc is thought to produce an 
endogenous ligand of PPARy 127. The transcription factors involved with white and brown 
adipose tissue development seem identical and in keeping with this, short term TZD 
treatment of CD-I rats lead to interscapular fat pad proliferation. This is a brown fat depot
198and no other pads were examined
Numerous other transcription factors are implicated in adipogenesis and some are 
noteworthy in relation to this thesis. Nuclear factor of activated T cells (NFAT) is a 
transcription factor that promotes aP2 expression. Cyclosporine, used by some in the
190treatment Graves’ ophthalmopathy , inhibits nuclear translocation of NFAT proteins to
1 ^ 0reduce adipogenesis but has no effect on differentiated cells . Cyclic AMP response 
element binding protein (CREB) activation alone can induce adipogenesis and conversely
ni.
blocking CREB can induce adipocyte apoptosis, this is discussed further in chapter 3
1 ^9 . Steroid receptor coactivators (SRC-1) have an important role in CREB induced 
transcription during in vitro adipogenesis 133,134. PPARy co-activator (PGC) is found 
solely in brown fat, while lacking the histone acetyltransferase required to manipulate
1 3Schromatin, it probably interacts with CREB that does . Given that brown and white fat 
share essentially the transcription processes in differentiation it is striking they have such 
opposite functions. PGC must in part be responsible for the mitochondrial biogenesis and 
uncoupling protein (UCP)-l expression that defines the thermogenic energy consuming 
brown fat.
Adipocyte differentiation and expression of TSHR is further discussed in chapter 3 and 5.
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2 The thyroid, orbit and ectopic thymus in TSHR immunized BALB\c; A Graves’ 
masquerade 
2.1 Introduction
2.1.1 An early history of modelled Graves’ ophthalmopathy
For an accurate model of Graves’ disease one would want to demonstrate as many of the 
following as possible; thyrotoxicosis, thyroiditis, goitre, extrathyroidal involvement, an 
immune background of thyrotropin receptor stimulating antibodies (TSAB), generalised 
weight loss and tachycardia. The exploration of such models was underway in the early 
part of the last century (reviewed in ). They attempted to raise circulating thyrotropin
(TSH) with pituitary extracts or methyl cyanide, to induce proptosis in ducks and rabbits 
. The proptosis could be reversed by cervical ganglion sympathectomy, suggesting 
the action was via the lid retractor, Mullers muscle. While lid lag is present in Graves’, a 
more convincing feature is an increase in the volume of orbital contents that was 
demonstrated in guinea pigs following treatment with pituitary extracts in 1936 139. Weight 
loss, thyroid hypertrophy and mild proptosis were present but the addition of 
thyroidectomy to the protocol resulted in severe proptosis. The orbital volume increased 
by 40%, mainly in the fat and lacrimal gland, in which lymphocytes, oedema and 
mucopolysaccharides were present. Additional work showed degeneration and oedema 
that was specific to extraocular muscles l4°. A non-invasive attempt to measure proptosis 
in guinea pigs described a “camera lucida” that involved using a bright light to startle a 
dark adapted subject, while transfixed and motionless the proptosis could be measured 141. 
The apparatus was not widely used probably due to the high sympathetic drive the startle 
induced. With hindsight these models were potentially liberating a range of thyroidal 
antigens during the thyroidectomy, followed by over stimulating extrathyroidal thyrotropin 
receptors with increasing TSH in animals spiraling into hypothyroidism.
More recent models have not all had an obvious antigen and have been driven by TSH 
alone. A factor in pituitary extracts given to goldfish produces proptosis, exophthalmic 
producing factor (EPS), this was initially thought to be TSH that had both thyrotropic and 
exophthalmic properties 142. EPS was further defined as being a tryptic fragment of the 
nearly intact p subunit and the amino terminus of the a  subunit of TSH 143. Both this
29
fragment and TSH caused a doubling in glycosaminoglycan content of the Harderian gland 
in guinea pigs with induced proptosis 144. EPS effects were dissociated from TSH in 
another guinea pig model where proptosis induced by thyroidectomy and augmented by 
radio-iodine or PTU was then treated with thyroxine replacement to remove any variation 
due to hypothyroidism 145. This reduced TSH levels but EPS and proptosis were unaltered 
suggesting the two were separate effects. Further evidence was that treatment with TRH 
could raise circulating TSH but did not induce proptosis or raise EPS. In these models 
antigen liberation is required in addition to EPS/TSH activity to induce proptosis.
None of these models have survived in use into this century unlike protocols that induce 
thyroiditis using thyroglobulin (Tg) or Tg sensitized clones l46,147,148:149. Similarly the 
EPS bioassay has fallen from use and was reported to have low specificity that varies 
seasonally with normal serum able to induce proptosis in the atlantic minow {fundus 
heteroclitus) 15°.
2.1.2 Thyrotropin Receptor in modelled Graves’ disease
Until TSHR was formally cloned, the low level expression on thyroid membranes and 
extracts prevented its use as an antigen to attempt induction of thyroiditis as had been done 
for Tg. TSHR peptides have been reported to induce TSAB, TBAB, TBII, raised 
thyroxine, but without thyroiditis in mice, rabbits and chickens 151: l52; 153; l54. Five different 
H-2 mouse strains were immunized with human TSHR that had been detergent extracted 
and affinity purified from a human thyroid cell line 155. MHC class II expressing, H-2S and 
H-2q mice developed antibodies to the receptor, had transient rises in T3 and a mild 
lymphocytic thyroid infiltrate.
To examine the response to a more complete range of TSHR epitopes, the extracellular 
domain (ECD) was expressed as a bacterial fusion protein with maltose binding protein 
(MBP) and initially showed TBII and TBAB activity with lowering of serum thyroxine in 
H-2 d BALB/c mice 156. An “atypical lymphoblastoid infiltration with follicular 
destruction” was present in some mice and further work confirmed the model phenotype as 
comprising; TBII, TBAB, lowered thyroxine, lymphocytic infiltration in 50% males and 
100% females 157,158. Using the same protocol in C57 (H-2 b) or CBA (H-2k) does not 
induce thyroiditis but TSHR antibodies are generated 159. In the same experiment, NOD
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(H-2 g) that develop a spontaneous thyroiditis in approximately 5%, had an increased 
incidence of destructive thyroiditis, with immunoreactivity for IFNy and few B-cells in 
contrast with the B ALB/c in which IL-4 and IL-10 and significant numbers of B-cells were 
present. From this profile it was assumed BALB/c have a Th2 based thyroiditis while
Y\ANOD have a Thl process. Interestingly the closely related NOD (H-2 ) develop a 
spontaneous thyroiditis that increases with raised dietary iodine 160.
The human ECD produced by baculovirus was found to raise thyroxine levels in BALB/c 
while murine ECD expressed in insect cells behaved similarly to ECD/MBP vaccination, 
but significantly, none have induced thyroiditis 161,162. In common with these methods 
attempting to produce correctly folded and glycosylated TSHR, eukaryotic expression 
vectors encoding the TSHR have been used. Plasmids are efficiently taken up into 
myocytes in 50pl volumes due to hydrostatic pressure within the anterior tibial muscle 
sheath 163. Myocytes then transfer the antigen to antigen presenting cells l64. The pcDNA3 
vector was cloned with the cDNA of human TSHR (pcDNA3-TSHR) downstream from its 
CMV promoter and used to immunize BALB/c 165. In general they responded similarly to 
those receiving ECD/MBP, but when applied to NMRI mice; 30% had TBAB and reduced 
thyroxine while 13% had TSAB, raised T3 and T4, suppressed TSH and thyroid and 
orbital changes (described in 2 .1 .3)166. Confirmation of these models have not been 
forthcoming in particular the reproducibility of the thyroiditis 167, l68,169' l7°.
Elsewhere success in developing a model with TSAB, hyperthyroidism and thyroid 
hypertrophy utilizing fibroblasts coexpressing compatible MHC II and human TSHR has 
been achieved in AKR/N (H-2k) mice 171. These findings have been confirmed by others 
and at no time has a thyroidal lymphocytic infiltrate been detected 169, l72. However when 
the technique was applied to Chinese hamsters some did develop the additional feature of
17Tfocal lymphocytic infiltration . The efficiency of TSHR inducing hyperthyroid TSAB 
models has significantly increased with the use of high transgene expressing adenovirus 
alone or infecting dendritic cells and lymphoblastoid B-cells known to coexpress MHC II 
and B-7 170,174,175. Infrequently the latter induces a focal thyroiditis and necrosis in older 
mice.
31
2.1.3 Thyrotropin Receptor in modelled Graves’ ophthalmopathy
Relatively few models of orbitopathy or other extrathyroidal involvement have been 
developed. In contrast, evidence of human orbital expression of TSHR has gathered
1 7 6 ’ 1 7 7 'implicating it as a prime contender for the role of shared thyroid and orbital antigen 
178; 179; 180; 181 transfer of TSHR primed T-cells to BALB/c results in changes to 68% 
of the mice orbits described as; “accumulation of adipose tissue, oedema caused by 
periodic acid Schiff positive material, dissociation of muscle fibers, the presence of TSHR 
immunoreactivity and infiltration by lymphocytes and mast cells” would seem to mimic 
Graves’ ophthalmopathy 182. Similar changes were present in NMRI mice immunized with 
pcDNA3-TSHR 166. Oedema, muscle separation and mast cell infiltration were also 
reported in the orbits of BALB/c and CD-I mice immunized using cDNA for TSHR and
1 R3G2s with or without cDNA for IL-4 or IL-12 . The reproducible models, where mice
have TSAB and hyperplastic thyroids, have normal ocular muscles 170' 175. Gross 
macroscopic changes such as proptosis or muscle hypertrophy have not been reported in 
any o f the models and confirmation of the ophthalmopathy models has not been 
forthcoming from other laboratories. In fact the only ophthalmopathy model to develop 
oedema, proptosis, ocular restriction, lymphocytic infiltration and GAG accumulation was 
generated in cats by ligating orbital veins, the changes are noteworthy but in need of
1 84association to an autoimmune trigger . Cats have an orbital venous system much closer 
in structure to humans than rats and mice.
2.1.4 Aims; Confirmation and further examination of pcDNA-TSHR and 
ECD/MBP induced Graves’ ophthalmopathy model
The only TSHR induced model of Graves’ disease reported to have a high incidence of 
thyroiditis with ophthalmopathy is that described by the Belgian group using TSHR 
primed splenocytes transferred to naive recipients. Initially our investigation aimed to 
confirm this model, examine if the model follows a Rundle’s-like curve and if frequency 
of disease differs between male and female BALBc from local and imported colonies. 
Inability to raise thyroiditis or ophthalmopathy by vaccination with TSHR either in protein 
or DNA plasmid form redirected us to investigate possible effects on the induced immune 
response resulting from regional dietary variations. We have been unable to replicate the 
existing model but demonstrate some interesting findings and propose areas of 
improvement in modelling Graves’ ophthalmopathy.
32
2.2 Materials and Methods
2.2.1 Production of the extracellular domain of thyrotropin receptor in E. coli
To produce sufficient TSHR protein for use in immunization and ELISA, expression and 
purification from a bacterial system was used. Frozen glycerol stocks of E. coli (TOPP 1 
strain, protein fusion and purification system, New England Biolabs) having previously 
been transformed with the vector pMAL-cRl-ECD containing the 1.2kb EcoRl-Xbal 
cDNA fragment of the human TSHR ECD (amino acids 20-414) were prepared for 
overnight culture 156. Ten millilitres of Luria broth (LB appendix (app) A), containing 
ampicillin (lOOpg/ml), was inoculated with transformed cells and incubated overnight in 
an orbital incubator (S I50, Stuart Scientific) at 37 C and 220rpm. The following morning 
the overnight culture (now cloudy in contrast with media not inoculated) was added to 1 
litre of LB rich broth (app. A), containing ampicillin (lOOpg/ml). This culture was 
returned to the orbital incubator at 30 C until the optical density (600nm) reached 0.3. 
Fusion protein production was then induced with 50pM isopropylthiogalactoside (IPTG) 
and the culture continued for 3-4 hours. IPTG inhibits the repressor activity of the lacl 
gene on the tac promoter that initiates translation of the fusion protein. Cells were then 
harvested by centrifugation (Mistral 3000, MSE) at 4000g for 10 minutes and the 
supernatants discarded and the pellet resuspended in lOmls of lysis buffer (app. A). 
Protease inhibitors were then added, aprotinin (lOpg/ml) and phenylmethylsulfonyl 
fluoride (PMSF) (lpg/ml). The pellets were stored on ice overnight at -20 C then subjected 
to four freeze thaw cycles followed by 3 pulses of sonication for 1 minute each. The lysed 
bacteria were then centrifuged (Rotina, Hettich) at 9000g for 20 minutes and the 
supernatants decanted and saved on ice.
2.2.2 Purification of ECD/MBP protein
Purification relies on the affinity o f the maltose element of the fusion protein for amylose. 
Fifteen millilitres of pre-swelled amylose (New England Biolabs) was inserted into a 50ml 
sterile syringe with glass wool in the tip and equilibrated with column buffer (app. A). 
Following washing with 2 volumes of column buffer the column was transferred to a cold 
room. The crude protein lysate was diluted 1:2-5 with column buffer and applied to the
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column, the flow through was reapplied to the column to maximize yield. Unbound protein 
was then washed off by running 7-8 volumes of column buffer through it. Elution buffer 
(column buffer with maltose and p-mercaptoethanol (both 10mM)) was applied to the 
column and 16 x 1.5ml aliquots were collected and stored at -20 C.
2.2.3 Protein estimation by trichloroacetic acid precipitation
A bovine serum albumin (BSA) standard was made by dissolving 10 mg of BSA in 10ml 
of elution buffer in a 37 C water bath. In a clear, 96-well plate, triplicates of 0, 5, 10, 25 
and 50pl of the BSA standard were placed, to which 50, 45, 40, 25 and Opl of elution 
buffer were added respectively to give a total well volume of 50pl in each. Duplicates of 
the eluted protein aliquots (sample (25pi) plus elution buffer (25 pi)) were similarly added 
to the plate. 50pl of 60% trichloroacetic acid was then added to each well and precipitation 
developed over 30 minutes at room temperature. A fluffy white precipitate developed. The 
optical density was read on a plate reader at 570nm and sample protein concentration 
calculated after a standard curve was constructed from the BSA standards.
2.2.4 Detection of ECD/MBP protein by SDS PAGE
An SDS gel was run to examine the induced ECD/MBP production. A gel apparatus (Mini 
protean, Bio-Rad) was prepared with a 12% resolving and a 4% stacking gel. 25-30pg 
samples of protein and lOpg of protein markers (broad range 175-6 kDa, New England 
Biolabs) were denatured at 95 C for 5 minutes in Laemlli buffer and then loaded onto the 
gel. Electrophoresis was carried out in' running buffer for 45 minutes at 200V (PS500X 
power pack, Hoeffer Scientific), followed by Coomassie staining for 30 minutes gently on 
an orbital mixer (Denley). Coomassie destaining solution was used to clear the gel after 3- 
4 changes every 20-30 minutes, gel drying solution was used for 30-40 minutes before 
dehydrating the gel onto blotting paper under a heated flat bed vacuum apparatus. (Gels 
and solutions see app. A).
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2.2.5 Confirmation of ECD/MBP protein by Western blot
Western blotting was performed on affinity purified ECD/MBP to confirm the presence of 
TSHR. A 12% SDS gel was run in parallel as above without staining with Coomassie blue. 
The gel was transferred to blocking buffer for 15 minutes while an equal sized piece of 
PVDF membrane (Hybond-P, Amersham) was soaked in methanol briefly and then placed 
in blocking buffer for 10 minutes. The blotting apparatus (Mini protean, 3 cell, Bio-Rad) 
was loaded, according to instructions (app. A), with the gel and PVDF membrane, transfer 
was carried out for 1 hour at 350mA. The pink pyronin y tracking dye, confirmed protein 
transfer to the membrane. The membrane was equilibrated briefly in TBS-T buffer (app. A) 
before placing in blocking buffer for 1 hour with shaking. The membrane was then rinsed 
twice for 2 minutes in TBS-T and incubated with the primary antibody, p60 (1:500), for 1 
hour with shaking. p60 is a polyclonal rabbit antibody previously raised against 
extracellular TSHR residues 350-369 (AHYYVFFEEQENEIIGFGQE) coded for by exon 
10 of the human TSHR gene 156. Washes of 1 x 15 minutes and 2 x 5  minutes were 
performed before the secondary antibody incubation with anti-rabbit polyclonal HRP IgG, 
diluted 1:5000, for one hour (Amersham Bioscience). Washes were repeated followed by 
detection using ECLplus reagent (Amersham Bioscience) that utilizes HRP breakdown of 
luminol to generate a sustained chemifluoresence at 440nm that was detected on 
Hyperfilm (Amersham).
2.2.6 Maxiprep purification of pcDNA3-TSHR
For each mouse the full course of DNA immunizations required 400pg of pcDNA3-TSHR. 
Therefore to obtain milligram quantities of plasmid a maxiprep plasmid purification kit 
(Qiagen) was used. It is based on alkaline lysis of bacteria and subsequent binding of DNA 
to resin on a column under low pH/salt conditions. A medium salt wash removed proteins 
and RNA, followed by a high salt elution of the plasmid DNA which is finally desalted 
and precipitated in isopropanol.
From glycerol stocks o f E. coli transformed with pcDNA3-TSHR, an overnight culture 
was prepared in 250mls LB (app. A) containing ampicillin (lOOpg/ml) and incubated in an 
orbital incubator at 37 C, two or four flasks were prepared. The next morning the cell 
pellets were centrifuged at 2500g for 15 minutes at 4 C, supernatant removed and the
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pellet vortexed in lOmls of resuspension buffer (all buffers app. A). After adding 10 mis of 
lysis buffer the mixture was inverted 6 times and left to stand for 5 minutes before adding 
lOmls of chilled neutralization buffer and inverting the mixture a further 6 times. The 
lysate was transferred to a filter cartridge and incubated for 10 minutes after which time a 
thick white protein and genomic DNA precipitate formed at the top of the cartridge. 
Meanwhile the anion exchange resin containing column was washed with lOmls of 
equilibration buffer and once drained completely, was filled with filtered lysate from the 
cartridge. The resin column was then washed twice with 30mls of wash buffer and eluted 
with 15mls of elution buffer. The DNA was precipitated by adding 10.5mls of isopropanol 
in a polypropylene tube, mixed and centrifuged (Rotina, Hettich) at 15000g for 30 minutes 
at 4 C. The supernatant was carefully removed and the pellet desalted with 5mls of 70% 
ethanol before further centrifugation at 15000g for 10 minutes and removal of the 
supernatant. The DNA pellet was air dried for 5 minutes and redissolved in 200pl of buffer 
TE (Tris/EDTA, app.A).
2.2.7 Measurement of pcDNA3-TSHR by spectrophotometry
An estimate of the quality and quantity of pcDNA3-TSHR was made by determining the 
absorbance ratios at 260 and 280nm in a spectrophotometer (Genequant pro, Biochrom 
ltd). For optical density readings to be reproducible, A260 values needed to be between 0.1- 
1.0, this required dilution of the resuspended DNA from 1:10-50 in buffer TE. The 
A260/A280 ratios ranged between 1.7 and 2.0 indicating good quality DNA.
2.2.8 Restriction digest and agarose gel electrophoresis of pcDNA3-TSHR
To confirm the presence of the TSHR insert within the pcDNA3-TSHR purified by 
maxiprep a restriction digest was performed. Enzyme restriction using the single cloning 
sites BamHl (cuts GGATCC) and Xhol (cuts CTCGAG) linearized the plasmid and 
excised the 2.3kb TSHR insert.
The restriction was carried out on 0.5-1 pg of DNA, using 5 units of Xhol and BamHl in 
buffer K (Amersham Bioscience) made up to a 20pl volume with distilled water and 
incubated for 1 hour at 37 C on a hot plate (QBT2, Grant Instruments). A 2% agarose gel
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was prepared by heating 0.8g of agarose in 40mls of TAE buffer (app. A) in a microwave 
(950W, Proline) until melted. This was allowed to cool before adding 0.5pg/ml ethidium 
bromide and then poured onto a 9cm gel tray (Bio-Rad), well combs inserted and allowed 
to set. Then, 2 pi of restriction products were added to 1 pi of 10 x gel loading buffer 
(Promega) and mixed with 7pl water. These were loaded into the wells of the gel 
submerged under TAE in a horizontal electrophoresis cell (Mini sub cell GT, Bio-Rad). In 
addition, a lkb ladder (Promega) and unrestricted plasmid DNA were loaded alongside 
and run at 80 volts for lhour. Once completed, the electrophoretically separated DNA 
stained with ethidium bromide was visualized under ultraviolet light and recorded digitally 
(Alpha imager, Alpha Innotech).
2.2.9 Home office licensing and GM approval
In accordance with the Animals (Scientific Procedures) Act 1986, project and personal 
license approval was required before commencing procedures on live mice. The project 
license (30/2304) states all procedures are carried under general anaesthesia and 
termination by approved schedule 1 methods. The immunizations, blood sampling and 
splenocyte transfer are classified as mild in grading the overall severity of the experiments. 
The personal license was obtained after completing the accredited course within the 
Biomedical Services Department, UWCM, for rodents, modules 1 to 4 inclusive.
2.2.10 ECD/MBP and pcDNA3-TSHR vaccination
There was a high incidence of induced thyroiditis reported in naive recipients of 
splenocytes primed against TSHR by the two step in vivo and in vitro protocol 185. The 
splenocytes were stored and used as required.
In vivo priming was carried out on 6 week old female BALB/c by Jico (Iffa Credo,
France). They were immunized according to two schedules under halothane anaesthesia. 
Anaesthesia was tolerated well overall but four out of the 94 mice were unable to be 
resuscitated following anaesthetic (female GI IB, male BECD 0, female FNP 2R and male 
FECD 2B). Immunizations were carried out on day 0 (with pre-immune blood sampling) 
and at three, six and nine weeks. One group of six mice received lOOjug of pcDNA3-TSHR
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in 25% sucrose shared equally between both anterior tibialis muscles 165. Another group of 
four mice had an initial lOOpg of ECD/MBP intra-peritoneally (ip), in a 200|ul volume of 
0.9% saline with adjuvant, 0.1% aluminium oxide, 0.4% magnesium hydroxide (Maalox, 
Rhone-Poulenc Rorer) and 50pl of acellular bordetella pertussis vaccine (W yeth)156. 
Thereafter immunizations used 50pg of ECD/MBP with adjuvant. Daily checks were 
made on mice after immunization to check vaccination sites, mobility, activity and tail 
bleeds. Generally DNA vaccination provoked little or no interruption to daily living with a 
full recovery by the following day. This contrasted with ECD/MBP which reduced activity 
and produced coat “staring” which settled 2-4 days after immunization. Mice were killed 
in a carbon dioxide chamber after 14 weeks, their serum stored and spleens, thyroids and 
orbital contents removed. Dissection of thyroids and orbits was initially performed using 
an operating microscope but once familiarized with the anatomy was performed without, 
apart from the dissection of ocular muscles from the globe.
Mice immunized with pcDNA3-TSHR were referred to as GI and those immunized with 
ECD/MBP as ECD. Individual mice were identified by rings of indelible marker around 
their tails that were redrawn every two weeks.
[NOTE: Pre-immune sampling of blood from young mice yielded 10-30pl volumes which 
once clotted and spun results in very small serum volumes 5-10pl. Pooling serum from the 
groups was the only way sufficient volumes were available for all the assays but is not 
ideal as it removes initial variations between individuals.]
2.2.11 Splenocyte storage and gradient separation
Spleens removed from immunized and control animals were transferred to RPMI (app. A), 
immediately mechanically disrupted using a blunt forceps and artery clips to empty the 
splenic capsule. The splenocytes were washed by centrifuging (Centaur 2, MSE) at 400g 
for 5 minutes, washed in RPMI, repeat centrifuged and resuspended in 1ml of freezing mix 
(fetal calf serum (FCS) with 10% dimethylsulfoxide (DMSO)). Splenocytes were stored in 
a 1.5ml cryovial, slow cooled to -80 C overnight before transferring to liquid nitrogen. 
Forty-eight hours prior to transfer, the frozen aliquots were rapidly thawed in a 37 C water 
bath, washed in 20mls of RPMI for 20 minutes to remove the DMSO and centrifuged at 
400g for 5 minutes. Splenocytes were resuspended in 3mls of RPMI and layered onto an
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equal volume of histopaque (1077, Sigma) gradient equilibrated to room temperature in a 
15ml falcon tube and centrifuged (Mistral 3000, MSE) 400g for 30 minutes at room 
temperature. The upper aqueous layer was removed before aspirating the opaque interface 
containing the splenocytes which was transferred to a new tube containing lOmls of RPMI 
and centrifuged at 250g for 10 minutes. The supernatant was discarded and this wash step 
was repeated to remove histopaque.
2.2.12 Transfer and in vitro priming of TSHR primed T-cells
By transferring the splenocytes we aimed to determine the incidence of disease induced in 
male versus female mice either imported from the same colony as used in the previously 
described model or the local colony. In the absence of thyroiditis, spleen cells were 
arbitrarily selected from the animals with the highest TSAB activity to use in the transfer.
Following washing to remove histopaque, splenocytes were resuspended and cultured in 
RPMI 1640 supplemented with 10% FCS, p-mercaptoethanol and 20pg/ml ECD/MBP for 
48 hours at 37 C (5% C02, Sanyo incubator). Naive 9-week-old mice were immunized via 
the tail veins, each with 5 x 105 splenocytes in 100pi phosphate buffered saline (PBS, app. 
A). In total, 36 BALB/c by J (Iffa Credo, France) were immunized, 7 male and female 
mice each received ECD/MBP or pcDNA3-TSHR primed cells and 4 male and female 
mice with non-primed cells. 28 BALB/c mice from the local colony were similarly 
immunized, 5 male and female with TSHR protein or DNA primed cells and 4 male and 
female mice with non-primed cells (Table 2-1). The non primed splenocytes were from 2 
male and female, 9 week BALB/c by J, whose sera and thyroids were included in the 
control group. Mice were killed at 10 weeks, excluding 6 male and female BALB/c by J ’s 
that were re-immunized at 15 weeks with 5 x 106 ECD/MBP or pcDNA3-TSHR primed 
cells. These mice were killed 12 weeks later.
Mice from the local colony were given the prefix “B” and those from the French colony 
“F”. This was suffixed by “ECD” for those receiving ECD/MBP primed cells and “GI” for 
those with pcDNA3-TSHR primed cells.
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Table 2-1 Summary of T-cell transfer
Method of T-cell 
preparation
French BA _,B/c x J Local BALB/c
Female Male Female Male
pcDNA3-TSHR primed 7 7 5 5
ECD/MBP primed 7 7 5 5
Non primed 4 4 4 4
2.2.13 Environmental modification of Graves’ ophthalmopathy model
The environment in which experimental models are housed can alter the induced disease. 
We attempted, as closely as possible, to reproduce the housing of the colony that 
developed disease in Belgium.
A second group of twenty imported BALB/c by J female mice were divided into two 
groups o f ten. On arrival they were all fed standard feed and were established on this for 3 
weeks. The two groups where then immunized (as above in 2.2.10) half with pcDNA3- 
TSHR and half with ECD/MBP with a modified adjuvant replacing acellular bordetella 
pertussis vaccine (now unavailable in monovalent form) with 0.2jug Pertussis toxin 
(Sigma). At immunization the two groups were subdivided; half continued standard local 
water, feed (Rat and Mouse (RM) Nol Maintenance, SDS) and bedding, the other had 
modifications of imported water, bedding and feed (RN-01-20K12, Carfil Nutrients) as 
used by IRIBHN, Brussels 182 (summarised in Table 2-2). After a total of four 
immunizations the mice were sacrificed at 14 weeks.
As before, mice were labeled as either “GI” or “ECD” depending on the vaccination 
method. With environment modifications the prefix “B” was used to denote Belgian 
environment modification and “L” for local conditions.
Table 2-2 Summary of second immunization
French female BALB/c x J
Immunization pcDNA3-TSHR ECD/MBP
Local conditions 5 5
Environment modified 5 5
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2.2.14 ELISA evaluation of circulating anti-ECD/MBP IgG
To study the kinetics o f the IgG response to the vaccination in the first immunized group 
and to test transfer o f anti-TSHR activity in the single T-cell transfer group, an ELISA was 
performed. While ECD/MBP can be cleaved by factor Xa, this gives very small protein 
yields of pure ECD. The conjugated ECD/MBP in this ELISA did not give a solely TSHR 
specific target for mice immunized by the ECD/MBP or receiving T-cells primed by this 
route.
Clear 96-well plates were coated overnight at 4 C with lOOpl/well of ECD/MBP (10pg/ml) 
in coating buffer and washed three times with wash buffer the following morning. Primary 
incubation was with test sera diluted 1:100 in diluent (lOOpl volume) and a positive 
control with anti-P59 156 (1:1000), in duplicate for two hours at room temperature followed 
by three washes. Secondary incubation used lOOpl of the conjugate, containing anti-mouse 
IgG horse radish peroxidase (HRP) for the test sera and anti-rabbit IgG HRP for the 
control, was for 30 minutes at room temperature followed by three washes. Detection used 
lOOpl of substrate and the optical density change was measured in a plate reader at 410nm 
with positive controls giving readings of greater than two. (Substrate, conjugate and 
coating, wash and diluent buffers see app. A).
2.2.15 Flow cytometry evaluation of anti-TSHR IgG
To avoid the dual recognition of antigen with the ECD/MBP based ELISA all sera were 
additionally examined by flow cytometry. Anti-TSHR IgG in sera would bind to Chinese 
hamster ovary cells (CHO-K1) expressing the TSHR kindly provided by Dr Phil Watson 
34. The full length extracellular domain was anchored by a glycophosphatidylinositol (GPI) 
link and was highly expressed. Bound cells could then be detected by anti-mouse IgG 
conjugated to fluorescein isothiocyante (FITC). When the cell suspension was 
hydrodynamically focused by the cytometer, laser excitation at 488nm of FITC produced a 
fluorescence output around 530nm that was measured in photomultiplier tubes. The cell 
population could then be described in relation to its fluorescent characteristics; the greater 
the number of fluorescent cells, the more anti-TSHR binding.
Eighty to ninety percent confluent CHO-K1-GPI cells were detached with 5mM 
EGTA/EDTA in PBS, washed three times with 0.1% bovine serum albumen (BSA) in PBS
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and then resuspended in PBS/BSA 0.1% at 2 x 106 cells/ml. Two microlitres of mouse 
serum was added to lOOpl aliquots (2 x 105 cells) of the cell suspension and incubated for 
lhr at room temperature. Cells were then washed in the same buffer three times before 
incubating with FITC conjugated F(ab*)2 fragment of goat anti-mouse immunoglobulins 
(DAKO, diluted 1:16) for 30 minutes at 4 C in the dark. Following three final washes, 
cells were counterstained with propidium iodide to allow gating out of damaged cells.
FITC fluorescence from 5000 cells incubated with test sera was measured by a FACScan 
flow cytometer (Becton Dickinson) and compared to pre-immune sera.
Statistically analyzing fluorescence data from photomultiplier tubes has inherent flaws due 
to the non linear output. In representing data there were also compromises, reporting 
fluorescence geometric means did not allow experiments to be compared if different 
machines or instrument settings were used, as was the case. In an attempt to normalize 
between experiments, the shifts on histograms were examined using Kolmogorov Smirnov 
(KS) statistics (Cellquest Pro software, Becton Dickinson). Cumulative FITC fluorescence 
curves were automatically plotted with test sera vs pre-immune and a ‘D’ value is 
calculated indicating a level of spread. The range of D values of non-primed recipients was
J.L
initially used to calculate the 97.5 centile, values lying above this were considered 
positive for anti-TSHR IgG. However, some non-primed recipients developed high D 
values and when considered alongside the histogram plots it became apparent that a 
descriptive scale can be applied whereby D values below 0.3 are negative (-), borderline 
(0.3-0.4(+/-)) and positive (>0.4 (+)).
2.2.16 Measurement of TSHR binding inhibiting immunoglobulins
TSH-binding inhibiting immunoglobulin (TBII) activity was measured by examining the 
binding of TSH to GPI cells expressing TSHR. Anti-TSHR antibodies in test sera 
competed with radio-labeled TSH binding of TSHR and any reduced radioactivity of 
solubilised cells was measured to give an index TSH binding inhibition (modified from 
186). TSHR expressing JP09 cells were previously used 157 but in preliminary experiments 
GPI cells were found to have higher binding and sensitivity.
GPI cells were maintained in Hams F12 complete medium (app. A) until 70-90% 
confluent. On day 1 they were trypsinised, plated in 96-well plates at 2 x 104 cells/well and
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cultured overnight. Following aspiration of the medium, working buffer (HBSS salt free,
12 5app. A) was used to rinse the cells twice. Working buffer was added to I labeled bovine 
TSH tracer (kindly provided by BRAHMS Diagnostica, Berlin, Germany) in equal 
volumes and 100pi aliquots added to 3 pi of serum (triplicates). Tracer was handled in a 
designated radioactive containment area. In addition to test and pre-immune sera, aliquots 
were made for total counts and non specific binding (NSB), by adding lOOmU of bovine 
TSH). Following a three-hour incubation at room temperature the cells were washed twice 
in ice-cold buffer, lysed with lOOpl IN NaOH (30mins, 4°C), transferred to counting 
tubes and radioactivity measured in a gamma counter (Cobra II auto gamma, Pachard). 
Results were expressed as a percentage of the counts per minute (cpm) bound by the test 
sera relative to the pre-immune value of 100% tracer binding after subtracting the NSB 
cpm. The TBII indices were then plotted against 97th and 3rd centiles constructed from 
individual non-primed (transfer group) or pre-immune (immunized groups 1 and 2) sera.
TBII= test sera (CPM) x 100 
Pre-immune sera (CPM)
2.2.17 Measurements of TSHR stimulating activity
TSHR stimulating activity (TSAB) can be demonstrated on non-thyroid cells such as 
Chinese hamster ovary (CHO) cells expressing recombinant human TSHR by measuring
« 1R7increases in cAMP following receptor binding . TSAB was assayed using LULU* cells 
expressing both hTSHR and cAMP- luciferase constructs 188 using a three day protocol. 
Sera containing either TSAB or TSH would stimulate cAMP accumulation via TSHR 
which in turn increased plasmid luciferase expression. When the cells were lysed, the 
luciferase acted on luciferase substrate to generate light output that was recorded in a 
luminometer.
On day one pre-confluent LULU* cells maintained in Hams F12 complete were 
trypsinised and plated in white opaque 96-well plates (Costar) at 2 x 104 cells/well. On day 
two, cells were switched to charcoal stripped Hams F I2 (app. A), cultured overnight and 
finally on day three, cells were washed with working buffer (Hams F I2 serum free 
medium, app. A). In triplicate, 5pi o f test serum was added to 50pi o f working buffer and 
incubated for 4 hrs at 37 C. A positive control of bovine TSH at 0.1, 1 and lOmU in 50pl 
working buffer was used. Following washing twice in 200pl of normal saline, the plates
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were air-dried and either stored at -20 C or analyzed immediately. Lysis buffer x 5 
(Promega) was thawed from -20 C, diluted 1:5 with distilled water and 50pl was added to 
each test well to lyse the cells while shaking (Microshaker, Camlab) for 20 minutes. 
Meanwhile, 1 bottle of luciferase assay buffer and luciferase assay reagent (Promega) were 
mixed to form the luciferase assay substrate. This was kept in the dark while equilibrated 
to room temperature and when ready to use was primed into the injector of the 
luminometer (Tropix Microplate luminometer, Applied Biosystems). The management of 
dispensing substrate and reading light output from test wells was under the control of 
proprietary software (Tropix Winglow, Applied Biosystems). The output of relative light 
units (RLU) from test sera was compared to pre-immune sera to give a stimulation index 
(SI). Test sera were considered positive when greater than the 97th centile of the non 
primed recipients this was calculated as SI>1.8.
TSAB SI = Test sera RLU
Pre-immune sera RLU
2.2.18 Measurement of serum thyroxine
Total serum free T4 was measured using a competitive radioimmunoassay (RIA). This 
commercial assay (Amerlex) relies on the competition between T4 in the test sera and 
labeled (I ) T4 for sheep anti-T4 antibody bound to magnetizable particles. T4 binding to 
thyroxine binding globulin is prevented by the reaction buffer. Magnetic separation of the 
particles removes unbound tracer and the amount of remaining tracer is inversely 
proportional to the T4 in the sample which is compared to a standard curve.
The assay was carried out in areas designated for the use, monitoring and disposal of 
radioactive materials. Duplicate 10pl volumes of standards, NSB and sera were placed in 
tubes. lOOpl of antibody suspension was added, the samples vortexed, covered and 
incubated at room temperature for 45 minutes. Magnetic separation was carried out for 15 
minutes, then, while still attached to the separator, the tubes were inverted and blotted 
leaving a dry rim of particles at the bottom of the tube. The samples were counted in an 
automated counter (Cobra II auto gamma, Pachard) in which standard curves were 
generated by a logit-log plot giving results in nmol/1. A correction factor was applied (T4 
nmol/1 x 0.0777) to report T4 in pg/dl.
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2.2.19 Splenocyte stimulation using TSHR or PMA/ionomycin
Splenocytes were used in the adoptive transfer of modeled Graves’ ophthalmopathy. We 
examined the splenocytes primed with pcDNA3-TSHR and ECD/MBP to assess if 
environmental modification altered the cytokine production and compared them to 
splenocytes from two pcDNA3-TSHR mice immunized in Brussels (generously provided 
by Dr Sabine Costagliola, IRIHBN) and non-immunized splenocytes.
Splenocytes were thawed, washed twice in lOmls RPMI 1640, centrifuged (400G, 5 
minutes), fluid aspirated, the pellet resuspended in 5mls RF10 medium (app. A) and cells 
allowed to recover overnight in an incubator (37 C, 5% CO2). Splenocytes were counted 
the following day using trypan blue exclusion to determine viable cell proportions (greater 
than 85%), centrifuged (400G, 5 minutes), and resuspended at 2 x 106 cells/ml in RF10.
PMA/ionomycin stimulation
Activation of splenocytes was carried out using a polyclonal stimulus with phorbol 12- 
myristate, 13-acetate (PMA) and ionomycin (both Sigma). These agents induce cytokine
1 QQ
production through protein kinase C and calcium ion influx . Monensin (Sigma) was 
added to block cytokine secretion for intracellular cytokine staining (ICCS). Even after 
monensin, ICCS can be relatively insensitive and therefore we examined in parallel the 
accumulation of cytokines within the supernatant while the splenocytes were undergoing 
stimulation. High levels of monensin may also inhibit cytokine production as well as 
secretion and it was omitted from assays for supernatant cytokine measurement.
Four aliquots of 0.5ml splenocyte suspension (1 x 106 cells) were taken for each mouse. 
Two aliquots were used for ICCS and two used for supernatant estimation of cytokine 
production in parallel experiments. For ICCS, the control sample was incubated for 4 
hours at 37 C with monensin (7pM) and then prepared for flow cytometry (2.2.20). The 
ICCS stimulated sample was incubated with PMA (25ng/ml), ionomycin (1 pg/ml) and 
monensin (7pM), both for 4 hours. For supernatant cytokine measurements the cells were 
incubated as for ICCS but without monensin, centrifuged (400g, 5minutes), supernatants 
aspirated and stored at -80 C until assayed for cytokines (2.2.21).
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TSHR stimulation
To compare the cytokine production induced by the polyclonal stimulus to a specific 
stimulus we used two sources of TSHR. Firstly, ECD/MBP was chosen because it was 
used in both in vitro and in vivo priming steps in the adoptive transfer model. Secondly, 
given that T-cells recognize short peptide fragments of antigens we also used synthetic 
peptides o f the TSHR (listed app. A, kindly provided by Dr P Watson).
96-well microplates were loaded with 250pl of splenocyte suspension (5 x 105 cells) in 
RF10. Triplicates for stimulation with ECD/MBP and TSHR peptides and control un­
stimulated conditions were plated. ECD/MBP was used at 1 Opg/ml and TSHR peptides 
(previously dissolved in DMSO) were used at 5pg/ml. After incubation at 37 C for 6 days, 
supernatants were pooled from the triplicate wells, centrifuged (400g, 5 minutes), 
supernatants aspirated and stored at -80 C until assayed for cytokines (2.2.21).
2.2.20 Splenocyte cytokine staining for flow cytometry, analysis of CD4, CD8, IL-4 
and IFN-y following PMA/ionomycin stimulation
Following polyclonal stimulation (2.2.19) surface staining of CD4 and CD8 was followed 
by permeabilisation for ICCS to asses their capacity to be stimulated to produce TH1 
(interferon (IFN)-y) and TH2 (IL-4) cytokines. Characterising the splenocytes used a four 
colour flow cytometer counting 105 events (FACSCaliber, Becton Dickinson).
Following the four hour incubation (2.2.19)106 splenocytes were washed in PBS/BSA 
0.5%, centrifuged (400G, 5 minutes) and resuspended in 1 ml PBS/BSA. Surface antigen 
detection used peridinin chlorophyll-^ protein (PerCP)-conjugated rat anti-mouse CD4 
(L3T4) and allophycocyanin (APC)-conjugated rat anti-mouse CD8a (Ly-2) monoclonal 
antibodies (Pharmingen). Both antibodies (lOpl) were added to each splenocyte 
suspension, incubated at room temperature in the dark for 30 minutes, washed in 3 ml 
PBS/BSA and centrifuged. Cells were then fixed and permeabilised using a kit (CPK-200, 
Cell permeabilisation kit, ImmunologicalsDirect.com). Two drops of solution A 
(formaldehyde based fixative) was added to the splenocytes, mixed, incubated in the dark 
for 15 minutes, PBS/BSA washed and centrifuged. Cells in the pellet were then 
permeabilised with 2 drops of solution B. Simultaneously, lOpl of anti-cytokine
46
monoclonal antibodies (Pharmingen) were added, r-phycoerythrin (PE)-conjugated rat 
anti-mouse IL-4 and FITC conjugated rat anti-mouse IFN-y, and incubated at room 
temperature in the dark for 30 minutes. 400pl of 2% paraformaldehyde was finally added 
and after a minimum of 10 minutes either analyzed or kept overnight at 4 C.
Results were plotted on dot plots using WinMDI 2.8 * and regions containing CD4 and 
CD8 populations were selected. Once gated according to surface markers the percentage of 
cells expressing IL-4 and IFN-y from control and stimulated splenocytes was measured 
using the same arbitrary quadrants for similar samples. The figure recorded was the 
percentage of cells expressing cytokines in the stimulated sample minus the un-stimulated, 
differences were examined for significance between groups.
A positive control for PMA/ionomycin stimulation was human peripheral blood 
mononuclear cells (PBMC) that were thawed and stimulated in parallel to the splenocytes. 
They were surface stained for anti-human CD4/8 and cytokine staining by anti-human 
IFN-y FITC (both Pharmingen).
*(http://publish.uwcm.ac.uk/study/medicine/haematology/cytonetuk/documents/software.h
tm)
2.2.21 ELISA evaluation of IL-4 and IFN-y in supernatants from TSHR and 
PMA/ionomycin stimulated splenocytes
Cytokines secreted from splenocytes stimulated by either polyclonal or specific stimuli 
were measured by commercial murine IFN-y and IL-4 ELISA (Duoset, R&D systems). 
While not specifying the cells producing cytokines, the ELISAs are highly sensitive, 
capable of detecting pg/ml quantities in the supernatants.
The primary antibodies; rat anti-mouse, IFN-y and IL-4 were diluted to 4pg/ml in PBS, 
lOOpl/well was added to a 96-well plate (Costar), sealed and left overnight at room 
temperature. The following day plates were emptied by rapid inversion and washed three 
times in wash buffer. Blocking buffer was added, 300pl/well, incubated for 1 hour at room 
temperature and the wash step repeated. Samples were analysed in duplicate and standards 
in triplicate, lOOpl/well, covered and incubated for 2 hours at room temperature. Standards
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were prepared using a seven point, two-fold serial dilution in the appropriate reagent 
diluents, with the high standard for IFN-y starting at 2000pg/ml and IL-4 at lOOOpg/ml. 
The wash step was repeated and lOOpl/well of the detection antibodies (biotinylated goat 
anti-mouse, IFN-y (400ng/ml) and IL-4 (200ng/ml)) were added for a further 2 hour 
incubation followed by a repeat set of Washes. The streptavidin-HRP provided in the kit 
was diluted 1:200, lOOpl/well added, incubated for 20 minutes at room temperature away 
from direct light and the wash steps repeated. Substrate solution was added, 100jnl/well, 
incubated for 20 minutes at room temperature away from direct light, before adding 
50pl/well of stop solution. Optical densities were measured at 450nm with wavelength 
correction set at 570nm. (Reagent diluents, substrate, stop solution, wash and blocking 
buffers, app. A).
Standard curves were plotted and fitted with trendlines whose equations were used to 
calculate the concentration of cytokines in pg/ml of sample supernatants. The value 
recorded is the amount of cytokine present in the stimulated sample minus that of the 
unstimulated sample.
2.2.22 Thyroid and orbital histology
Thyroids and ocular muscles from the first immunized group were processed for light 
microscopy with haematoxylin and eosin (H&E) and periodic acid and Schiff s reagent 
(PAS) staining on paraffin sections. T-cell recipients and the second immunization group 
had the thyroids separated by dividing the trachea. The thyroids of T-cell recipients were 
processed for frozen and plastic sections and thyroids and ocular muscles from the second 
immunization group were all processed for plastic sections.
Paraffin sections
Specimens were fixed in 10% phosphate buffered formalin with 2% acetic acid for a 
minimum of 48hours. Processing was carried out in an Automated Duplex processor (app. 
A) and then embedded in paraffin wax using a Blockmaster II embedding machine. 
Sections were trimmed on a Bright microtome at 10pm, cut at 5 pm and floated onto water 
before placing on a microscope slide and dried overnight in a 37 C oven.
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Prior to staining, the sections were placed in a 60 C oven for 20 minutes, deparaffinised 
with two 5 minute changes of xylene, descending grades of alcohol (100% x 2, 90% and 
70%, 2 minutes each), washed in tap water for 5 minutes and then a distilled water rinse. 
For H&E, sections were stained in Harris’s haematoxylin for 5 minutes, washed in running 
water for 5 minutes, rinsed in distilled water, before 2 minutes staining in 1% eosin. For 
PAS, sections were treated with 1% periodic acid for 7 minutes, washed in distilled water 
(3 changes, 1 minute), transferred to Schiff s reagent for 10 minutes, rinsed in distilled 
water and then counterstained with haematoxylin for 5 minutes. Finally excess stain was 
washed off in tap water, dehydration was in ascending grades of alcohol (90% wash, 100% 
x 3 for 2 minutes each) and cleared in xylene (3 changes, 5 minutes). Sections were 
mounted in Ralmount on a charcoal filter extractor and left to set in an oven overnight at 
45 C.
Plastic sections
Specimens were fixed overnight in 0.2% glutaraldehyde, 4% formaldehyde in Sorensons 
phosphate buffer, transferred to phosphate buffer and stored at 4 C the following day. The 
specimens were then dehydrated, post-fixed in uranyl acetate and embedded in LR white 
in the department o f medical microscopic sciences (UWCM, app. A). Specimens were 
then cut from the plastic capsule using a hacksaw and re-orientated. Sections were 
trimmed with a hacksaw initially, then using a glass knife (knifemaker, LKB 7801) on an 
ultramicrotome (Ultracut, Reichert Jung), trimmed further and finally cut at 0.3-0.5pm. 
Series of sections at different levels were dried onto a microscope slide in a 40 C oven for 
2 hours or on a hot plate for 10 minutes and stained with toluidine blue (3 minutes), rinsed 
in tap water, returned to the oven overnight, mounted in DPX and finally dried in an oven.
Frozen sections
Specimens were placed directly into OCT mount on a small piece o f cork board and snap 
frozen in a cooling chamber containing hexane surrounded by solid CO2 pellets in 
methylated alcohol. Once frozen through, the block was transferred to a cryo tube and 
stored in liquid nitrogen. For cutting sections the cork board was frozen to a cryostat chuck 
before cutting 6pm section that were allowed to dry overnight in a 40 C oven. Local non­
primed mice had cryostat sections cut for staining with H&E and toluidine blue to practice
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cryostat sectioning but in the absence of thyroiditis in the treated animals, further 
immunohistochemistry was not performed.
2.2.23 Statistical Analysis
Data was analysed using software, SPSS for Windows (version 11.0.1) or the DOS based 
INSTAT (version 2.0, GraphPad Software). Categorical data was examined using chi 
square with Fisher’s exact test where required and continuous data using T tests, ANOVA 
or Kruskal Wallis where appropriate. Homogeneity of variance was assessed by Levene’s 
(SPSS) or Bartlett’s (INSTAT) statistics and post hoc testing mainly by Tukey honestly 
significantly different (HSD). Test values are reported with p values and test type.
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2.3 Results
2.3.1 Confirmation of purified immunogens: ECD/MBP protein and pcDNA3- 
TSHR
The elution profile of protein concentration is shown in Figure 2.1 and represents the final 
products of a representative initial 1 litre culture. From this 1 litre approximately 62mg of 
ECD/MBP was affinity purified, this compares with New England Biolabs reported ranges 
of yields from 10-100mg/l of culture. The IPTG induction of the 89kDa ECD/MBP and its 
affinity purification is demonstrated in the coomassie stained gel of Figure 2.2. Western 
blotting confirmed the presence of TSHR like peptide in the affinity purified ECD/MBP of 
the appropriate size but also other smaller proteins that represent either breakdown or 
incompletely translated ECD/MBP as previously reported for this antibody 156 (Figure 
2.3).
Following maxiprep purification, pcDNA3-TSHR concentrations ranged between 2.5- 
4p,g/pl giving 500 to 800pg of DNA per maxiprep. This was enzyme restricted to 
demonstrate the 2.3kb TSHR insert on ethidium bromide stained agarose gels (Figure 2.4).
Figure 2.1 ECD/MBP fusion protein eluted from an amylose column
Fusion protein was eluted from an amylase column with maltose (lOmM) and 1.5ml 
aliquots collected. Protein concentration was determined by trichloroacetic acid 
precipitation.
MBP/ECD protein eluted from amylose column
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Figure 2.2 ECD/MBP IPTG induction and amylose column purification
Coomassie blue gel of crude bacterial lysate from TOPP1 E.coli transformed with the 
vector pMAL-cRl-ECD; pre-IPTG (lane 2) and post-IPTG induction (lane 3-6, samples 
taken at 30 minute intervals post-IPTG) of the 89kDa ECD/MBP. Affinity purified 
ECD/MBP (*) and the smaller 45kDa MBP protein (-): early elution fraction (lane 7), peak 
fraction (lane 8), late fraction (lane 9) and column flow through (lane 10). (Lane 1, protein 
markers).
83kDa>
62kDa"*
48kDa>
Figure 2.3 Confirmation of TSHR production by Western blotting
Detection of the extracellular portion of TSHR used western blotting with polyclonal 
antibody p60: crude bacterial lysate (lane 1) and affinity purified ECD/MBP from early, 
peak and late column fractions (lanes 2, 3 and 4 respectively). Full length ECD/MBP is 
detected around 89kDa and a smaller protein is also detected that may represent either 
incomplete translation or breakdown of the full length protein.
83 kDa 
62 kDa
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Figure 2.5 ECD/MBP ELISA, first immunized group
ELISA from the first immunized group (Gl-genetically immunized, ECD-protein) showing 
immune response to TSHR-ECD/MBP. The ECD group has a rapid and robust response 
potentially recognizing both antigens. The GI group responds slower and less vigorously 
to the plasmid expressed single TSHR antigen.
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Much lower magnitudes of change in optical densities (OD) were seen in the single 
splenocyte transfer group. Local mice had ODs below or within the 3rd-97th centiles of 
their non-primed controls. Overall 0/19 local and 6/16 French mice had OD’s greater than 
their controls (x =8.588, p=0.003) suggesting an inability to transfer the anti-ECD/MBP 
immunity to local mice by splenocytes primed in the French mice (Figure 2.6).
Given there is a greater immune response with the protein immunization we also wanted to 
understand if immunological transfer was similarly influenced. The French recipients 
(male and female) of ECD/MBP primed splenocytes had, on average, greater optical 
densities than pcDNA3-TSHR primed cells, but did not achieve significance (0.4897 vs. 
0.3737, p=0.065 (Welch’s approximate t)). Alternatively, when considered as proportions, 
1/8 were positive from the pcDNA3-TSHR primed cells and 5/8 from ECD/MBP primed 
cells, suggesting there may be transfer of combined reactivity to ECD/MBP with less from 
the pcDNA3-TSHR priming, however with the small sample size significance is not
54
achieved (x2=4.2, p=0.12, Fisher’s exact). The difference between the local and French 
groups is due to immunity transferred in the main by ECD/MBP primed cells.
Interestingly, average ODs for the local non-primed groups (females 0.61 and males 0.51) 
were higher than French non-primed groups (females 0.42 and males 0.36 (Table 2-3)). 
This is significant (F=6.9, p=0.007, ANOVA, (p=0.248 (Levene)) and is further defined as 
significant differences between local females versus; French males (p=0.006) and French 
females (p=0.043, Tukey-HSD). The non-primed recipients received 5 x 106 cells in 
contrast to 5 x 105 cells in the primed splenocyte group and this may be causing an 
increased polyclonal response.
Figure 2.6 ECD/MBP ELISA, single T-cell transfer group
Local mice receiving primed T-cells have statistically significant (* p<0.05) lower optical 
densities than their non-primed controls suggesting no transfer of immunity (shaded area 
represents non-primed range 3rd to 97th centiles). The French recipients of primed T-cells 
show some individual elevations in OD above their non primed controls but this does not 
achieve significance as a group and implies some limited transfer of immunity. French 
mice almost exclusively from TSHR-ECD/MBP primed T-cell transfer develop reactivity, 
while no local mice have any evidence of an immune response
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Figure 2.7 Anti-TSHR IgG flow histograms: Immunized group 1
Outlined histogram represents pre-immune sera and solid histogram sera at 14 weeks. All 
mice were positive for anti-TSHR IgG indicated by a right shift in the solid histogram. 
(GI-pcDNA3-TSHR and ECD-ECD/MBP immunized).
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Figure 2.8 Anti-TSHR IgG flow histograms: Immunized group 2 with environment 
modifications
Histograms for GIL and GIB represent sera after 14 weeks whereas for MBL and MBB the 
sera was from 9 weeks. (pcDNA3-TSHR immunized/local environment (GIL), pcDNA3- 
TSHR immunized/Belgian environment (GIB), ECD/MBP immunized, local environment 
(MBL) and Belgian environment (MBB).
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Figure 2.9 Anti-TSHR flow cytometer “D” values for groups 1 and 2 immunized mice
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Figure 2.10 Anti-TSHR IgG flow histograms, splenocyte transfer to local colony 
females
All mice were negative for anti-TSHR. (B-local colony, GI-pcDNA3-TSHR primed 
splenocytes, ECD- ECD/MBP primed splenocytes, NP-non-primed splenocyte).
10* t o ’ 10* 10 ’)* 10’ 5* 10’
ai-HaignFU-MmM
BGI female 0 
D=0.1
BGI female 1R 
D=0.06
io^ ~
ai-M«gH
BE CD female 0
D=0.12
10* 10* 10* to*
1
ai -Htttn )• to' io* i'o‘ To*
D=0.07
BGI female 2R 
D=0.13
i. ■:
BGI female IB 
D=0.07
1  “I
BGI female 2B 
D=0.09
ko io‘ U10* 10' 10* 10* '1b# to1 iV to* fo4ai^ HgM FU-Metf* at
BECD female 2R BECD female IB BECD female 2B
D=0.1 D=0.2 D=0.16
at+tagrt
BNP female 1R
D=0.09
ai+t«5r<
BNP female 2R 
D=0.16
BNP female IB
D=0.II
BNP female 2B 
D=0.17
58
Figure 2.11 Anti-TSHR flow cytometer “D” values for splenocyte transfer groups
(B-local colony, F-French colony, GI-pcDNA3-TSHR primed splenocytes, ECD- 
ECD/MBP primed splenocytes). Circled is BECD 1R whose D value represents a left shift, 
not a positive right shift.
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Amongst the French single splenocyte transfer group a similar overall picture of transfer 
failure is present (Figure 2.11 and Tables 2-11 and 2-12). Seven out of eight males and 
females were negative and 1/8 males (FECD 2R) and 1/8 females (FECD 1R) were 
inconclusive. Four out of four male and 2/3 female non primed recipients were negative, 
1/3 female non-primed (FNP 1R) mouse was positive and this mouse did not have an 
elevated ECD/MBP ELISA OD. The second splenocyte transfer resulted in 4/6 female and 
5/5 males that remained negative, 1/6 females inconclusive (FGI 3B) and 1/6 females 
positive (FGI 2B).
In total there were 12 groups divided by sex, colony, and type of splenocyte transferred. 
Analyzing mean D values demonstrates no significant difference between the groups 
(F=0.926, p=0.524, ANOVA, Levene p=0.014, therefore non-parametrically (x2=7.43, 
p=0.736, Kruskal Wallis).
From the group of French male and female primed splenocyte recipients there was no 
correlation between elevated ECD/MBP ELISA ODs and anti-TSHR by flow cytometry 
(rho=0.07, p=0.797, Pearson).
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In the second immunization group all mice from local and environment modified groups 
developed anti-TSHR when immunized with ECD/MBP (8/8, Figure 2.8). Whereas 
pcDNA3-TSHR immunization lead to the local group having significantly less mice with 
anti-TSHR (1/5) compared to the modified group (5/5) (p=0.048, Fisher’s exact test). 
When the first and second groups mean D values were analyzed by ANOVA significant 
differences in variation are confirmed (F=l 1.496, p<0.0001) with post hoc testing 
confirming the pcDNA3-TSHR locally maintained group to have significantly lower anti- 
TSHR than all the other groups (q=6.2-8.9, p<0.01 -<0.001, Tukey-Kramer multiple 
comparisons).
2.3.4 TBII activity is present in immunized group 1, is not reproducible in
immunized group 2 irrespective of environmental modification and is not 
significantly transferred by splenocytes
TBII activity was detected in the first pcDNA3-TSHR immunized group in 3/5 and in 1/4 
o f the ECD/MBP mice (Figure 2.12). None of the 18 mice from the second immunized 
group had any TBII activity irrespective of environmental modification. The difference 
between the TBII activity when the groups are considered individually is just significant 
(X =7.6, p=0.043, Fisher exact) but analysis o f small sample sets is inaccurate. Therefore, 
if considered as two different experiments; the first group have 4/9 positive for TBII and 
0/18 for the second group, this becomes highly significant (x2==9.39, p=0.007, Fisher 
exact). This demonstrates an inconstancy in TBII development between the two 
experiments.
Very little evidence of TBII activity was found in the transfer recipients, only 2/4 local 
male mice that received ECD/MBP primed splenocytes developed any significant activity 
(Figure 2.13). Considering all groups individually there was no significant difference in 
the proportions with significant TBII activity (x =13.2, p=0.067, Fisher exact) and as two 
groups, local (2/19) and French (0/26), there remained no significant difference (x2=2.86, 
p=0.173, Fisher exact).
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Figure 2.12 TBII activity in immunized groups 1 and 2
3/5 pcDNA3-TSHR and 1/4 ECD/MBP immunized mice from group 1 have TBII activity. 
No mice from group 2 have any TBII. (Values below the 3rd centile show significant TBII
activity).
160
140
120
X 100<D
■oc 80
m 60
i-
40
20
0
:  » ............M
•  -  
°  qP * * ■
©
•  □
97th centile 
3 rd centile
Immunised G roup 1 Immunised G roup 2
Immunised french colony females 
•  Gl ■ ECD •  GIL •  GIB ■ ECDL ■ ECDB
Figure 2.13 TBII activity in splenocyte transfer groups
Only 2/4 local colony male mice receiving ECD/MBP primed splenocytes demonstrated 
TBII activity.
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A considerable number of test samples in the splenocyte transfer experiments, rather than 
showing inhibition, demonstrate greater binding than the control pre-immune serum 
(Figure 2.13). The calculation of the TBII index using pooled pre-immune samples as the 
standard representing 100% TSH binding may be biased. When groups in the pool, like the 
female BNP, have some inherent capacity to bind TSHR, as evidenced by their ECD/MBP 
ELISA results, their sera might compete for TSH binding giving an artificially low cpm 
against which the TBII index is calculated. In an attempt to minimize this potential bias 
and reintroduce the range of individuals’ activities, 97th-3rd centiles were constructed from 
non-primed sera in the transfer group and individual pre-immune sera in the second 
immunization group.
2.3.5 TSAB activity is exclusively found in group 1 immunized mice and were not 
transferred or reproduced
By luciferase assay, 3/5 pcDNA3-TSHR and 2/4 ECD/MBP immunized mice from group 
1 had TSABs and 0/18 of those in group 2 (Figure 2.14 & Figure 2.15). The difference 
between the two groups is significant (x2=12.27, p=0.002, Fisher exact) and as for the 
TBII results there is inconstancy between experiments. No mice from the splenocyte 
transfer group had TSABs.
Figure 2.14 Relative light unit output from luciferase assay group 1 immunized mice
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Figure 2.15 TSAB activity in immunized groups 1 and 2
In total, 5/9 group 1 and 0/18 group 2 mice had detectable TSABs.
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Some degree of caution should be mentioned about the methodology of this assay. The 
development of this in-house assay initially used serum free medium conditions to carry 
out the final incubation . While our model was being investigated the TSAB luciferase 
assay was being optimized. When switched to a salt free/5% polyethylene glycol (PEG) 
buffer, the SI could be twice that of serum free conditions at four hours and a six hour 
incubation was optimum for TSAB binding in serum free media 190. Therefore the results 
we report may lack sensitivity.
2.3.6 T4 values are higher in group 1 immunized mice than group 2
Total T4 values were largely within a wide normal range (Table 2-4) but differences 
existed between the two groups and within group 2 (Figure 2.16). Significantly higher 
average T4 was found in group 1 than group 2 immunized mice, 8.64 vs. 3.67pg/dl 
(p<0.0001, Mann Whitney U). While there are some differences present in the means of 
GIL (3.92), GIB (4.3), ECDL (3.86) and the lowest, ECDB (3.1), this does not achieve 
significance (F=2.125, p=0.143, ANOVA (p=0.102, Levene)).
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The splenocyte transfer groups total T4 were largely within the normal range with 
variations present between the groups (% =22.67, p=0.002, Kruskal Wallis) (Figure 2.17). 
One exception was the male BECD mice whose levels were low but differed significantly 
only from female BGI mice (p<0.01, Dunn’s Multiple Comparison). The local colony 
BECD males were unusual in their T4 values were both low and homogenous (mean=2.5, 
sd=0.141) in contrast with the French FECD males heterogeneity (mean=7.7, sd=2.65). 
There is no significant correlation between TSAB, TBII, T4 or anti-TSHR in immunized 
group 1 and 2 or the splenocyte transfer group.
Table 2-4 Total T4 values from individual non-primed recipients, pre-immune and 
control mice
Mean Standard deviation 97th-3rd centiles
Female non-primed 5.77pg/dl n=7 2.75 10.22-3.34
Male non-primed 5.86pg/dl n=8 1.95 8.91-3.81
Pre-immune/control 4.27pg/dl n=9 2.40 8.91-2.57
Figure 2.16 Total thyroxine levels from immunized groups 1 and 2
Group 1 levels while within the normal range are higher than group 2 (p<0.0001, Mann 
Whitney U). The apparent difference between group ECDB and the other members of 
group 2 is not statistically significant.
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Figure 2.17 Total T4 values from splenocyte transfer group
Differences exist between groups (p=0.02, ANOVA). The means of FECD vs BECD male 
are significantly different (p=0.006, Tukey HSD) while there are no differences between 
the female groups.
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2.3.7 Splenocyte TH1 and TH2 cytokine expression determined by ICCS is similar 
in all groups, whereas CD4/CD8 ratio is altered by immunization
Increases in cytokine production from CD4 and CD 8 splenocyte populations by 
PMA/ionomycin stimulation are shown in Table 2-5 and summarized in Figure 2.19. A 
representative output from the flow cytometer in the form of dot plots is shown in Figure 
2.18. Graphically there is a suggestion the protein immunized environment modified 
(MBB) group have higher percentages of CD4+/IFN-y+ and IL-4+. However the average 
percentages of polyclonaly stimulated CD4+/IFN-y+ splenocytes did not differ significantly 
between groups (%2=6.74, p=0.150, Kruskal Wallis). Differences in CD4+/IL-4+ 
percentages were present (x2=l 1.57, p=0.0419, Kruskal Wallis), but none of the groups 
differed significantly between experimental groups and controls on post hoc testing (Dunn 
Multiple Comparison).
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Figure 2.18 Flow cytometry dot plots demonstrating CD4, CD8 surface staining and 
11-4, IFN-y intracellular cytokine staining of splenocytes
Plots (C-E) show that only low level increases in cytokine populations followed 
stimulation with PMA/ionomycin (Normal spleen 5).
A. Forward and side scatter plot for initial population gating.
B. CD4+/CD8+ plot for region selection of surface markers.
C. CD4+/ IFN-y+. D. CD4+/ II 4+. * E. CD8+/ INF-y+. F.CD8+/ II 4+.
G. Positive control for PMA/ionomycin stimulation. Human peripheral blood mononuclear 
cells surface stained for anti-human CD3 PerCP and cytokine staining by anti-human IFN- 
y FITC. Stimulation results in an 8% increase of the IFN-y+ population.
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Figure 2.19 Percentages of CD4+ and CD8+ splenocytes stimulated to express IFN-y 
and II 4
Splenocytes from immunized group 2, Brussels (BRUS) and non-immunized (NORM) 
mice. Low levels of stimulation were detected in all groups and none were statistically 
different from the control normal splenocytes. The small Brussels group did not 
significantly differ from the locally immunized group 2 mice.
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Figure 2.20 CD4/CD8 ratios from control and stimulated splenocytes
CD4/CD8 ratios are higher in protein immunized mice, lower with local and Brussels 
genetically immunized mice and lowest in non-immunized.
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CD8+/IFN-y+ percentages do not differ between the groups (x2=3.27, p=0.513, Kruskal 
Wallis). Neither are there differences between experimental and control groups of 
CD8+/IL-4+ (x2= 10.96, p=0.0519, Kruskal Wallis).
While the MBB group appeared to have higher cytokine expression than a number of other 
groups it was never significantly greater than that of non-immunized mice. Overall the 
levels of cytokine stimulation were low in both CD4 and CD8 splenocyte populations. 
They did not differ between mice immunized in Brussels, local non-immunized and 
immunized mice, irrespective o f the method of immunization or environmental 
modification. However, the protein immunized mice (MBB and MBL) had an 
accompanying elevation in the CD4/CD8 ratio with the highest ratio (mean=15.4) that 
differed significantly from the other groups (p<0.0001, Figure 2.20). The local genetically 
immunized mice (GIB and GIL) were the next highest (mean=9.46) and differed 
significantly from protein immunized and non-immunized (p<0.0001), but not from those 
genetically immunized in Brussels (p=0.061). The lowest ratio was found in the non- 
immunized group (mean=4.0) and this did not differ from the genetically immunized 
Brussels mice (mean=6.5, p=0.239(all Tukey HSD)). This relationship was not altered by 
stimulation of the splenocytes. [Note: Counting 105 cells the CD4+ events range from 2.8- 
4.0 x 104 and CD8+ from 0.2-0.4 x 104.]
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Table 2-5 Percentage of CD4+ and CD8+ splenocytes stimulated to express IFN-y and 
IL-4 from immunized group 2, Brussels and non-immunized mice
CD4+ Cytokine 
expression %
CD8+ Cytokine 
expression %
CD4+ /CD8+ 
Ratio
IFN-y 114 IFN-y 114 Control Stimulated
MBB 0 3.28 1.72 1.95 1.22 17.76 16.08
MBB 1R 2 1.74 2.19 1.02 13.60 16.74
MBB 2B 3.89 3.13 2.93 1.03 14.92 14.95
MBL 0 1.19 0.83 3.47 0 15.11 15.29
MBL 1R 2.43 0.6 3.13 0.41 16.28 16.06
MBL 2R 0.7 0.32 2.12 0 16.07 13.03
MBL IB 1.66 0.95 2.84 0.17 12.24 15.67
GIBO 0.75 0.54 1.74 0.6 12.14 13.01
GIB 1R 2.12 1.6 2.51 1.1 12.63 9.51
GIB IB 2.16 1.77 2.95 0.75 9.35 8.61
GIB 2B 1.59 1.06 3.17 0.51 9.12 7.86
GILO 2.23 1.6 2.97 0.7 14.39 11.34
GIL 1R 2.16 1.54 3.14 0.96 10.55 9.46
GIL 2R 0.88 0.26 1.19 0 8.93 7.96
GIL IB 0.27 0.2 1.73 0.57 9.30 8.83
GIL 2B 0 0 0.28 0 7.02 8.54
Brussels a 0.46 0.25 2.72 0.46 6.10 6.90
Brussels b 0.45 0 1.21 0 5.90 6.05
Normal 5 2.2 1.8 3.6 1.4 3.41 3.50
Normal 6 0.34 0.97 ‘3.07 0.94 4.43 4.75
Normal 7 0 0.86 0.06 0.07 3.96 3.72
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2.3.8 IFN-y secreted is mostly below the limit of detection and can be stimulated in a 
small proportion of splenocytes by ECD/MBP. Low levels of IL-4 are 
detectable but none differ significantly from non-immunized mice
IFN-y was below the limit of detection from all splenocytes stimulated by both peptides 
and PMA/ionomycin (Table 2-6, sample standard curves app. A). ECD/MBP stimulation 
resulted in low level IFN-y production in 2/7 ECD/MBP immunized mice, 1/11 pcDNA3- 
TSHR mice and 0/3 normal mice. Neither in terms of proportions (x =1.63, p=0.71, Fisher 
exact) or group means (F=2.02, p=0.163, ANOVA) was there a significant difference. The 
difference between detectable IFN-y in the presence o f ECD/MBP (3/21) with none 
stimulated by PMA/ionomycin (0/21) or TSHR peptide (0/21) achieved significance 
(X2=6.3,p=0.043).
11-4 levels were low but generally within detectable ranges (Tables 2.6 & 2.7 and Figure 
2.21)). TSHR peptides induced no significant difference in IL-4 between groups (F=1.805, 
p=0.172, ANOVA, (Levene p=0.203)). PMA/ionomycin was similar with no significant 
differences (F=0.519, p=0.758, ANOVA (Levene p=0.889)). ECD/MBP stimulation 
increased IL-4 secretion in four protein immunized mice above that of normal splenocytes 
but again no group differed significantly (p=0.064, ANOVA (Levene p=0.009, therefore, 
Kruskal Wallis, %2=6.63, p=0.085)).
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Table 2-6 Levels of IFN-y and IL-4 stimulated in splenocyte supernatants
IFN-y pg/ml IL-4 pg/ml
Peptides
ECD/
MBP
PMA/
Ionomycin
Peptides
ECD/
MBP
PMA/
Ionomycin
MBBO 0 0 0 1.9 0 0
MBB 1R 0 36.3 0 3.4 12.2 0
MBB 2B 0 0 0 0.3 2.8 14.1
MBLO 0 0 0 0 12.5 3.6
MBL 1R 0 25.3 0 4.7 3.4 2.0
MBL 2R 0 0 0 1.6 22.2 15.8
MBL IB 0 0 0 0 25.6 11.7
GIBO 0 0 0 0 0 15.8
GIB 1R 0 0 0 2.2 2.2 0
GIB IB 0 2.3 0 2.8 6.6 9.2
GIB 2B 0 0 0 0 1.6 14.2
GILO 0 0 0 6.8 7.3 0
GIL 1R 0 0 0 1.8 2.7 0.8
GIL 2R 0 0 0 5.9 0 0.8
GIL IB 0 0 0 1.8 2.7 14.2
GIL 2B 0 0 0 3.6 2.7 7.5
Brussels
a 0 0 0 0 1.4 6.7
Brussels
b 0 0 0 0 0 0
Normal 5 0 0 0 1.8 3.2 13.3
Normal 6 0 0 0 1.4 8.2 10.8
Normal 7 0 0 0 4.1 0.5 1.7
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Figure 2.21 IL-4 in splenocyte supernatants following stimulation with TSHR
peptides, PMA/ionomycin and ECD/MBP
MBB MBL GIB GIL BRUS NORM
2.3.9 Thyroiditis is not induced or transferred. Thyroid follicles demonstrate 
normal ranges of appearances and intrathyroidal ectopic thymus 
masquerades as focal lymphocytic aggregates
Thyroid sections were examined using several techniques in the course of the experiments 
(2.2.22). Macroscopically there were no thyroids that appeared enlarged. Immunized group 
1 thyroids were mounted in paraffin as a pair and sections cut through the entire block. 
Thyroid follicular structure was frequently disrupted by the brittle nature of the colloid 
(Figure 2.22.A). Commenting on subtle changes such as thyrocyte height was not possible 
using 5pm slices as the section was a composite of more than one thyrocyte. No 
intrathyroidal lymphocytic infiltrates were present. However, in the absence of a murine 
histology atlas to illustrate normal parathyroid structure, a descriptive text reporting the 
parathyroid to be composed of clear, intermediate and darkly stained cells initially meant 
the structures seen in Figure 2.22.B-E, were discounted as being normal parathyroid. This 
was supported by the presence of similar structures in non-immunized and non-primed 
transfer recipients (Figure 2.23.B-F). The darkly stained cells were always encapsulated 
with the parathyroid gland but occasionally, depending on orientation and slice depth, the 
darkly stained cells could appear to be alone within the thyroid follicles, but further 
sectioning could always trace their origin adjacent to the parathyroid gland.
With the problems o f colloid fracturing in paraffin the subsequent splenocyte transfer 
group had thyroids prepared for semi-thin and cryostat histology. The preservation of 
structure in semi-thin was understandably greater than cryostat sections and the absence of 
lymphocytic infiltrates meant no ICC characterisation was carried out. From semi-thin 
sections normal thyroid histology was seen to comprise follicular size and thyrocyte depth 
heterogeneity with occasional apical budding and colloid endocytosis (Figure 2.24. A-B). 
The ability to recognise clear, intermediate and darkly stained cells in parathyroids was 
straightforward with excellent resolution of microvilli present in the parathyroid cysts 
(Figure 2.24.C-D). Again, discrete clusters of darkly stained, large nucleated cells adjacent 
to normal parathyroid were present in non-primed recipients and largely disregarded. The 
capsule did not stain well with toluidine blue in comparison to H&E.
Group 2 immunized mice also showed no intrathyroidal infiltrates and a normal range of 
heterogeneous follicles. Individual mast cells were seen occasionally resident within 
connective tissue adjacent and within thyroids with no greater frequency between 
immunized and control mice.
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While reviewing the histology and comparing it to that published previously it became
• • 1SR*apparent the parathyroid associated cells were present in models from both locations 
165,185 -phe clusters were characterised previously as primarily being T-cells CD3+, Il-2+ 
and B-cells. From our initial impression the parathyroid associated cells were not 
exclusively present in immunized mice hinting towards an anatomical rather than 
pathological finding. Further literature searching reminded us of the possibility of ectopic 
thymus adjacent to the parathyroid gland 191,192.
To further understand the distribution and incidence of ectopic thymus in control and 
immunized mice, available sections were re-examined and remaining blocks cut with 
closer 100- 150pm intervals. In the absence of TSHR immunity in the splenocyte transfer 
group only non-primed recipients were sectioned further to serve as controls. From the 
more detailed sections a wide range of thyroid/parathyroid/thymic appearances were seen 
ranging from extensive and extra thyroidal (Figure 2.25.A-B) to a more intrathyroidal 
location (Figure 2.26.A-D). Mostly the parathyroid and thymus was separated by a thin 
layer o f connective tissue but occasionally was seen as a paired structure (Figure 2.25.C- 
D). The level of the section produced some artefacts underlining the importance of 
multiple sections at frequent intervals. When at the tip of a parathyroid some parathyroid 
cells could extend between follicles mimicking an infiltrate but further sections confirm 
the cells’ parathyroid origins (Figure 2.25.E). Similarly a small piece of medullary thymic 
tissue could be difficult to distinguish from parathyroid, but the presence of murine 
equivalents of Hassal bodies and clustering of lymphocytes around venules aided the 
histological diagnosis along with further sections (Figure 2.26.A-D). Cortical thymus had a 
more uniform appearance with densely packed, dark stained cells with large nuclei (Figure 
2.24.E-F, Figure 2.25.A-B). Another occasional appearance was the thymus gradually 
faded towards the edge of the gland, became less well defined and developed an atrophic 
appearance with vacuolated adipocytes (Figure 2.26.E-F). This may represent involution 
of the thymus, an age related process, whereby replacement with fibroadipose tissue 
occurs. Overall, the appearance, size and orientation of the ectopic thymus were highly 
variable.
It was not always possible to detect parathyroid in the sections (Table 2-7). Lacking 
awareness of the need to cut 100-150pm sections at the outset is the most likely cause of 
this. When cutting plastic sections the smaller the area cut, the greater the performance and 
durability o f the glass knife, as a result, extensive trimming of tissue around the thyroid
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was performed to such an extent that a thymus the size of that in Figure 2.2 5. A-B may 
inadvertently be removed along with the parathyroid. Due to pairing of the parathyroid 
with ectopic thymus in all cases, if the parathyroid was not seen it is probable that thymus 
could be missed and we may be unintentionally under-reporting the incidence of ectopic 
parathyroid thymus.
In order to determine if  TSHR immunization influenced the number of mice with ectopic 
thymus they were grouped as, TSHR immunized (GI, ECD, MBL, MBB, GIL and GIB) or 
non-immunized (non-immunized and FNP), 13/26 and 6/9 mice, respectively, have thymus 
present and the difference was not significant (p=0.46, Fisher’s exact). Returning to blocks 
previously sectioned without having frequent uniform sections cut made attempts to 
estimate volumes by image analysis unworkable.
Table 2-7 Proportion of mice with histologically detectable parathyroid and thymic 
tissue
Parathyroid
detected
Parathyroid and 
thymus
Non-immunized 2/2 (100%) 2/2 (100%)
FNP 7/7 (100%) 4/7 (57%)
GI 3/5 (60%) 3/5 (60%)
ECD 1/4 (25%) 1/4 (25%)
MBL 3/4 (75%) 2/4 (50%)
MBB 3/3 . (100%) 2/3 (60%)
GIL 4/5 (80%) 2/5 (40%)
GIB 4/5 (80%) 3/5 (60%)
2.3.10 Orbital connective tissue and fat do not demonstrate inflammatory changes. 
Artefactual muscle contraction exaggerates normal muscle fibre separation
No significant macroscopic changes were present in terms of proptosis, orbital fat 
expansion or extraocular muscle hypertrophy. For group 1 (GI and ECD) and control mice, 
paraffin sections were prepared. Normal ocular muscle in cross-section had areas where 
connective tissue was common between muscle fibres corresponding to the singly
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innervated orbital muscle layers (Figure 221. A). In none of these areas did PAS positive 
material accumulate suggesting no abnormal glycosaminoglycan deposition (Figure
2.27.C). No lymphocytic infiltration was present in any immunized mice. Artefactual 
separation of fibres due to fracturing o f the section could also be seen similar to that 
occurring with the thyroid colloid (Figure 2.27.B).
For group 2 (GIL, GIB, MBL and MBB) and splenocyte recipients plastic sections were 
prepared. In splenocyte transfer recipients and control mice, ocular muscle with a packed 
appearance towards the centre o f the largest part of the sample, were the multiply 
innervated global muscle fibres (Figure 2.28.A). Adjacent orbital layer muscle fibres had 
areas o f contracted, buckled myofibrils routinely. Buckling deformed the connective tissue 
and could give rise to the false impression of oedema. Similar changes were present in 
group 2 immunized mice with sections of myofibrils appearing normal adjacent to 
segments with contraction bands and knots without any evidence of inflammatory infiltrate 
(Figure 2.28.C/D/E). Elsewhere, striated muscle attached to the thyroid usually appeared 
tightly packed but contraction and buckling could similarly be seen at the edge of the 
specimen demonstrating the changes were not restricted to the ocular muscles (Figure
2.28.E). The normal connective tissue separation of orbital muscle fibres could be 
exaggerated further by crease artifacts that developed when insufficient temperature was 
used to dehydrate the section onto the slides (Figure 2.28.B).
In summary, the ocular muscles from immunized, transfer and control groups had no 
evidence o f hypertrophy, inflammatory infiltrate, glycosaminoglycan deposition and a 
false impression of oedema could occur due to muscle contraction. Orbital fat appearances 
were similar in control and immunized animals. Organised lobules of fat were bordered by 
connective tissue within which scatterings of mast cells were resident with no lymphocytic 
accumulations present (Figure 2.27.E). Sporadic multi-vacuolated adipocytes were found 
within areas of connective tissue in control and immunized mice representing the normal 
background o f adipogenesis (Figure 2.27.D).
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Figure legends
Figure 2.22 Thyroid sections from Group 1 immunized mice
A. Normal thyroid follicles found adjacent to muscle and cartilage. Colloid had a brittle 
nature tending to cause fractures across follicles. [GI 1R, paraffin, H&E, xlO].
B-C. Darkly stained thymocytes separated from parathyroid cells by a parathyroid cyst. 
[B-ECD 0, C-GI 3R, paraffin, H&E, xlO].
D-E. Ectopic thymus sizes varied significantly in relation to the parathyroid gland. [D-GI 
2B, E-GI 0, paraffin, H&E, xlO and x20 respectively].
Figure 2.23 Non-immunized and non-primed recipient thyroid sections.
A. Normal thyroid follicles o f non-immunized control. [C3, cryostat, tol. blue, xlO].
B. Darkly stained more compact cells representing thymocytes could be distinguished 
from paler stained less tightly packed parathyroid cells. [C2, cryostat, tol. blue, xlO].
C-D. Cutting sections through an entire thyroid lobe allowed for an appreciation of how 
the tail o f the thymus in D could be misinterpreted as a focal lymphoid aggregate when not 
viewed with its adjacent parathyroid gland in C. [C l, cryostat, tol. blue, xlO].
E-F. Cryostat sections did not preserve structure well, these consecutively cut sections 
show areas difficult to distinguish parathyroid or thymic origin. Contrast these images with 
2.12.4.C-D from plastic sections in which ultrastructure is well conserved. [BNP male 2B, 
cryostat, tol.blue-E, H&E-F].
Figure 2.24 Splenocyte transfer recipient thyroid sections.
A. Thyrocyte depth varied significantly within follicles irrespective of immunization or 
splenocyte transfer. Similarly, follicular heterogeneity was a normal feature. [FNP female 
1R, LR white, tol.blue, x40].
B. Occasional follicles with active apical thyrocyte endocytosis (arrowed) were normal 
features, no more common in immunized or control thyroid glands. [FGI female 1R, LR 
white, tol.blue, x20].
C. Parathyroid glands were composed o f clear (C), intermediate (I) and darkly (D) stained 
cells. A bundle of neural tissue (N) is seen adjacent to this thyroid. [FNP male IB, LR 
white, tol.blue, xlO].
D. Parathyroid cysts are remnants of the ultimobranchial vesicle with microvilli lining 
their cavities. [FGI female 1R, LR white, tol.blue, x20].
E-F. Ectopic cortical thymus present in non-primed recipient, densely packed large 
nucleated thymocytes. [FNP male 2R, LR white, tol.blue, x 10-20].
Figure 2.25 Immunized group 2 thyroid sections, varying thymic and parathyroid 
appearances.
A-B. Ectopic thymus (T) could be large but was always seen closely associated with 
parathyroid tissue (P). [MBB 0, LR white, tol.blue, x4-10].
C-D. Thymus and parathyroid could be found separated by a capsule and connective tissue 
(C) or form a single structure (D). Thymus can have a medullary appearance with large, 
pale staining cells (C) and a cortical appearance with densely packed dark cells (D) [GIB 
1R (C), GIL IB (D), LR white, tol.blue, xlO].
E. When at the tip of a parathyroid (P), sectioning artefact could give the impression of 
being an intrathyroidal infiltrate but located adjacent to the cyst (C) and thymus (T) were
77
useful indicators o f parathyroid tissue (confirmed by further sectioning) [GIB 0, LR 
white, tol.blue, xlO].
Figure 2.26 Immunised group 2 and splenocyte recipient thyroid sections.
A-D. A small edge o f medullary thymus could be difficult to distinguish from parathyroid 
in a single section (A). The larger pale staining cells of the medulla contrasted with the 
smaller, denser cells clustered around the small venule, likely to be mature thymocytes 
(B). Murine Hassal bodies (HB) were smaller then human equivalents and contain less 
keratin but further aid the detection of thymus. Further into the section it becomes easier to 
differentiate between parathyroid and thymus (D). Mast cells (MC) were seen individually, 
mostly in their normal location, the connective tissue septae, but occasionally in 
parathyroid tissue (B). [GIL 1R, LR white, tol.blue, xlO A/C, x20 B, x40 C].
E-F. This thin strip of thymus gradually faded towards the edge of the gland, became less 
well defined and developed an atrophic appearance with adipocytes. This may represent 
thymic involution and replacement by fibroadipose tissue an age related change [FNP male 
IB, LR white, tol.blue, xlO].
Figure 2.27 Orbital histology from immunized group 1 and non-immunized mice.
A. Normal ocular muscle in cross-section showed connective tissue intervening muscle 
bundles. [C 2, paraffin, H&E, xlO].
B. Ocular muscle showing an artifactual separation of fibres due to fracturing of the 
section. No lymphocytic infiltration developed in any immunized mice. [GI 2R, paraffin, 
H&E, xlO].
C. No accumulation o f PAS positive mucopolysaccharides developed between ocular 
muscles (M) or connective tissue o f immunized group 1. [GI 2R, paraffin, PAS, xlO].
D. Sporadic multi-vacuolated adipocytes were found within areas of connective tissue in 
control and immunized mice representing the normal background of adipogenesis. [FNP 
1R, LR white, tol.blue, xlO].
E. Mast cells were normal residents in the connective tissue adjacent to lobules of orbital 
fat in control and immunized mice, no lymphocytic accumulations were present. [MBL 
1R, LR white, tol.blue, xlO].
Figure 2.28 Striated muscle from immunized group 2 and splenocyte recipients.
A-B. Ocular muscle with a packed appearance represents the global muscle layers (A). 
Adjacent sections of orbital muscle layers had buckled muscle fibres caused by 
contraction, the connective tissue spaces between them exaggerated in this section by 
crease artifact. [FNP 2R, LR white, tol.blue, xlO].
C. Ocular muscles o f immunized mice show similar contraction with no evidence of 
inflammatory changes.
D. Myofibrils have normal appearances (N) alongside knots (K) and areas of dense 
contraction bands (CB) [GIB 2R, LR white, tol.blue, xlO].
E. On cross-section contraction bands are less evident [GIB IB, LR white, tol.blue, xlO].
F. Striated muscle attached to the thyroid usually appeared tightly packed but contractions 
could also be seen, tending to be at the edge o f the specimen, indicating the changes were 
not restricted to the ocular muscles. [FNP male IB, LR white, tol.blue, xlO].
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Figure 2.22 Immunized Group 1 thyroid histology
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Figure 2.23 Non-immunized and non-primed recipient thyroid sections
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Figure 2.24 Splenocyte transfer recipient thyroid sections
Figure 2.25 Immunized group 2 thyroid sections, varying thymic and parathyroid 
appearances
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Figure 2.27 Orbital histology from immunized group 1 and non-immunized mice
*
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Figure 2.28 Striated muscle from immunized group 2 and splenocyte recipients
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Figure 2.29 Embryological origin of thyroid, parathyroid and thymus
A. Formation of organ primordia within branchial pouches.
B . Ventral descent of organs to normal resting sites.
(Adapted from 193)
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Table 2-8 Individual results of immunized group 1 females
Immunized 
group 1 
females
Anti-
ecd/mbp
ELISA
OD
Anti-
TSHR
Flow
‘D’
TSAB si TBII %
T4
pg/ 100ml
GI 0 0.67 0.84 1.5 108 10.5
GI 1R 0.39 0.52 2 93 9.4
G I2R 1 0.8 13.7 32 6.5
GI 3R 0.48 0.72 2.1 70 8.8
GI 2B 0.48 0.41 1.3 57 -
ECD 0 1.89 0.9 2.9 27 -
ECD 1R 1.79 0.81 21.5 102 8
ECD 2R 1.85 0.82 1.6 87 8.8
ECD IB 2.59 0.66 0.4 85 8.5
Table 2-9 Individual results of local female single splenocyte transfer recipients
Single
transfer
female
local
Anti-
ecd/mbp
ELISA
OD
Anti- 
TSHR 
Flow ‘D’
TSAB si TBII %
T4
pg/100ml
BGIO 0.655 0.1 0.7 120 6.3
BG I1R 0.386 0.06 0.8 130 5.6
BG I2R 0.3385 0.13 1 144 6.1
BGI IB 0.364 0.07 1.1 115 8.5
BGI 2B 0.2845 0.09 0.8 139 12
BECDO 0.2615 0.12 1.1 120 7.5
BECD1R 0.3805 0.1 1.3 116 6.3
BECD2R 0.369 0.14 1.8 104 6
BECD1B 0.305 0.29 0.9 123 5.2
BECD2B 0.3845 0.16 1.1 110 5.7
BNP 1R 0.64 0.09 0.8 79 4.3
BNP 2R 0.6605 0.16 1 115 3.3
BNP IB 0.4635 0.11 1 115 8.5
BNP 2B 0.6755 0.17 0.9 104 5.4
Table 2-10 Individual results of local male single splenocyte transfer recipients
Single
transfer
male
local
Anti-
ecd/mbp
ELISA
OD
Anti- 
TSHR 
Flow ‘D’
TSAB si TBII %
T4
fig/100ml
BGI 0 0.1745 0.1 1.4 97 4.7
BGI 1R 0.1955 0.12 1.5 102 3.3
BGI 2R 0.2205 0.1 0.9 90 2.2
BGI IB 0.272 0.14 1.1 87 9.8
BGI 2B 0.2545 0.29 (!) 0.8 106 2.9
BECD1R 0.152 0.44 (!) 0.9 71 2.7
BECD2R 0.2975 0.16 1.1 39 2.4
BECD1B 0.201 0.08 1 79 2.4
BECD2B 0.265 0.31 1.4 115 2.5
BNP 1R 0.476 0.2 0.9 76 3.7
BNP 2R 0.483 0.06 0.6 91 5.5
BNP IB 0.6295 0.6 0.6 93 6.6
BNP 2B 0.438 0.3 0.5 81 5.3
(!) bias o f D value calculation indicating a left shift but not positive result
Table 2-11 Individual results of French female single and double splenocyte transfer
recipients
Single
transfer
female
French
Anti-
ecd/mbp
ELISA
OD
Anti-
TSHR
Flow
‘D ’
TSAB si TBII % T4
jLXg/ 100ml
FGI 0 0.392 0.06 0.6 129 4.8
FGI 1R 0.277 0.07 0!6 86 4.6
FGI 2R 0.366 0.27 0.7 54 4.6
FGI 3R 0.345 0.18 0.7 121 4.9
FECDO 0.355 0.11 0.8 74 4.5
FECD1R 0.5575 0.31 1 167 7.3
FECD2R 0.7525 0.1 1.3 116 5.6
FECD3R 0.511 0.14 1.2 64 3.9
FNP1R 0.424 0.44 0.7 68 10.6
FNP1B 0.434 0.21 0.6 53 3.5
FNP2B 0.3955 0.02 0.8 104 4.8
Control 1 - - 1 101 4.2
Control 2 - - 1 126 3.4
Female
double
transfer
French
FGI IB - 0.04 0.8 76 4.8
FGI 2B - 0.62 0.7 68 4.7
FGI 3B - 0.31 0.8 75 4.2
FECD1B - 0.24 0.9 88 5.8
FECD2B - 0.18 0.6 88 5.1
FECD3B - 0.18 1.1 72 4.6
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Table 2-12 Individual results of French male single and double splenocyte transfer
recipients
Male
single
transfer
French
Anti-
ecd/mbp
ELISA
OD
Anti-
TSHR
Flow
‘D’
TSAB si TBII % T4
|iig/100ml
FGI 0 0.5535 0.06 1.4 126 4.5
FGI 1R 0.358 0.23 1.4 253 5.6
FGI 2R 0.345 0.11 2 233 4.7
FGI 3R 0.3535 0.22 0.6 49 5.7
FECDO 0.508 0.06 0.9 202 3.9
FECD1R 0.3155 0.12 0.8 137 8
FECD2R 0.5335 0.36 1.4 225 10.5
FECD3R 0.385 0.12 1 192 10.1
FNP 1R 0.2635 0.15 1 122 9.1
FNP 2R 0.326 0.05 1.8 140 8.2
FNP IB 0.438 0.2 1.6 75 4.2
FNP 2B 0.4265 0.2 1 45 4.4
Control 1 - - 1 101 2.8
Control 2 - - 1 94 4.0
Male
Double
Transfer
French
FGI IB - 0.28 0.8 108 5.1
FGI 2B - 0.05 0:9 93 2.5
FGI 3B - 0.17 0.9 - 4.4
FECD1B - 0.09 0.9 112 4.5
FECD3B - 0.10 1 113 6
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Table 2-13 Individual results of immunized group 2 females
Immunised 
group 2 
females
Anti-
TSHR
Flow
‘D’
TSAB SI TBII %
T4
pg/ 100ml
GILO 0.17 0.8 125 4.3
GIL 1R 0.08 0.7 102 4.1
GIL 2R 0.07 0.1 112 4.3
GIL IB 0.6 0.9 110 4.2
GIL 2B 0.24 1 137 2.7
GIBO 0.42 1.1 90 4
GIB 1R 0.57 1.2 95 4.7
GIB 2R 0.75 1.1 120 4.4
GIB IB 0.82 1 126 4.9
GIB 2B 0.72 1.4 125 3.5
ECDLO 0.8 0.8 103 3.5
ECDL 1R 0.99 0.9 116 3.9
ECDL2R 0.84 0.8 145 4.1
EC D LIB 0.8 0.8 139 4
ECDBO 0.89 0.9 121 2.6
ECDB 1R 0.87 0.7 141 4.3
ECDB IB 0.82 0.8 124 -
ECDB 2B 0.93 1.1 132 2.4
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2.4. Discussion
Outside o f Belgium there has been little success in using human TSHR DNA or protein 
vaccination to reproduce thyroiditis or ophthalmopathy in mice. In view of the reported 
model having the highest incidence o f TSHR induced thyroiditis we aimed to 
independently confirm the findings and extend knowledge of the model by replicating 
conditions used previously as closely as possible. Instead, we find no evidence of 
thyroiditis and ophthalmopathy and discuss our experimental findings, limitations and 
possible improvements.
Immunized group 1 and 2 largely share a high incidence o f forming anti-TSHR IgG but 
the presence of limited TSAB and TBII activity and elevated T4 values is exclusive to 
group 1. An instant impression might be that the first group behaves like the outbred strain 
NMRI Graves’ model whereas group 2 has no inhibiting/stimulating antibodies induced by 
TSHR immunization. However in group 1, T4 and TSAB do not correlate (p= -0.635, 
p=0.126, Pearson), questioning the finding. Positive TSAB in group 1 could be artefactual, 
the result o f not using an IgG fraction, as seen in two female mice immunized with MBP
1 58alone . With the wide range o f assays used and the need for repeats, the volume of 
serum available was limited and insufficient for an IgG fraction. The potential loss of 
sensitivity using whole serum is an issue if  a small proportion o f mice are false positives. 
However, BALB/c do produce TSAB 94,194 and our original assay not being fully 
optimized for TSAB may be lacking in sensitivity. More reliable future TSAB 
measurement would use a modified TSAB selective working buffer 19°.
Initially in the reported adoptive transfer model of thyroiditis, naive recipients had no 
transfer o f IgG antibody response to; ECD/MBP, CD4+ enriched cells or non-primed cells, 
when assessed by ECD/MBP ELISA after 16 days 185. When this was repeated in 
subsequent experiments up to 12 weeks after transfer, ODs ranging from 0.4-1.2 were
1 S ')reported as positive . From the ECD/MBP ELISA results o f the single transfer group, 
reactivity to the ECD/MBP was unable to be transferred to the local colony. In contrast, 
6/16 French recipients had ODs between 0.5-0.75 that were considered positive against 
controls and 5/16 o f these received ECD/MBP primed cells. If the response were from a 
residual ECD/MBP contaminant during the in vitro priming step one might expect more of 
the pcDNA3-TSHR primed recipients to also be positive. ECD/MBP reactivity did not 
correlate with the negative flow anti-TSHR results (p=0.07, p=0.796), but there is a
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suggestion that limited transfer is occurring in the main from ECD/MBP primed 
splenocytes.
Modifying environmental conditions had no effect on the high incidence of anti-TSHR 
IgG detected by flow cytometry in the ECD/MBP immunized groups. In the pcDNA3- 
TSHR group, environment modifications lead to higher numbers of mice with anti-TSHR. 
This is at odds with the fact that the entire pcDNA3-TSHR first immunized group 
developed anti-TSHR while housed in local conditions. Subtle differences exist between 
the first and second groups that may be significant. On importation, the second 
immunization group was established on local feed, water and bedding for a period of three 
weeks. This resulted in their immunization being delayed to 9 weeks in comparison to the 
first group who were immunized at 6 weeks. Environment modifications were made at the 
time o f immunization for the second group, the mice were exposed to a difference in 
dietary iodine, a factor thought to alter the susceptibility to thyroiditis in several animal 
models (reviewed 195). In the autoimmune prone BB rat, the increased incidence of 
spontaneous “thyroiditis” with higher dietary iodine, is carefully re-described as being 
“thyroid associated lymphoid tissue” given its high degree o f organisation similar to 
secondary lymphoid organs and absence of follicular destruction 196,197,198. However in 
NOD-H-2h4 mice the term “thyroiditis” is used to describe the increased spontaneous 
infiltration seen in line with raised iodine ,6°. The local feed (RM1, SDS) has 1 mg/kg 
iodine while the feed used in Brussels (RN-01, Carfil) has 4.5mg/kg. An enriched iodine 
diet can be induced using water with iodine at 6.5 mg/litre, not far off the 4.5mg/kg used in 
the feed 199. Mice on average will drink 3-7 mis of water per day and eat 3-4 g of feed. In 
order to confirm the high iodine diet is ingested requires measurement of urinary iodine at 
50-100 pg/day (normal levels 7 pg/day). Additionally, the drinking water iodine 
concentrations should be determined given approximately equal volumes of feed and water 
is ingested.
Wishing not to overdraw the role of iodine or environmental processes an alternative 
explanation can be given. Flow histograms for ECD/MBP mice were from the fourth 
immunization point (9 weeks) and were all positive for anti-TSHR. At this time 1/5 locally 
treated and 2/5 environment modified pcDNA3-TSHR immunized mice were positive. The 
pcDNA3-TSHR flow histograms illustrated (figure 2.6.1&7) are from five weeks later (14 
weeks), at time o f sacrifice, when there has been an increase in the environment modified 
group to 5/5 and no increase in the locally treated. This, along with the ECD/MBP ELISA
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results (figure 2.5.1) confirm a slower antibody response to the genetic immunization and 
is slightly later than reported previously when most mice were positive at 11 weeks 165. 
This paper shows that cardiotoxin pretreatment brings forward the anti-TSHR response by 
several weeks in comparison to the vector in sucrose. We were unable to use this adjuvant 
and the pcDNA3-TSHR mice from group 1 and 2 mice were kept in identical conditions 
and only differ by a 3 week delay in the immunization, the apparent lack of anti-TSHR in 
the environment modified group could be due to them still evolving an anti-TSHR 
response and the statistically significant difference may represent a type 1 error. The high 
incidence o f anti-TSHR induced in pcDNA3-TSHR immunized mice 11/15 (groups 1 and 
2) is slightly at odds with other reports using plasmid DNA vaccination 167? 169. This may 
be a sampling effect due to antibodies measured at an earlier time point in these studies, 
strain and environment variation.
While the flow detection of anti-TSHR would seem highly specific it produced positive 
results from two non-primed recipients. Occasionally when using GPI based flow 
cytometry to detect anti-TSHR IgG and IgA in humans there are normal individuals who 
demonstrate binding o f TSHR who are otherwise TBII and TSAB negative 34. One out of 
eleven mice receiving a double splenocyte transfer was positive for anti-TSHR, it is likely 
this represents a similarly non-specific event.
There were slightly lower T4 values in the protein immunized mice of the second group. It 
is noteworthy to mention the overall worse morbidity in protein immunized mice noticed 
in the first immunized group (2.2.10). This deteriorated in the second group when the 
pertussis vaccine had to be substituted for the toxin. Mortality rates rose with 3/10 mice 
dying within 3 days of an immunization. The mice were lost following different 
immunizations, one lost at second, third and fourth points, with no mice dying following 
any genetic immunizations. The changes in T4 may be related to a non-thyroidal illness 
related to the adjuvant.
Examining the cytokine profiles of splenocytes proposed to transfer thyroiditis we see no 
significant differences in the major TH1 and 2 cytokines irrespective of method of 
stimulation or environment in which the mice are raised. However, cryotherapy adversely 
affects proliferative and cytokine responses o f most splenocytes 200,201 and the very low 
levels o f cytokines produced by these thawed splenocytes differ from those used fresh in
1 f - t .  i  z o
other studies on TSHR induced murine Graves’ disease ’ . Given the very low
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responses o f thawed splenocytes, their capacity to transfer disease may similarly be 
affected and it would be interesting to track them in vivo. The homing of H3-thymidine 
labeled splenocytes to the lungs in a transfer model o f viral respiratory infection illustrates 
a possible technique that could clarify'further attempts to transfer thyroiditis to naive 
recipients . Ex vivo splenocytes, without freezing, would ideally be transferred and 
examined for cytokine/proliferation responses in future studies.
The presence o f ectopic thymus in parathyroids/thyroids has been detected in several 
mammals; dogs, cats, guinea pigs, bats, mice, rats, baboons and humans 191; 192; 203,204,205; 
206 and conversely, ectopic parathyroid can be found in the thymus 207. In the cat the almost 
constant appearance of the anomaly was referred to as the “internal thymic lobule of the 
thyreoid’ 208. Discussion on the origins initially centred on a IV pharyngeal pouch 
structure but included suggestions that the thymic tissue within the thyroid may be related 
to thyrocyte transformation 191, but embryological studies demonstrate this to be a 
developmental anomaly. The murine third pharyngeal endodermal pouch produces a 
parathyroid from a small dorsal segment and thymus from a larger ventral segment. This 
situation only exists in mammals with all other higher vertebrates forming parathyroid 
ventrally and thymus dorsally 209. At 11 days gestation the parathyroid primordium 
appears in the third pharyngeal pouch roughly at the same time as the equivalent area in 
the cranial portion o f the fourth pouch degenerates (Figure 2.14. A). This region in other 
mammals forms the superior parathyroid and its degeneration explains the presence of 
only two parathyroids in mice compared with four in humans. At the end of day 11 the 
branchial complex is separating from its ecto/endodermal membrane origin with the 
parathyroid anlage at its cranial portion connected to the caudal thymic anlage. Thymic 
ectoderm is destined to form the medulla, endoderm the cortex and by 1214 days the two 
complexes are no longer distinct following invasion of blood vessels and lymphoblasts. It 
is also at this time the fourth branchial pouch derived ultimobranchial vesicle reduces to 
form a small epithelial nodule that may persist (figure 2.12.1 .B/C). By day 13, thymus and 
parathyroid separate or can remain connected by a thin cord of cells, they migrate ventrally 
to meet the thyroid and during day 14 the parathyroid should remain with the thyroid while 
the thymus continues its ventral descent (figure 2.14.B). It is at this point a fragment of 
thymic tissue can remain attached to parathyroid and incorporated into the thyroid on days
91 n14 and 15 . We find this to be a common anomaly amongst BALB/c in agreement with
others 192’204. Misinterpretation as focal lymphoid infiltrates, in both BALB/c and NOD 
mice, can arise due to variation in appearances of medullary and cortical thymus. Serial
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sections tracing the full extent of any such areas and their association to the parathyroid 
gland should be available when proposing any histological evidence of focal thyroiditis.
Incidence o f ectopic thymus in B ALB/c thyroids approaches 100%, is often unilateral and 
is sometimes seen only as a collection o f lymphocytes rather like those in Figure 2.12.3.F 
(personal communication from Thelma Dunn quoted in 204). Given such a high incidence, 
one can speculate on the likely presence o f mutations/polymorphisms or possibly common 
environmental factors acting to produce such a frequent anomaly in the inbred BALB/c. In 
looking for reasons for the failure of thymus and parathyroid separation during 
embryological descent, clues are given by previous experiments. During early thymic 
development, prothymocytes are attracted to the thymic anlage by embryonic chemokines; 
stromal cell-derived factor 1 (SDF-1), secondary lymphoid tissue chemokine (SLC) and 
thymus-expressed chemokine (TECK). Absence o f TECK and SDF-1 in the nude mouse 
thymic anlage cause prothymocytes to home to the parathyroid anlage, resulting in an 
abnormal thymus . In another model, insufficient retinoic acid synthesis caused a 
generalised pharyngeal pouch maldevelopment that is lethal and resembles the human 
DiGeorge syndrome . The formation of the pharyngeal arches is largely fashioned by 
neural crest cells and gene defects in; Hoxa3, Pax-1, EYA-1, GCM2 and FOXnl are 
important in parathyroid and thymus development 193 2I3;214> Ectopic thymus develops in 
two mutants; heterozygous, Hoxa3+/'Paxr ~ and homozygous Pax9'A, due to delayed 
separation from the pharynx, however the resultant ectopic thymus is hypoplastic and not 
thyroid associated in contrast with the BALB/c we have examined 215;216.
While we were unable to give volumetric estimates of ectopic thymus or make any 
comment on whether TSHR immunization influences this, we would report a wide range 
in the sizes o f ectopic thymus present. It leads us to review previous reports linking the 
thyroid and thymus. Factors influencing the thymus to cause hypertrophy include TSH and
• 917*918  •thyroxine ’ . An enriched iodine diet produced a transiently increased incidence of
thyroid associated ectopic thymic tissue in Wistar rats after 3-6 weeks and occurs 
alongside lowered anti-colloid antibodies 199. In an unrelated model, a possibly 
immunosuppressive role is hinted at in null l a  hydroxylase mice that have enlarged 
parathyroid lymphoid tissue (morphologically ectopic thymus) had a reduced CD4+ and 
CD8+ peripheral lymphocyte count219. Meanwhile in humans the role of an enlarged 
thymus and benefits o f it’s excision in Graves’ disease has been considered to have 
varying degrees of success for many years and remind us of an alternative cause of a
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990* 991 * 999breathless thyrotoxic patient ’ ’ . The presence o f thymic medullary lymphoid
follicles in patients with Graves’ differ subtly from those of other patients with 
autoimmunity; myasthenia gravis, rheumatoid arthritis and systemic lupus erythematosus 
and are rarely found in non toxic nodular goitre or after parenteral immunization 223,224.
The role o f such follicles in myasthenia gravis is the expansion and affinity maturation of
99<r
B-cell clones (reviewed in ). Thymectomy for thymoma has shown only moderate
99 f\clinical benefits in myasthenia gravis , an explanation for this may be the persistence of
997ectopic thymic tissue such as that associated with the thyroid . In any case, the enlarged 
thymus in Graves’ disease patients has been shown to reduce in volume and density 
following antithyroid treatment in parallel with reduced anti-thyroid and anti-TSHR 
antibodies 224; 228. The latter group also detected TSHR mRNA and protein in normal 
thymus. A further Graves’ related effect is thymocytes have been shown to proliferate in
• 990response to immunoglobulins from a patient with Graves’ and an enlarged thymus 
Altogether with the more recent report of structures within thymic epithelium that 
resemble thyroid follicles and contain thyroglobulin 230, give a sense of the thymus being 
another possible extrathyroidal autoimmune target rather than a bystander to the 
generalised thyrotoxicosis. However, it remains that reduction in thymus size on treatment 
with antithyroid therapy, like the improved thyroiditis itself, could be due to a drug related
9T1immunosuppression or to normalization of the thyrotoxicosis , but in all probability, 
results from a combination o f both. None of the models utilizing TSHR as an antigen have 
so far examined the possible thyroid and thymus relationship and it would seem worthy of 
further investigation.
Improved techniques characterising thyroiditis such as whole thyroid flow cytometry are 
an interesting and essential part of future investigations promising a more quantifiable
9^9
index of cellular infiltrates and possibly distinguishing them from ectopic thymus 
Identifying some o f the thymocytes could be done, as suggested, by identifying double 
positive CD4+ and CD8+ cells but more markers would be required to identify the 
significant proportion of mature thymocytes that are singly CD4+ or CD8+ and the
9TTprogenitor thymocytes that are pre-TCR expression
Noteworthy fixation artefacts were present in the parathyroid and ocular muscles. Firstly, 
the apparent light, intermediate and darkly stained parathyroid cells were originally 
thought to represent the level of secretory activity of these cells. It has since been shown to 
be due to the level o f cellular disorganization caused by incomplete immersion fixation
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234. Disintegration of organelle membranes produced pale stained cells with intermediate 
forms, while well preserved cells stained darkly. The heterogeneous staining could be 
corrected either by perfusion fixation or altering buffer properties, but for our purposes of 
parathyroid identification the artifact is a useful aid to recognition. Secondly, was the 
appearance of irregular spaces between ocular and some skeletal muscles, suggestive of 
oedema. During routine preparation ocular muscles were excised from the common 
tendinous insertion at the orbital apex and then from the globe, involving a significant 
degree o f manipulation for a delicate tissue prior to fixation. While stretched in vivo they 
measured approximately 3.5mm but when cut, rapidly contract to less than 1.5mm, their 
size prevented us fixing them stretched. Classically packed skeletal muscle appearances 
were seen in those attached to the trachea and thyroid, muscle contraction was only present 
at the edge o f these specimens. Skeletal muscle differs significantly in organisation and 
molecular constituents to the highly specialized ocular muscles, the appearance of packed
n n c .  9"3A
ocular muscle corresponded to the global muscle layer (reviewed and references in ’ ).
Adjacent ocular muscles organised into smaller bundles with more connective tissue 
intervening were the orbital layers and here the contraction artefact produced an irregular 
redistribution o f the connective tissue that might be interpreted as oedema. An awareness 
o f the anatomical variations within ocular muscles is important especially when 
compounded by artefacts of contraction and hyper-contraction . These changes could be
reduced by perfusion fixation, but would restrict onward use of the spleen or thyroids to 
histology. Alternatively, excising the globe en bloc is possible, leaving the muscles 
attached to annulus of Zinn, splinted by the optic nerve, then fixed before excising and 
embedding. The larger size might be sectioned more efficiently in paraffin blocks rather 
than plastic sections. The process of, fixation after manipulation, that produces contraction 
artefacts is the same as that used in the BALB/c and NMRI models, contraction artifacts 
are present in these papers illustrations but are not commented on.
The concept o f how delayed the evolution of anti-TSHR to pcDNA3-TSHR has not been 
emphasized by experiments comparing this method to far more robust immunizations in 
which co-stimulation enhance the immune response 167,169. Techniques using TSHR 
immunization with co-stimulation are more reliable in raising TSAB, causing thyrocyte 
hypertrophy and infrequently in older mice, lymphocytic infiltration 170,171 ’172,173. 
Dendritic cells are thought to be important at an early stage o f thyroiditis. They are present 
in significant numbers in normal thyroids, regulate growth and function o f thyrocytes,
1 n c .  9 9 9 . 9 9 C *  9 ' ) Q
express TSHR and can be used to induce experimental thyroiditis ’ ’ ’ . As an
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aside, pertussis toxin used as an adjuvant for TH2 responses in experimental Graves’ 
disease in BALB/c 172 is shown to promote TH1 inflammatory responses via dendritic cells 
in another organ specific autoimmune BALB\c model, experimental autoimmune uveitis 
240. The advancing complexity of models is inevitable and the importance o f inbred and 
out-bred strains is likewise essential. The newer Graves’ models currently do not 
distinguish an immune infiltrate that is a strain dependent response to thyrocyte/dendritic 
cell proliferation secondary to TSHR stimulation by TSAB, from a targeted anti-TSHR T 
cell mediated response. Inclusion of controls receiving recombinant TSH might resolve 
this. Clarifying existing models is particularly pertinent given the recent description of 
another stimulating antibody, directed towards IGF-1, indicating a more widespread loss 
o f tolerance occurring in Graves’ disease that will likely need to be incorporated into our 
model systems 42.
In general terms it has been established that DNA vaccination is characterised by strong 
cell mediated immune responses and significantly weaker antibody responses in 
comparison to protein based vaccinations with adjuvant, so our model actually performs as 
predicted once the ectopic thymus red herring is removed 2 4 This skew in antibody 
response may be related to the increased CD4/CD8 ratio present in protein immunized 
mice. If we are to pursue the potential of TSHR DNA based vaccination inducing TSAB, 
thyroid hyperplasia and thyroiditis, attempts to strengthen antigenicity need exploring and 
murine TSHR may make a more logical target to induce thyroiditis 174. The addition of
conventional aluminium adjuvants to DNA vaccination has been shown to greatly increase
• •  • • • antibody responses and may be a start point . Additionally, raising cell mediated
immune responses has been engineered by Fas mediated apoptotic death of cells
expressing antigen 243. There followed an increase in antigen uptake by antigen presenting
cells, elaboration of TH-1 cytokines and enhanced antigen specific cytotoxic T-
lymphocytes beyond that seen with a standard pcDNA3 vector. The co-expression of
antigen and mutant caspase apoptotic proteins can induce apoptosis while antigen
expression is not interfered with 244. This has particular interest because the adjuvant
activity enhanced B-cell as well as T-cell responses and this approach can incorporate
gene gun delivery to amplify TH-2 responses 245. DNA-TSHR immunization requires
adjuvants in future attempts to model Graves’ ophthalmopathy.
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3 Increasing TSHR activation in differentiated orbital preadipocytes has variable 
effects on lipid accumulation 
3.1 Introduction
3.1.1 Extrathyroidal thyrotropin receptor expression in fat
Proposing the TSHR to be an antigen in Graves’ ophthalmopathy required evidence of 
orbital expression. Extrathyroidal expression of TSHR was first suggested by White and 
Engel who reported, as an aside, a low level lipolytic effect of TSH on rat epididymal 
adipose cells that was less potent than adrenocorticotrophic hormone (ACTH) 246. This 
work was confirmed and developed further in the same cell types in rats and guinea pigs in 
which TSH also increased oxygen consumption, glucose utilization, release of free fatty 
acids and could be substituted for by LATS 247,248,249,25°. Following this, some years later, 
the presence o f TSHR in orbital fat had been implied by TSH binding and cAMP 
production from retro-orbital membranes o f both humans and guinea pigs 25252. In 
humans, membranes were from connective tissue and fat cells but in guinea pigs the main 
target for TSH binding was the membranes o f the Harderian gland which is absent in 
humans. Another group, using similar techniques of examining membrane preparations, 
did not demonstrate TSH binding to human orbital fat but supported its presence in guinea
253pigs .
Elsewhere evidence of functional extrathyroidal TSHR expression is in neonates in whom 
TSH is the main stimulus for lipolysis but the effect decreases by childhood and further 
into adulthood, at which time catecholamine effects predominate 254. Again the TSHR 
ligand, TSH, could be substituted for by TSAB and lipolysis reciprocally blocked by 
TBAB . Despite the reduced TSHR expression in adult adipocytes, the thyroid axis still 
affects fat stores whereby thyrotoxicosis causes lipolysis by an indirect effect, increasing 
adipocyte p2-adrenoreceptors expression and their cAMP production . The apparent 
change in TSH sensitivity from infant to adult may reflect the reduction in preadipocytes 
and preponderance of adipocytes comprising the adult fat organ.
Following cloning of the human TSHR it became possible to investigate the presence of
o i . 7 C 7
extrathyroidal mRNA transcripts ’ . Initially it was detected in whole orbital tissues of
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Graves’ ophthalmopathy patients and non-thyroid autoimmune individuals but attempts to 
identify the cell type did not include orbital fat . A TSHR variant transcript was detected 
in extraocular muscles and, to a lesser extent, orbital fibroblasts and fat, but the protein
9 5Qwas non-functional for signalling, lacking the required trans-membrane segment 
Similarly, from cultured orbital fibroblasts extracellular TSHR mRNA was reproducibly
960* 961detected ’ . These qualitative techniques are vulnerable to illegitimate transcription,
unlike northern blotting and in situ hybridisation that eventually confirmed TSHR mRNA 
in orbital fat of Graves’ ophthalmopathy patients 178;262,263.
Fibroblasts were the focus o f a large proportion of ophthalmopathy research until 1996 
when preadipocyte 3T3-L1 cells were the first non-thyroidal cell line shown to have 
inducible TSHR expression on differentiation 264. The same group demonstrated rat
9£c
preadipocytes also express TSHR on differentiation . Shortly after, the capacity of a 
small proportion of human orbital preadipocytes to undergo differentiation in vitro was 
reported50. In common with the 3T3-L1 and rat preadipocytes, orbital preadipocyte
9 / /
differentiation induced TSHR expression . Subdividing the orbital contents into 
preadipocytes and adipocytes demonstrated a functional TSHR only in adipocytes or 
differentiating preadipocytes but not from undifferentiated preadipocytes 179. TSHR 
expression seems therefore to be a marker o f adipocyte differentiation. Furthermore, the 
detection o f TSHR mRNA in Graves’ patients orbital and cervical fat ex vivo by sensitive 
quantitative real-time PCR, would imply an active adipogenic process that is not exclusive
177 0to the orbit and is commented on in early histological reports .
3.1.2 TSHR expression and signalling in differentiated preadipocytes
The expression o f functional TSHR on differentiated preadipocytes has been demonstrated 
but how this might relate to the pathogenesis of Graves’ ophthalmopathy first requires 
investigation o f the effects of TSH on preadipocytes in reproducible cellular models.
From their initial cloning of rat TSHR from epididymal fat 267, Onaya’s group went on to 
examine TSHR expression and signalling in rat and murine preadipocytes and compared it 
to the well characterised thyroid FRTL-5 cell line. Initially they demonstrated TSHR 
expression and TSH dependent cAMP production in differentiated but not undifferentiated 
3T3-L1264. TSHR mRNA expression started around day 5, peaked on day 7, coinciding
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with lipid accumulation. In keeping with this, TSH (10-100mU) stimulated cAMP 
production started on day 7 and increased on days 9 and 11. Expression required 
dexamethasone and IBMX in the first three days. From day 4, insulin alone could induce 
TSHR expression whereas dexamethasone and IBMX alone could not. When the culture 
was continued from day 4 with all three agents (insulin/dexamethasone/IBMX) lipid 
accumulated but cells did not express TSHR. An insulin response element is present in the 
promoter region of the TSHR gene (downstream of TTF-1). In subsequent experiments 
TSH was shown to reduce TSHR expression in differentiated 3T3-L1 in a cAMP 
dependent manner that continued from 1-4 hours . This was different to the initial 
transient increase in cAMP seen in FRTL-5 cells, in addition, adipocytes lacked TTF-1, it 
was concluded that different CRE like activity in the TSHR promoter occurred in the two 
cell types. Further work suggested that differentiation resulted in reduced suppression of 
interaction between two promoters, the CRE like element and an Ets-binding motif that are
• • •  1f \Qpresent upstream of the TSHR gene, that after differentiation can act synergistically . 
Considering the three main transcription factors identified in adipogenesis; C/EBPa,
ADD1 and PPARy, the TSHR promoter lacks both the CCAAT and E-box binding sites of 
C/EBPa and ADD1 respectively. PPARy2 dimerises with RXRa and binds to DR-1, half 
its binding site corresponds to the CRE like element, giving a possible link with the main 
adipogenic transcription factors and TSHR gene expression.
Other factors influencing preadipocyte differentiation and TSHR expression include 
possible effects from cytokines and TSH. The inflammatory cytokines TNFa, hTGFPi and 
IFNy, reduce lipid accumulation, terminal markers of differentiation (LPL, aP2), TSH 
dependent cAMP production and TSHR expression in rat preadipocytes . Despite widely 
different mechanisms of cell signalling the cytokines had a common negative effect on 
adipogenesis. In differentiating rat preadipocytes, TSH resulted in an increase in
771proliferation in a dose dependent fashion and did not decrease apoptosis . (These effects 
occurred in the first 5 days of differentiation which is curious given the expression of 
TSHR mRNA in 3T3-L1 only appeared at 5 days 264). The terminal marker LPL was 
decreased by TSH alongside reduced lipid vacuole size and number. Prolonged incubation 
with TSH rendered the differentiating preadipocytes incapable o f developing lipid droplet 
formation. However, when stimulating cAMP directly using forskolin or dibutyryl cAMP 
almost the opposite was seen. Cell numbers were decreased by high levels of dibutyryl 
cAMP and LPL mRNA expression increased slightly. These effects may be due to other
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signalling pathways being activated by TSH or by the transient rise in cAMP produced by 
TSH signalling contrasted with the continuous stimulation of forskolin and dibutyryl 
cAMP. One such alternative pathway that has been demonstrated in 3T3-L1, human orbital 
and abdominal differentiated preadipocytes is TSH activation of p70 S6 kinase via
• • • 9 7 9 - 977 •phosphoinositol 3-kinase ’ . cAMP may in fact only have a very short window of effect
in the expression o f terminal markers as seen in differentiating 3T3-L1 cells274. In this 
model, cAMP increases aP2 expression by effects on a negative element in the promoter 
but only in confluent preadipocytes, it has no effect on proliferating or differentiated cells. 
In contrast, differentiated 3T3-F442A cells show a marked reduction in LPL and
97Sglycerophosphate dehydrogenase m response to forskolin . From the illustrated 
variability o f cAMP effects on lipid metabolism it is apparent that the pleiotropic nature is 
determined by cell and differentiation specific events.
3.1.3 Cell lines and retroviral transduction
Human orbital preadipocytes can be derived from collagenase digests or from explant
976cultures of orbital fat biopsies . Given the difficulties of small numbers of surgical 
specimens and slower growth rates o f human primary cells we also selected cell lines that 
have adipogenic potential, 3T3-L1, HC C l and MG63. 3T3-L1 cells are a well 
characterised preadipocyte murine cell have already been discussed. MG63 cells are from 
a human osteosarcoma cell line that despite their osteoblastic potential can be switched to 
adipocytes accumulating lipid, expressing PPARy and aP2 when cultured in rabbit serum
977 . HC C l is a recently established human osteoblastic cell line from a bone marrow
9 7 0
aspirate with osteoblastic and adipogenic potential depending on culture conditions
Introducing standard vectors into cells often produce transient expression of the gene of 
interest. Retroviral vectors incorporate into the host genome and result in a permanent 
transduction for prolonged gene expression rather than a temporary transfection. A 
retroviral construct is engineered with the gene of interest downstream of a promoter. The 
retroviral construct then requires further modification by the addition of matrix, capsid and 
nucleoproteins (gag), reverse transcriptase and integrase (pol) and the protein envelope 
(1env) to form complete viral particles that can penetrate cells. Lacking the coding regions 
(gag, pol and env) pLNSX constructs, once packaged, are capable of only one round of 
infection, so-called “replication incompetent retroviruses”. It has been previously
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demonstrated pLNSX vectors containing activating mutant forms o f TSHR have varying 
effects on function and cellular proliferation when examined in COS-7, human thyrocytes 
and FRTL-5 cells 89. The basal cAMP levels of the L629F and M453T mutants were 
similar when examined in COS 7, whereas in FRTL-5 the highest constitutive cAMP
O Q
levels were in M453T transduced cells with L629F having less . In addition, in a case
97Qwith germline M453T mutation, possible proptosis was reported . These two mutations 
could potentially influence preadipocytes with a medium and high level constitutive cAMP 
effect in an attempt to reproduce the sustained stimulation brought about by the action of 
TSAB or TSH.
3.1.4 Aims: to investigate the effects of TSHR activation on adipogenesis using gain- 
of-function TSHR mutations
1. To develop a modified explant preadipocyte harvesting method from small surgical 
specimens.
2. To determine the effects of elevated cAMP from gain-of-function TSHR 
mutations on the proliferation and differentiation of preadipocytes.
This work outlines a method of harvesting primary orbital preadipocytes from small
9 lf\human orbital fat samples modified from a previously described technique 
Human primary orbital preadipocytes from Graves’ ophthalmopathy and normal 
individuals, 3T3-L1, HC Cl and MG63 cells were transduced with retroviral vectors 
expressing activating mutant forms o f TSHR. The different levels of constitutive cAMP 
production induced by the mutant TSHRs were assessed on cell proliferation before 
differentiation. The transduced cells and controls were then differentiated to determine 
effects on lipid accumulation. From previous research we hypothesize cAMP from TSHR 
might have lipolytic effects. Conversely, given the orbital fat proliferation seen in Graves’ 
ophthalmopathy, TSHR activation may also have a proadipogenic role.
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3.2 Materials and Methods
3.2.1 Preadipocyte explant cultures
Human orbital fat samples were obtained with informed consent according to LREC 
approval (information sheet and consent, app.B). Graves’ tissue was retrieved at the time 
of orbital decompression surgery or during routine lid surgery where fat removal was 
beneficial to patient outcome, such as a fat blepharoplasty. Unlike fat samples derived 
from abdominal surgery, orbital fat samples were small (0.25-1.25ml). Collagenase digest 
resulted in low yields of preadipocytes so, as an alternative, undigested fat explants were 
used. This allowed repeated harvesting of preadipocytes from the explants for several 
months.
Samples were transported from theatre on damp swabs or gauze and washed twice in 
DMEM/HAMS/10% FCS in a tissue culture hood (Microflow biological safety cabinet). 
The explants were cut into small pieces (~2-3mm) using sterile blades in 60mm petri 
dishes containing 3ml of red blood cell lysis buffer. The samples were always divided 
between at least two dishes, preferably three, to allow continued preadipocyte harvesting 
in remaining dishes if mould/yeast infections overtook individual culture dishes. The 
explants were evenly spread, 5-10mm apart, on a 60mm petri dish that had been pre-wet 
with 1.4 ml of medium. Fluid volumes were important, too much and the explants floated 
off, too little and the dish would occasionally dry out. Explants were allowed 2-3 days to 
attach, then the medium was changed gently to remove any remaining erythrocytes and 
replaced with 1.5-2.0ml. If explants floated off, the volume was reduced back to 1.4 ml 
and allowed a further 3 days to attach before changing the medium again.
These primary cultures required daily reviews where possible and in the event of a single 
mould colony growing, unaffected explants could be thoroughly rinsed in fresh medium, 
replanted on a new dish and cultures could frequently be continued without regrowth. 
Usually after 4-6 weeks the base of the dishes would be approaching confluence, explants 
were transferred to new dishes and the cycle repeated. Adherent preadipocytes were 
washed with HBSS (app.B) and then detached with 350pl of trypsin (containing 500pM
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EDTA/EGTA, cell lines did not require this addition). Cells were washed twice in 5ml of 
fresh medium, transferred to freezing mix, stored and thawed when required as in 2 .2 .1 1 . 
The longest this cycle was repeated was 9 months. The most significant factor influencing 
duration of culture was the yeast and mould infections of these relatively slow growing 
cells. The explants gradually diminished in size, but however small, if  one could transfer 
and get them to attach by reducing the volume to 1- 1 .5ml, it would continue to seed cells 
onto the dish. In total 11 samples from Graves’ ophthalmopathy patients and 10 from 
patients undergoing other eyelid procedures were collected and stored (patient summaries 
in app.B).
3.2.2 Transformation of competent cells with retroviral constructs
Activating mutant TSHRs had previously been subcloned from an initial pSVL vector into
•  O Q
the retroviral pLNSX vector . Amplification of these constructs required transformation 
o f JM109 competent cells (Promega). pLNSX plasmids (gi:208844) containing the 
following constructs were transformed; L629F280, M453T279, V656F, Del 613-621281, 
C672Y, V509A282, wild type (WT) TSHR and neo.
Competent cells were thawed on ice for 5 minutes, 200pl were added and mixed with lng 
o f each pLNSX construct in tubes chilled on ice and incubated for 30 minutes. Cells were 
then heat shocked at 42 C (Clifton water bath) for 90 seconds to facilitate DNA entry, 
allowed to recover for 2 minutes on ice, before adding 800pl of SOC (app.B) and 
incubating at 37 C in an orbital shaker for one hour. The cell suspension, lOOpl, was then 
streaked onto an LB agar plate (app.B) and incubated overnight at 37 C.
3.2.3 Small and large scale plasmid preparation
Following successful transformation, confirmation o f the plasmid construct and creation of 
a glycerol stock was required. In a small scale plasmid DNA preparation, a single colony 
was picked from the agar plate, inoculated into 5ml LB broth (app. A) and incubated 
overnight in an orbital shaker at 37C. One and a half millilitres o f the overnight culture 
was centrifuged at 8000g (Mikro 22R) for 1 minute. The supernatant was aspirated and the 
pellet vortex washed in 1ml o f SET (app.B), repeat centrifuged, aspirated and the pellet
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resuspended in 150jnl of SET. Five microlitres of lOmg/ml DNAse free RNAse A (app.B) 
was added, vortexed, lysed with 350pl o f lysis buffer (app.B), inverted five times and left 
to stand on ice for 5 minutes. The lysis reaction was stopped with 250pl of sodium acetate 
(app.B), inverted five times, left on ice for 30 minutes and then centrifuged at 8000g, 4 C 
for 30 minutes. The supernatant was transferred to a new tube with an equal volume of 
isopropanol and the DNA pelleted by centrifuging at 8000g, 20C for 30 minutes. The 
pellet was washed twice in ethanol (70% made up in TE app.A), air dried and redissolved 
in 20pl o f TE. Two-three micrograms of DNA was restriction digested with BstEII to 
generate two fragments, 4 and 4.4kb in size, from WT and mutant TSHR plasmids 
(app.B). The products were run on a 1% agarose gel (section 2.2.8) to confirm 
transformation.
For the glycerol stock; 500pl of overnight culture was added to 500pi o f glycerol in a 
1.5ml eppendorf, inverted ten times and stored at -80 C. These stocks were used for 
maxipreps (section 2.2.6) to generate large quantities of DNA for transfection of the 
packaging cells.
3.2.4 Transfection of <|>NX packaging cells with pLNSX-TSHR constructs
The phoenix (<|>NX) packaging cells provided a transient transfection method to create high 
titres o f complete virus particles containing pLNSX constructs 283 and were handled in a 
class 2 biosafety facility observing established guidelines (app.B). Selection was possible 
through the resistance gene for geneticin.
<|>NX cells were maintained in DMEM with 10% heat inactivated FCS. When 70-80% 
confluent, they were detached with a single slap to the flask and plated at 1 x 10 6 cells in a 
35mm petri dish and transfected at 50-60% confluence. For each plate a transfection 
solution was prepared with 5pg of plasmid DNA (WT/neo/629/453) and 50pl of 2.5M 
CaCl2, made up to 500pl with distilled water. This solution was transferred to a 5 ml 
polypropylene tube and while air was bubbled through an automatic pipette, 500pl o f 2  x 
HEPES (app.B) was added dropwise. The solution was left to stand for 20 minutes at 37 C 
and once a white precipitate had formed, it was added to the <|>NX cells. Five minutes 
before the addition o f the transfection solution, 25 pM chloroquine (Sigma) was added to 
the cells. The transfection incubation was continued for 16 hours at 37 C, after which, the
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transfection solution was gently removed and replaced with fresh medium. Retroviral 
supernatants were harvested at 32 C, collected at 24, 48 and 72 hour timepoints after 
transfection and stored in sealed bags at -80 C.
3.2.5 Retroviral transduction of preadipocytes
A group o f preadipocyte cells were selected to create an in vitro model to study the effects 
of increased TSHR stimulation on adipogenesis. Cells were maintained in appropriate 
media; murine 3T3-L1284 (DMEM/CS 10%), human preadipocytes (DMEM/HAMS/ FCS 
10%), human osteo/adipoprogenitor MG63 277(DMEM/FCS 10%) and HCC1278 
(MEM/FCS 10%), all at 37 C in 5% CO2 . Retroviral uptake and insertion of reverse 
transcribed cDNA into the cellular genome resulted in permanent transduction. The 
expression o f TSHR variants were under the control o f the SV 40 late promoter from the 
pLNSX.
Cells were plated when at 60-80% confluence, 3T3-L1, MG63, HCC1 (lxlO 5 cells/35mm 
well) and human preadipocytes IL, HM, GC (5xl03 cells/3 5mm well). After 1 day the cell 
lines were at subconfluent readiness and were incubated in fresh medium containing 
hexadimethrine bromide (polybrene, 8 pg/ml) for 1 hour at 37 C (the primary cells seeded 
at lower densities and slower in growth required up to 6  days). Meanwhile, retroviral 
supernatants containing pLNSX-WT/neo/629/453 were thawed and filtered through a pre­
rinsed 0.45pm filter and polybrene (8 pg/ml) added. The wells were aspirated and 1ml of 
retroviral supernatant was added to duplicates/triplicates of each cell type, incubated for 3 
hours at 37 C, followed by the addition of fresh medium. Geneticin selection was 
commenced 3 days later and continued. As colonies expanded they were transferred firstly 
to T25 and then T75 flasks and when confluent subdivided and frozen (2.2.11). 
Preadipocytes were examined by phase contrast microscopy throughout expansion.
3.2.6 RNA extraction and reverse transcription
Following expansion of the transduced 3T3-L1, MG63 and HCC1 colonies, RNA was 
extracted and reverse transcribed to cDNA in the first step to detect TSHR mRNA. Given 
the slow growth the primary preadipocytes, these cells were reserved for other
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experiments. However the same retroviral supernatants were used to transduce the 
primaries and the MG63 and HCC1 cells.
To confluent 35mm wells, 1ml of Trizol (Invitrogen) was added, aspirated and re-pipetted 
three times and transferred to RNAse free 1.5ml eppendorf tubes. Two hundred microlitres 
of chloroform was added, vortexed, incubated at room temperature for 2  minutes and 
centrifuged for 15 minutes, 4 C, at 12,000g. The clear aqueous layer was removed, taking 
care not to disturb the interface and transferred to a new tube. RNA was precipitated in 
500pi o f isopropanol, mixed, incubated at room temperature for 10 minutes and the RNA 
pelleted by centrifugation for 10 minutes, 4 C, at 12,000g. The supernatant was removed, 
the RNA washed in 1ml of ethanol (75%) and centrifuged for 5 minutes, 4 C, at 7,500g. 
The supernatant was removed, the pellet air-dried and resuspended in 13 pi of TE.
The RNA was then heated to 65 C for 5 minutes (QBT2 hotplate, Grant instruments) and 
3pl used to measure 260/280nm ODs to estimate RNA concentration (2.2.7). One to two 
micrograms of RNA was made up to a volume of lOpl in DEPC water, heated to 65 C for 
10 minutes and lOpl o f RT master mix (app.B) was added. The RNA was reverse 
transcribed (1XA hours, 37 C), enzyme denatured (10 minutes, 95 C) and returned to hold 
(4C) in a thermal cycler (Genius, Techne). The cDNA was stored at -20 C.
3.2.7 PCR amplification of cDNA and PEG precipitation
PCR amplification o f reverse transcribed cDNA was followed by PEG precipitation to 
purify the cDNA before direct sequencing. The human TSHR was amplified from 
transduced murine 3T3-L1 cells using TSHR primers (pair A, Table 3-1) that crossed exon 
7 to 9 prior to sequencing (TSHR mRNA; human (gi:4507700) and murine (gi:6755896)). 
These primers were selected because they specifically amplified human TSHR but not 
murine TSHR. Murine p-actin was amplified using primer pair B to confirm the presence 
o f murine cDNA.
PCR reactions were then performed on 3T3-L1, MG63 and HCC1 using human TSHR 
primers (Table 3-1) to different regions of exon 10: C (WT and 453) and D (629). (PCR 
reactions and programs were carried out as shown in app.B). Resulting cDNAs were added 
to equal volumes of polyethylene glycol (PEG) and left standing for 10 minutes.
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Precipitated DNA was then centrifuged for 30 minutes at 12,000g, the supernatant 
decanted and discarded and the pellet washed with 500pl ethanol 70%. Following another 
centrifugation, 10  minutes at 1 2 ,0 0 0 g and supernatant aspiration, the pellet was air dried 
for 10 minutes in a 40 C oven before finally re-suspending in 1 OOpl of distilled water. 
Confirmation o f the purified product was shown using agarose gel electrophoresis (2.2.8).
Table 3-1 TSHR PCR primers
Forward Reverse Amplicon
A CAA TGG GAC AAA GCT 
GGATG
TCT GAT TTT CTT CTG ATT 
CTT
287bp
B TGT GAT GGT GGG AAT 
GGG TCA
TTT GAT GTC ACG CAC 
GAT TTC C
514bp
C AAA AAC CCC CAG GAA 
GAG AC
GTC CAT GGG CAG GCA 
GAT AC
609bp
D ACT GTC TTT GCA AGC 
GAG TT
GAT GCC AAA CTT GCT 
GAG TAG G
594bp
3.2.8 Direct DNA sequencing of RV transduced 3T3-L1, HCC1 and MG63 cells
Forward and reverse strands o f purified hTSHR were amplified and then sequenced using 
a Dye Rhodamine Terminator kit. Firstly, 10pi single strand PCR reactions were 
performed (app.B) followed by precipitation in sodium acetate (3M, pH5.2). One 
microlitre o f sodium acetate was added to the lOpl PCR product with 30pl 100% ethanol, 
vortexed and precipitated for 10 minutes. Then re-centrifugation, 12,000g for 30 minutes, 
supernatant discarded, the pellet washed in 500pl 70% ethanol before centrifuging 12,000g 
for 10 minutes, supernatant discarded and finally air-drying the pellet. The dye labelled 
cDNA was then analysed on an ABI automatic sequencer.
3.2.9 Cell proliferation and counting
Transduced and non-transduced cell proliferation was determined by direct cell counting 
of trypsinised cells in a Coulter counter (Beckman Coulter), following 3 and 5 days of 
growth in 3T3-L1 and HC C l, 3 days in MG 63, and 7 days in primary preadipocytes.
I l l
Sub-confluent cultures were trypsinised and counted in a haemocytometer chamber and 
after washing were resuspended to give 2 x 104 cells/ml. One millitre was added to six- 
well plates (Costar) allowing triplicate determinations for day 3, and day 5 when required, 
and the plate tilted gently to cover well bottoms. This initial seeding density, 2 x 104 
cells/well, ensured the five day growth was not post confluent. After the required growth 
period, cells were detached, washed and resuspended in 500pl of Isoton (Beckman 
Coulter) and counted in a coulter counter. Cell numbers were reported as a percent relative 
to non-transduced cells.
3.2.10 cAMP accumulation and measurement by RIA
Basal and stimulated cAMP levels were measured in all transduced and non-transduced 
cells. Basal cAMP levels were recorded after a four hour incubation with the 
phosphodiesterase inhibitor isobutylmethylxanthine (IBMX). In addition cells were 
stimulated with TSH and the adenylate cyclase stimulator, forskolin.
Six well plates were loaded with each cell type at 4 x 104 cell/well and left in their 
respective standard media for 24 hours at which time 70% confluence was usually 
achieved. Into all wells fresh medium containing 250mM IBMX was added with 
duplicates for basal (IBMX), 1 and 10 mU of TSH and lOpM forskolin. After a four hour 
incubation cAMP was extracted in 500pl/well of hydrochloric acid (0.1N) and samples 
speedvac dried overnight before storing at -80 C. The cAMP levels were determined in a 
radioimmunoassay with sensitivity to below 5 fM and were carried out by Dr M Ludgate 
. One well was used to determine cellular protein levels to normalise for differences in 
cellular proliferation. The trichloroacetic acid precipitation method was used for protein 
estimation (2.2.3).
3.2.11 TSHR immunocytochemistry
Cells were allowed to attach to coverslips placed in 6 -well plates overnight. They were 
then rinsed with PBS and fixed with ice-cold acetone for 5 seconds. Endogenous 
peroxidase was inhibited with 0.025% periodic acid and rinsed with PBS-T-gelatine (PGT, 
app.B) for 5 minutes. A Vectastatin Elite ABC kit (Vector Labs) was used for the
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following protocol (www.vectorlabs.com/data/descriptions/pdf/PK7200.pdf). Samples 
were blocked in diluted horse serum for 10  minutes, followed by an avidin/biotin blocking 
step and washing with PGT. Primary antibodies were diluted 1:100 and incubated for 90 
minutes followed by 3, 5 minute washes with PGT. The negative control omitted the 
primary antibody. The secondary antibody incubation was for 30 minutes with biotinylated 
anti-mouse IgG followed by 2, 5 minute washes with PGT. Avidin/biotin crosslinking 
required 5 minutes incubation with the ABC reagent and was washed twice for 2 minutes 
with PGT. Antibody/biotin/avidin/ peroxidase complexes were visualised with the 
chromogen diaminobenzidine tetrahydrochloride (DAB) 0.001% and hydrogen peroxide 
0.01% in PBS for 2-3 minutes and washed in PGT twice for 10 minutes. Counter staining 
with haematoxylin required 30 seconds, a tap water wash, dehydration in 100% alcohol 
twice, fixed in xylene twice and then mounted with DPX (Sigma-Aldrich) onto 
microscope slides. Images were captured using a Zeiss digital charge coupled device 
(Axiocam).
3.2.12 Lipid staining
Following differentiation or when assessment o f lipid content was required oil red-0 
(ORO) staining was performed. Stock solution of ORO was diluted 3:2 with distilled 
water, mixed, allowed to stand for 15 minutes and then filtered before using. Cells 
mounted on coverslips were fixed in 60% isopropanol for 1 minute, stained with ORO for 
15 minutes and washed 3-4 times in 60% isopropanol. Cells were counterstained with 
haematoxylin for 1 -2  minutes, fixed in 60% isopropanol for 1 minute and then mounted in 
glycerol. The average percentage, from two coverslips, o f cells containing lipid inclusions 
used a 1 0  x 1 0  eyepiece mounted graticule in a 10  times field of magnification and 
averaged ten continuous non-adjacent sampled areas per coverslip.
3.2.13 Preadipocyte differentiation
The full differentiating conditions for 3T3-L1 cells were in DMEM medium containing 
10% fetal bovine serum (FBS), lOmg/ml insulin, 0.2mg/ml dexamethasone and 0.5 mM 
IBMX for 3 days (Sigma). After which, cells were kept in DMEM containing 10% FBS 
and lOmg/ml insulin and re-fed on alternate days 264. Human preadipocytes were
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differentiated in medium consisting of DMEM: F-12 (1:1) supplemented with 3% FCS,
160 mM insulin, 1 pM dexamethasone, and for the first 3 days only, 1 pM pioglitazone 
and 250 pM IBMX (modified from ). Cultures were maintained in this medium for 14 
days. Cell percentages containing lipid were determined as above (3.2.12).
3.2.14 Nile red flow cytometry for lipid accumulation
The high level of ORO staining in post confluent undifferentiated 3T3-L1 made it difficult 
to distinguish differences between the differentiation methods. Nile red is a fluorescent 
lipophyllic dye that is highly selective for lipid vesicles in cells. It has been used in flow 
cytometry to quantify proportions of differentiated orbital preadipocyte populations 
accumulating lipid
3T3-L1 transduced and non transduced cells were treated as above with either the full 
differentiating or non-differentiating protocol. Cells were detached with 5mM 
EGTA/EDTA in PBS/BSA (section 2.2.15), fixed in 0.5% paraformaldehyde and then 
stained in O.lpg/ml Nile red for 10 minutes. Stained cells were washed and resuspended in 
PBS/BSA and fluorescence (530-6lOnm) measured in the FL2 channel FACScan 
cytometer. Forward and side scatter plots were generated to gate out non viable cells. 
Gated plots with forward scatter on the x axis and FL2 on the y were examined for a right 
shift with larger cells staining with lipid.
3.2.15 Statistical analysis
Means were compared non-parametrically by Kruskal Wallis and post hoc by Dunns 
multiple comparison test and parametrically by ANOVA with post hoc TUKEY HSD 
using software as in 2.2.23.
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3.3 Results
3.3.1 Explants shrink in long term culture but can exert a positive effect on 
adjacent cell lipid content
During the long term explant cultures it was possible to harvest preadipocytes every 6 -8  
weeks for as long as 9 months. During this time explants decreased in size with lipid 
accumulating on the surface of the media suggesting lipolysis. Additionally, lipid filled 
preadipocytes would cluster, adjacent, beneath, and at the end of thin strands of connective 
tissue remaining following explant contraction (Figure 3.1.A and B). These vacuoles were 
visible by contrast microscopic examination and lipid confirmed by oil red- 0  staining 
(Figure 3.1.C). Once present, the vacuolated cells seemed to persist and a cluster of cells 
could often be recognised unaltered until the cells were harvested. These appearances 
could be modified. Adding excess media, detaching the explants and not allowing them to 
reattach and continuing the culture for two weeks reduced the numbers of cells staining 
with lipid (Figure 3.2.B). If the explant was completely removed from the well for the 
same length of time (2  weeks) the cells assumed a uniform fibroblastic appearance with no 
lipid (Figure 3.2.C). Another recognisable feature was the further away from the attached 
explant the fewer cells were found to contain lipid, but still contained vacuoles (Figure 
3.2.D). Therefore, both the presence and proximity to the explant seemed to alter the cell 
monolayer. The florid appearances seen in Figure 3.1 were infrequent, but developed in 
some of both the Graves’ and normal tissue samples.
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Figure legends
Figure 3.1 Fat explants
A. Some fat explants, whether from Graves’ orbits or normal orbits, had vacuolated cells 
adjacent to them. These cells, once present did not appear to alter in morphology. (Insert 
shows the proximity o f vacuolated cells to the explant (dark shadow, bottom edge)). [PSM, 
contrast microscopic image, xlO insert and x40 main].
B. Vacuolated cells can gather at the edge of thin strands o f connective tissue that 
remained after the explants had contracted. [PSM, contrast microscope x40].
C. Vacuolated cells contain lipid. [PSM, oil red-0 x40].
Figure 3.2 Fat explants
A. Rounded lipid containing cells present, beneath and adjacent to undisturbed explants. 
[PSM, or-O x40].
B. Detaching the explants and allowing them to float in the media above the cell 
monolayer for two weeks reduced lipid containing cells number and volume. [PSM, or-0 
x2 0 ].
C. Removing the explants from the cell monolayer for the same period resulted in cells 
with a uniform fibroblastic appearance and no lipid inclusions. [PSM, or-0 x20].
D. Some cell clusters could be identified away from explants that by altering the condenser 
on the microscope, have numerous small vacuoles but only faint traces of lipid staining. 
The florid lipid filled morphology was only a feature of cells adjacent to or beneath 
explants as in A. [PSM, or-0  x40].
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Figure 3.1 Fat explants
Figure 3.2 Fat explants
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3.3.2 Competent cells were transform ed with pLNSX constructs and sequencing 
confirmed m utant forms of TSHR
JM 109 cells were transform ed w ith pLN SX  constructs and transform ation was confirm ed 
by endonuclease restriction w ith BstEII (Figure 3.3), transform ed cells w ere used for 
m axipreps. The purified D N A was packaged into com plete viral particles by <|>NX 
packaging cells and supernatants collected for transduction o f  preadipocytes. To confirm  
retroviral transduction o f  preadipocytes, direct DNA sequencing was perform ed after 
G418 antibiotic selection. Forw ard and reverse strands o f  m RN A  were shown to contain 
the appropriate nucleotides. M ethionine to threonine substitution occurs from  an ATG- 
A C G  m utation at point 453 and leucine to phenylalanine occurs at point 629 from a TTG- 
TTT m utation (Figure 3.4).
Figure 3.3 Restriction digest of pLNSX-TSHR transform ed cells
BstEII restriction o f  pLN SX  transform ed cells. W T and m utant TSH R cut (long arrow) to 
produce 4 and 4.4kb fragm ents. (Unrestricted plasm ids-short arrows. pLN SX  neo has only 
one BstEII restriction site and is linearized).
Ladder
1kb
pLNSX-WT pLNSX-Neo pLNSX-629 pLNSX-453 pLNSX-656 672 509 DEL
I i * * *
5kb
4kb
f *
« .
9  :  2 * » ww  W  w  W
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Figure 3.4.DNA sequencing of transduced cells
Transduction o f  preadipocytes w ith TSH R was confirm ed by direct sequencing. 
E lectropherogram s showing peak dye fluorescence o f  PC R am plified cDNA, nucleotides 
are shown from  pLN SX  transduced HC C l cells. The M 453T m utation results from  an 
A TG  to A C G  point nucleotide substitution and the L629F results from  a TTG  to TTT 
m utation.
Forward
sequence
Wild type 
sequence
TCTdAT'dTG CAAC  
2J40
M453T 
sequence
T C T (oA C ‘GT g c a a c  
‘ 2 4 0
L629F
sequence
' TGT d f  T T & T C T T  C
370
Reverse
sequence
1 T GCAC A V.G AG AA
G 418 selection o f  cells transduced w ith the W T, M 453T and L629F resulted in the 
appearance o f  resistant colonies. H ow ever the neo retroviral supernatants did not generate 
antibiotic resistant cells. Consequently non-transduced and pLN SX W T cells served as 
control for com parison w ith the m utant transduced cells.
3.3.3 Varying effects on cell proliferation are seen in transduced cells, inhibition 
predominates in human preadipocytes with activating TSHR mutations
A range o f  effects on cell proliferation were seen on the transduced cells (Table 3-2).
Cells were initially exam ined after 3 days growth, stim ulation developed in 3T3-L1, 
inhibition in HCC1 and hum an prim aries and no apparent effect on M G63 w hen com pared 
to non-transduced cells. Further experim ents looked at proliferation over 3 and 5 days in 
3T3-L1 and HCC1 cells.
A .G  A '|A A 7 jjC A C A G  C
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Firstly 3T3-L1 stimulation, significant differences were present between the cell types 
(p<0.0005 KW, Figure 3.5). At both 3 and 5 days, L629F showed increased cell numbers 
relative to non transduced cells (190% (p<0.001)- 158% (p<0.05)(Dunn post hoc)). 
However, at 5 days WT cells proliferated significantly relative to non transduced cells 
(150%, p<0.05) and at no time was L629F proliferation significantly greater than WT. 
M453T cells proliferation o f 121% was not significantly greater than WT or non 
transduced cells at either time point.
In HCC1 cells, some inhibition was present in transduced cells on both days (p<0.0124- 
p<0.001 (KW), Figure 3.6). Significant WT inhibition was seen at 3 and 5 days 
(83%(p<0.01)-58%(p<0.001). Inhibition o f L629F and M453T was minor and only 
significant in M453T at 5 days (70%, p<0.01). At no timepoint was there a significant 
difference between WT, M453T and L629F transduced cells.
Before transduction the differences in proliferation rates between cell lines and primary 
preadipocytes was already profound. After transduction, cell lines would require flask 
passages 2-3 times/week while primary preadipocytes would be passaged once in 3-6 
weeks, particularly longer in those cells transduced with activating mutations. 
Accumulating enough cells for other experiments at these growth rates made studying the 
primary preadipocytes a lengthy procedure. The reduced proliferation rate required 
experiments lasting 7 days. Graves’ orbital preadipocytes showed reduced proliferation in 
transduced cells relative to non transduced (p<0.0001(ANOVA), Figure 3.8). Reduced WT 
(77%, p=0.064) was not significant while both L629F (67%, p=0.009) and M453T (34%, 
p<0.0001) were significant, relative to non-transduced. M453T proliferation was 
significantly less than WT (p=0.002) and L629F (p=0.012), but L629F and WT did not 
differ significantly.
Normal orbital preadipocytes showed reduced proliferation in all transduced cells relative 
to non transduced at three days (p=0.0036(KW), Figure 3.9). The severely reduced 
proliferation in growth o f the M453T transduced cells was such that despite several 
colonies resistant to G418 selection, even after 4 months of growth, insufficient cells grew 
to allow any experiments to be performed. The only significant reduction between the 
groups o f cells was between non-transduced and L629F (38%, p<0.05).
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In MG63 differences in proliferation effects were seen (p=0.002 (KW), Figure 3.7). 
Relative to non-transduced, WT (84%) showed inhibition while L629F (114%) and 
M453T (113%) proliferated slightly, no differences were significant. However there was 
apparent stimulation when comparing WT to both L629F (p<0.01) and M453T (p<0.05).
Table 3-2 Transduced vs normal cell proliferation rates
Proliferation percentage calculated by: numbers o f transduced/ non-transduced cells 
expressed as a percentage (non-transduced shown as 100%). Mean and standard error of 
mean are recorded. ( * p<0.05 relative to non-transduced. # p<0.05 relative to WT).
Non-
transduced pLNSX WT pLNSX 629 pLNSX 453
3T3-L1: 
3 days 
(n=1 2 ) 
5 days
100 (1.9) 133.9 (8.7) 190.5 (11.6) * 121.9 (15.3)
1 0 0  (0 .8 ) 150.0 (9.3)* 158.6 (18.6) * 121.4 (11.9)
HC C l: 
3 days 
(n=15) 
5 days
100 (0.7) 82.8 (4.4)* 95.9 (6.5) 92.7 (2.9)
1 0 0  (0 .6 ) 57.9 (5.7)* 79.5 (6.2) 70.2 (4.8)*
MG 63 (n=6 ) 100 (2.7) 84.3 (5.0) 114.3 (1.3)# 113.8 (6.2)#
Non GO 
(n=3) 100 (9.9) 62.9 (4.0)* 38.3 (1.3)* -
GO (n=3) 100 (7.9) 77.2 (5.1) 66.5 (4.1)* 34.4 (2.6)*#
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Figure 3.5 Proliferation of 3T3-L1 cells
Cell proliferation of transduced 3T3-L1 cells relative to non-transduced. Significant 
proliferation is shown in L629F transduced cells but also WT (Dunn post hoc).
P<0.05 ♦
______________________________P<0.05
____________________P<0.001
non infected pLNSX-WT-TSHR pLNSX-629-TSHR pLNSX-453-TSHR
3T3-L1 cell types
■ 3 days grow th ■ 5 days grow th
Figure 3.6 Proliferation of HC C l cells
Cell proliferation in HC Cl cells is reduced in WT while only minor effects are seen on 
L629F and M453T cells that are greater at 5 days.
PC0.001 
___________________P<0.01 ^
1 2 0 --------------------------------
non transduced pLNSXW m -R pLNSX629-TSKR pLNSX453-TSI-R
HC Cl oell types
1 3  days cell growth n 5 days cell growth
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Figure 3.7 Proliferation in MG63 cells
Proliferation in M G63 cells showed m inor reduction in W T num bers and m inor 
proliferation w ith L629F and M 453T but changes were not significant at three days 
relative to non transduced cells. W ith these opposite effects, significance w as seen 
betw een the inhibited W T and the proliferating L629F and the M 453T.
4_____________________________________________________P < 0 .05  #
*______________________P<0.01 #
1401-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
non transduced pLNSX-WT-TSHR pLNSX-629-TSI-f! pLNSX453-TSHR
MG63 cell line
Figure 3.8 Proliferation in Graves’ orbital preadipocytes
G raves’ orbital preadipocytes showed reduced proliferation in all transduced cells relative 
to non transduced at seven days and was significant in L629F and M 453T. M 453T 
proliferation was significantly less than than W T and L629F, but L629F and W T did not 
differ significantly.
non transduced pLNSX-WT-TSHR pl_NSX-629-TSHR pLNSX-453-TSHR
GO preadipocytes
Figure 3.9 Proliferation in normal orbital preadipocytes
N orm al orbital preadipocytes showed reduced proliferation in all transduced cells relative 
to non transduced at seven days and was significant in L629F. L629F and W T did not 
differ significantly. Proliferation in the M 453T cells was so profound that insufficient cell 
num bers could be collected for experim entation.
P < 0 .05
non transduced pLNSX-WT-TSHR pLNSX-629-TSHR
Non GO preadipocytes
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3.3.4 Basal cAMP production can be elevated by transduction with activating 
TSHR mutations. M453T generates more basal cAMP than L629F
In 3T3-L1 cells basal cAMP showed some low level increase in transduced cells but was 
not significant (p=0.174(KW), Figure 3.10). Presence o f a functioning TSHR in the WT 
transduced cells was suggested by the positive dose response effect seen with a rising 
concentration o f TSH.
In HCC1 cells basal cAMP was raised in WT transduced but not L629F or M453T 
activating mutations but did not achieve significance (p=0.342, KW, Figure 3.11). There 
was no dose response effect present in WT transduced cells questioning the expression of 
receptor in these cells while there was a slight rise at ImU TSH in the M453T transduced 
cells.
In the MG63 cells, transduced cells had less basal cAMP than non transduced (p=0.01, 
KW, but none were significant with post hoc testing, Figure 3.12). The presence o f a dose 
response TSH effect in WT transduced and non transduced raised the possibility of TSHR 
expression in the non transduced cells.
In Grave’s orbital preadipocytes transduced cells had less basal cAMP than non transduced 
(p=0.328, ANOVA, Figure 3.13) and a normal WT transduced TSH dose response effect.
In normal orbital preadipocytes a slight rise in transduced cells basal cAMP was present 
(p=0.102, KW, Figure 3.14) and a normal WT transduced TSH dose response effect.
The predicted basal rise o f cAMP of activating mutations above non transduced cells was 
present in only 3T3-L1 and normal orbital preadipocytes. However it is noteworthy that in 
all cell types L629F basal levels are lower than M453T.
The response to TSH in the mutant transduced cells was in general only very slight and did 
not achieve significance in either 1 or lOmU of TSH (3T3-L1, HCC1, MG63, normal 
orbital). The only group in which TSH signalling appeared to continue in both 1 and 1 OmU 
TSH (pO.OOOl and p=0.007 respectively, KW) was the Graves’ preadipocytes.
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Figure 3.10 cAMP production by 3T3-L1 cells
Basal cAMP production in 3T3-L1 cells is slightly elevated by activating mutants L629F 
and M453T. There is an expected dose response effect of increasing TSH concentration on 
the WT transduced cells. Forskolin activates cAMP in all cell types. (N=2, hence no error 
bars).
■  non transduced ■  pLNSX-WT-TSHR □  pLNSX-629-TSHR npLNSX-453-TSHR
IBMX Im uT SH  10m uTSH Forskolin
3T3-L1 cAMP stimulation conditions
Figure 3.11 cAMP production by HCC1 cells
HCC1 cells cAMP production shows no elevation by the activating mutants and lacks a 
dose response effect from the WT transduced cells. (N=2, hence no error bars).
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IBMX Im uT SH  10m uTSH Forskolin
HCC1 cAMP stimulation conditions
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Figure 3.12 cAMP production by MG63 cells
M G63 cells show no increase in basal cAM P in the transduced cells. The TSH dose 
response effect is seen in both W T transduced and non transduced cells suggesting 
functional TSH R in these cells. Low response to forskolin may suggest a 
phosphodiesterase insensitive to IBM X. (N=2, hence no error bars).
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IBMX Im uT SH  10m uTSH Forskolin
MG63 cAMP stimulation conditions
Figure 3.13 cAMP production by Graves’ orbital preadipocytes
G raves’ orbital preadipocytes showed no increase in basal cAM P in transduced cells. W T 
transduced cells showed the expected dose response effect while both m utant form s appear 
to respond to TSH stim ulation. (N=4)
3 0 0  1------------------------------------------------------------------------------------------------------------------------------------------------------------------
25 0
IBMX Im u T S H  10m uT SH  Forskolin
GO preadipocytes cAMP stimulation conditions
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Figure 3.14 cAMP production by normal orbital preadipocytes
N orm al orbital preadipocytes show an increase in basal cAM P in transduced cells along 
w ith the expected TSH dose response effect in the W T transduced cells. Response to 
forskolin is low  in W T and L629F cells.
25  -------------------------------------------------------------------------------------------------------------------------------------------------------------
IBMX Im uT S H  10m uTSH Forskolin
Non GO preadipocytes cAMP stimulation conditions
3.3.5 HCC1 cells did not uniformly express TSHR, while transduced and non 
transduced MG63 cells express TSHR and accumulate lipid
ICC for TSH R on HCC1 cells showed some sporadic staining using antibody 3G4 (and 
23.1) o f  M 453T transduced cells that also showed a m ild rise in cAM P on stim ulation w ith 
Im U  o f TSH (Figure 3.15). O ther cell types exhibited background staining in keeping with 
absence o f  dose response effects to TSH in cAM P production (Figure 3.11).
ICC for TSH R on the MG63 cells showed transduced and non transduced cells both 
expressed low  levels o f  the receptor including the sulphated form (Figure 3.16). This is 
consistent w ith the increased levels o f  cAM P seen by stim ulating these cells w ith TSH 
(Figure 3.12). In keeping w ith differentiating preadipocytes expressing TSHR, alm ost 
universally, M G63 cells accum ulate small lipid vesicles in transduced and non transduced 
cells. No HCC1 cells accum ulated lipid. W ith the expression o f  both TSH R and lipid in 
the MG63 cell line it would suggest they are further along the pathw ay from  preadipocytes 
to adipocyte than the other preadipocytes exam ined here.
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Figure legends
Figure 3.15 Immunocytochemistry for TSHR on HCC1 cells
Very faint background staining developed with both antibodies in transduced and non 
transduced cells. Some sporadic M453T transduced cells showed specific staining with 
3G4 antibody similar to the positive control cells, GPI-TSHR. These M453T cells also 
showed a slight rise in cAMP with 1 mU o f TSH. (Mag.x40, chromogen-DAB, 
counterstain-haematoxylin).
Figure 3.16 Immunocytochemistry for TSHR and oil red-O staining of MG63 cells
In keeping with the cAMP rise caused by TSH, both transduced and non transduced cells 
demonstrate mild positive staining by ICC for TSHR that was easier to detect with 
antibody 3G4 than 23.1. Additionally, lipid accumulation in small vesicles o f all cell types 
supports the link between TSHR expression and preadipocytes differentiation. (ICC; 
mag.x40, chromogen-DAB, counterstain-haematoxylin. Lipid; mag.x20, oil red-O, 
counterstain-haematoxylin).
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Figure 3.15 Immunocytochemistry for TSHR on HCC1
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Figure 3.16 Immunocytochemistry for TSHR and oil red-O staining on MG63
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3.3.6 Cell proliferation inhibition has contrasting effects on lipid accumulation in 
prim ary preadipocytes
Activating TSH R transduction produced no spontaneous lipid accum ulation within the 
norm ally passaged cultures o f  3T3-L1, HCC1, normal and G raves’ orbital preadipocytes. 
As m entioned previously non transduced MG63 cells accum ulate lipid with no discernable 
effects o f  transduction when assessed by ORO staining.
In differentiating conditions both transduced and non-transduced 3T3-L1 cells accum ulate 
small lipid vacuoles spontaneously after growth arrest at confluence that occurred early in 
the 14 day culture. Quantification by visible lipid accum ulation could not detect variations 
in differentiation in the 3T3-L1 cells transduced with activating m utations. For both 3T3- 
L1 and M G63 lipid assessm ent by this m eans lacked sensitivity. Flow cytom etry using 
N ile red was carried out on differentiated, undifferentiated, transduced and non transduced 
3T3-L1. This dem onstrated the same problem  in that all cells would take up Nile red and 
fluoresce ju st as they had done for ORO (Figure 3.17). Other fat cell m arkers such as 
m RNA for PPARy, aP2 or triglyceride would be required to further assess cellular 
differentiation.
Figure 3.17 Nile red flow cytometry in 3T3-L1 cells
Undifferentiated (open histogram ) and differentiated (filled histogram ) 3T3-L1 cells 
universally accum ulate variable sized lipid vacuoles after reaching confluence. W ithout 
the lipophyllic nile red stain, fluorescence is less than 102 for both groups o f  cells. 
Fluorescence increases equally with nile red in both groups confirm ing the finding with oil 
red -0  that all 3T3-L1 cells accum ulate lipid in these conditions.
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In hum an preadipocytes no lipid accum ulation was seen in the non-differentiating 
conditions. PPARy induced differentiation showed significant variation betw een the lipid 
accum ulation o f  transduced cells from  a G raves’ orbit relative to non transduced 
(p<0.0001, KW ), W T (44% ), L629F (445% ) and M 453T (0%) (Figure 3.18). Post hoc 
testing did not identify significant differences betw een the groups because o f  the small 
sample size and inability to repeat experim ents w ith the slowly proliferating cells. 
Similarly in the transduced norm al orbital preadipocytes, lipid accum ulation was 
significantly different (pO.OOOl, KW ), W T (225% ) and L629F (0%) but no significant 
differences were present betw een transduced and non-transduced cells. There appeared to 
be a biphasic pattern o f  lipid accum ulation in relation to cell proliferation in hum an 
prim ary preadipocytes. In transduced cells w ith a m oderate reduction in proliferation 
(-6 5 %  relative to non-transduced) there was an increase in lipid accum ulation, G raves’ 
L629F (444% ) and norm al W T (225%). In contrast, in cells whose proliferation was 
inhibited the greatest (-30% ), despite m orphological changes characteristic o f  
adipogenesis, cell clustering and rounding up o f  the normally slender fibroblast, no lipid 
accum ulation developed in either G raves’ M 453T or normal L629F (Figure 3.19). In the 
normal orbital, L629F, the failure o f  lipid accum ulation and greatest reduction in 
proliferation also coincides w ith the cell type with the highest basal cAM P.
Figure 3.18 Lipid accumulation in prim ary preadipocytes varies in transduced cells
In normal orbital preadipocytes, W T transduced cells accum ulate m ore lipid than non 
transduced and L629F don’t accum ulate any lipid. In G raves’ preadipocytes there are also 
variations. The cell types that don’t accum ulate any lipid (non GO L629F and GO 
M 453T). (N=2)
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Figure 3.19 Lipid accumulation in Graves’ orbital preadipocytes
Discrete cells developed lipid containing vacuoles when differentiated in the presence of 
PPARy agonist apart from those whose proliferation was inhibited the greatest, M453T 
(upper panel). Differentiated cells also tend to cluster and alter shape becoming rounded 
and lose the slender fibroblastic appearance of their undifferentiated counterparts (lower 
panel).
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3.4 Discussion
Orbital fat is scarce for investigators to come by and highly passaged preadipocytes lose 
their ability to differentiate. Standard practise for explant cultures is to discard the explant 
after sufficient cells have gathered and then to continue monolayer cultures to expand cell
77Anumbers . Modifying the culture by removing the explant and allowing them to reattach, 
we were able to harvest first passage preadipocytes for many months from the same 
explants. Fat explants in long term culture reduced progressively in size, liberated lipid 
into the medium and away from the explants themselves, underwent morphological 
changes to that o f a fibroblast. These changes were consistent with adipocyte 
dedifferentiation. A time course study o f explanted fat showed changes occur within the
7R7first 48 hours . The medium of explants developed increased, TNFa, anaerobic 
glycolysis and lipolysis. There was also a rapid reduction in expression of adipocyte 
specific genes; hormone sensitive lipase, lipoprotein lipase and PPARy2. These changes 
could be reduced by agents that elevate cAMP (IBMX/forskolin). In our experience, 
despite the explants’ dedifferentiation and inexorable shrinkage, outgrowth of cells 
continued undiminished with the rate-limiting factor for culture duration always being 
mould infection.
In some cultures, cells adjacent to explants accumulated lipid and maintained vacuoles that 
did not appear to dedifferentiate over 6-8 weeks of culture. This morphology did not 
persist when explants were removed. This raises interesting possibilities that explants 
either; maintain the morphology of partially dedifferentiated adipocytes that have migrated 
onto the plate or that preadipocytes are being differentiated and maintained by paracrine 
factors present in the explant. The fact that fat conditioned medium (fat floating in the 
medium) does not maintain the phenotype might suggest soluble factors alone are 
insufficient and that either cell contact or extracellular matrix are important. Two 
preadipocyte surface receptors that may be involved with this paracrine action; leukaemia 
inhibitory factor (LIF) receptor and prostacyclin receptor, have proadipogenic effects via
780both C/EBPs . However, both LIF and prostacyclin are secreted by preadipocytes and 
not adipocytes. LIF signals via the extracellular signal related kinase (ERK) pathway, 
prostacylin by cAMP production and both have a common downstream effector, cAMP 
responsive element binding protein/activated transcription factor 1 (CREB/ATF1)290.
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Returning to our primary aim of examining adipogenesis in the presence of elevated 
cAMP using gain-of-function TSHR mutations, perhaps the clearest effects were 
demonstrated in the normal orbital preadipocytes. We show increased basal cAMP, 
significant inhibition o f undifferentiated preadipocyte proliferation and reduced lipid 
accumulation despite morphological changes suggestive of differentiation. The inhibition 
in the M453T transduced cells was so profound that from the initial colonies sufficient 
cells never accumulated to be studied..This inhibitory trend on proliferation was also seen 
in the Grave’s orbital preadipocytes and HCC1 cells. This reduced proliferation is in
901keeping with the effects seen m NIH3T3 cells expressing activated Gas . The cAMP 
stimulation activated protein kinase A (PKA), inhibited Ras proliferative signalling and 
arrested fibroblasts in Gj.
Different effects were seen on the cell proliferation of transduced 3T3-L1 cells. A 
moderate rise in basal cAMP induced by the L629F mutation was accompanied by an 
increase in cell proliferation at 3 days but after 5 days the WT/L629F transduced cells 
were all shown to proliferate significantly relative to non-transduced. However, the 
increase in cell numbers is affected by cell density and this is particularly an issue with the
971rapidly proliferating 3T3-L1 cells , whereby the number o f L629F cells may have been 
inhibited by approaching confluence after 5 days of culture and the data at 3 days may be 
more representative. Similarly in MG63 cells proliferation was seen with L629F and 
M453T above that o f WT but not above non transduced cells. These seemingly opposite 
effects occurring in the cell types are likely to be due to different cell specific cAMP 
signalling and recruitment of pathways such as mitogen-activated protein kinase (MAPK)
909' 909among others (reviewed in ’ ). Uncommonly cells proliferate in the presence o f cAMP
(thyroid/pituitary) as did the transduced 3T3-L1 and MG63. Additional similarities: 3T3- 
L1 readily differentiate into adipocytes that express TSHR and MG63 cells already express 
TSHR and accumulate lipid. (The MG63 cell line has previously been shown to express 
TSHR294 and our ICC and cAMP data support these findings). More commonly cAMP has 
inhibitory effects on cell growth as in the transduced human preadipocytes and HCC1 
cells, as mentioned above, similar to the effects seen in NIH3T3 cells expressing activated
901Gas • Alternatively other pathways such as the inositol phosphate-diacylglycerol cascade
9qc
have also been shown to be activated by mutant forms o f TSHR and the Gpy protein
subunits may be signalling 296.
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In differentiated normal preadipocytes a slight rise in basal cAMP increased lipid 
accumulation, higher levels completely inhibited lipid accumulation in what appeared to 
be differentiated cells. From these studies it is unclear whether this represents variation in 
cAMP induced lipolysis or altered adipocyte differentiation. During differentiation cAMP
9Q7
elicits a pro-adipogenic effect first described in 1976 using IBMX and PGF2a
• • Q^O
Elevation o f cAMP by IBMX rapidly reduces the differentiation suppressing WntlOb 
CREB activation alone was shown to be sufficient to induce adipogenesis in 3T3-L1131 
and CREB induced the important PPARy co-activator, P G C -la  gene expression 299. 
Alternatively the lipolytic potential o f cAMP has long been described (1970), whereby 
cAMP activated protein kinase increases lipase activity 30°. Adrenergic induced cAMP 
elevation causes translocation of hormone sensitive lipase from the cytosol to the
™ i
membranes o f lipid vesicles prior to the release of glycerol . However the changes of 
apparent adipocyte morphology without the lipid vacuole formation has been seen 
previously, reported in 1981, in the presence of prolonged elevation of cAMP during 
adipocyte differentiation . The altered morphology was probably due to reduction in 
actin (amongst other proteins). The lipid accumulation was reduced due to decreases in 
key lipogenic enzymes (fatty acid synthase, malic acid and glycerophosphate 
dehydrogenase) and was not as a result o f increased lipolysis.
Similarly in differentiated Graves’ orbital preadipocytes a slight reduction in proliferation 
was seen in line with increased lipid accumulation whereas greater inhibition of 
proliferation completely stopped visible lipid accumulation. However, proportional 
changes in basal cAMP were not detected and this maybe due to sampling error. We would 
have predicted that all cells transduced with L629F and M453T would have had basal 
increases in cAMP. This was not the case; one possible explanation is the presence of a 
phosphodiesterase insensitive to IBMX. Alternatively we measured basal increase cAMP
OQ
after four hours, similar to that used for FRTL-5 cells, but longer than the 30 minutes 
used by other groups for 3T3-L1 264. With the action o f multiple different 
phosphodiesterases terminating cAMP signalling, time course studies o f cAMP kinetics 
would ideally be undertaken for each cell type to understand possible variation in cAMP 
levels developing in the transduced cells.
An impression o f the negative effects o f TSHR activation on lipid accumulation in human 
preadipocytes is given by our experiments. The impact of TSHR activation in 3T3-L1 is 
not evident from our experiments. A much shorter differentiation time is required for
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murine and rat preadipocytes (7-9 days) than human (15-20 days). Our experiments 
allowed both to proceed for 14 days. In rat preadipocytes lipid accumulates in 85% of cells
971after 5 days and increases to greater than 90% at 9 days . Direct cell counting o f ORO 
stained cells was our only method to assess adipogenesis, other groups include estimation
770 •  •of lipid vacuole size . Difficulties counting large numbers of lipid staining 3T3-L1 cells 
manually lead us to Nile red staining with flow cytometric counting. This confirmed what 
we found with direct cell counting but may be o f use when smaller proportions o f the cells 
populations accumulate lipid as in human preadipocytes. Conversely ORO could miss cells 
(fig 3.1.2.D) that have possibly undergone lipolysis whose vacuoles do not stain. Relying 
on lipid staining to measure adipogenesis is insufficient and additional parameters such as 
glycerol, free fatty acids or markers o f terminal differentiation (LPL, PPARy, ACRP30) 
would be supportive o f adipogenesis in future work.
The use o f pLNSX-WT cellular transduction with activating mutations was effective in the 
main in inducing a TSH dose response elevating cAMP (apart from HCC1 cells). TSH 
dose response effects from mutant expressing cells were generally low in all cell types but 
the Graves’ orbital preadipocytes. TSH signalling was maintained in these cells in both 
pharmacological concentrations (1 and lOmU). It has been shown both in vitro and in vivo 
that activating mutations are often poorly expressed at the surface o f cells contrasting with
• 7JMV 'lA'lthe high surface expression of TSHR in Graves’ disease ’ ’ . It is a curious finding in
Graves’ disease that in spite o f continual receptor stimulation by TSAB the normal 
inducible cAMP early repressor mechanism of down-regulation of TSHR does not occur 
304. It would seem similarly uncharacteristic that mutant forms o f TSHR are readily 
signalling in preadipocytes derived from a Graves’ patient and one can only speculate on 
possible causes o f both these processes.
How then might TSHR activation via TSAB have a proadipogenic role in Graves’ 
ophthalmopathy? From our work we see that a moderate reduction in cell proliferation 
seen with a parallel moderate increase in cAMP results in enhanced adipogenesis, 
underlining the already well established role o f elevated cAMP in preadipocyte 
differentiation. Higher levels of cAMP induced by activating mutations reduce lipid 
accumulation possibly due to reduced expression of lipogenic enzymes, rather than 
inducing lipolysis. Our model is not faithful to the physiological pattern of TSHR 
expression in adipogenesis because it is continually driven by the retroviral SV40 
promoter. Differentiating preadipocytes express TSHR from day 5 onwards and as lipid is
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already accumulating by day 7, TSHR expression is peaking in 3T3-L1 cells. Ideally we 
would investigate TSHR activation following this pattern using inducible vectors/TSAB 
monclonals. Additionally we need to determine the TSHR expression pattern accurately in 
human primaries to be able to replicate the experiments. TSAB or TSH would seem to 
have a relatively brief period in which it could affect adipogenesis given TSHR expression 
in mature adipocytes is low. It is currently questionable that TSHR on preadipocytes signal 
greatly given the in vitro TSH concentrations (10-100mU) required to do so are above 
normal physiological levels. However TSAB could be a supra-physiological stimulus or 
have higher affinities for TSHR on differentiating preadipocytes. It is also interesting that 
o f all our transduced cells, the Graves’ ophthalmopathy patient had the clearest dose 
responsive TSH signalling. Is it possible that the normal mechanism of TSHR down- 
regulation seen in thyrocytes is impaired in Graves’ disease and ophthalmopathy? Does 
this promote later stages o f adipocyte differentiation producing cells whose volumes once 
lipid laden is vast compared to its precursor cell? Clarifying our understanding o f these 
very basic models is necessary before we can extrapolate to the complexity of orbital cells 
and cytokines present in Graves’ ophthalmopathy. Had TSHR activation resulted in 
proadipogenic effects like those seen with PPARy agonists a case for a direct role in 
adipogenesis could have easily been argued. However, our model needs to be adapted to 
more closely follow the pattern of TSHR expression in adipogenesis to answer our 
question. If a role for TSHR activation in adipogenesis cannot be identified perhaps more 
direct effects are exerted either towards vascular structures or immune cells to cause 
orbital congestion in Graves’ ophthalmopathy.
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4 Characterisation of the alterations in tear composition in smokers and patients 
with Graves’ ophthalmopathy 
4.1 Introduction
4.1.1 Effects of smoking on Graves’ ophthalmopathy
Smoking has been identified as an environmental factor that may promote ophthalmopathy 
in Graves’ disease patients (reviewed in60,305,306). Smoking effects are immediate, linked 
to current, not lifetime smoking patterns and Graves’ disease smokers are more likely to
• 2fi7develop ocular motility disturbance and proptosis . A cohort o f newly diagnosed 
Graves’ disease patients showed smokers had a 1:3 fold increase in symptomatic 
ophthalmopathy with objective measurements of proptosis and diplopia being 2.6 and 3.1 
times more common respectively. One possible mechanism investigated, smoking induced 
hypoxia, showed orbital fibroblasts (but not dermal fibroblasts) produced increased 
glycosaminoglycans on stimulation with TNFa, INFy and IL-1 in vitro, compared with
->A O
normal oxygen tension . Both Graves’ ophthalmopathy patients and healthy smoking 
female controls have elevated levels o f antibodies to HSP72, but antibodies do not 
correlate with severity, suggesting a marker o f autoimmune susceptibility rather than a 
disease specific marker 309. Cigarette smoke constituents, tar and nicotine, in the presence 
o f INFy, promote expression o f HLA-DR in orbital fibroblasts 31°. The enhanced antigen 
presentation in smokers could increase their susceptibility. Mast cells exposed to cigarette 
smoke in vitro release several cytokines including IL-4, 5, 10 and 13 and TNFa and are
'y  11
thought to have pro-allergic effects . IL-4 and 13 induce class switching to IgE and 
while Graves’ ophthalmopathy is not an allergic disease, TN Fa is a major cytokine 
implicated in several aspects of pathogenesis . Smoking not only modifies the 
presentation o f disease but also prolongs recovery in terms of soft tissue swelling and 
ocular motility when treated with steroid and radiotherapy for moderate (CAS 2-6)
TilGraves’ ophthalmopathy
4.1.2 Tear film and content abnormalities in Graves’ ophthalmopathy
Dry, burning, watery eyes are some of the most widely experienced symptoms of Graves’ 
ophthalmopathy patients. Reduced tear break up times (TBUT) are common in Graves’
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ophthalmopathy314 but the causes are many. These symptoms can be contributed to by 
factors that increase corneal exposure and tear evaporation: vertical palpebral aperture, 
proptosis, blink rate, lagophthalmos and lid lag. Tear osmolarity is commonly elevated in 
Graves’ ophthalmopathy associated with greater palpebral apertures and higher blink rates
 ^i c
. Blink related micro-trauma is a process explaining the pathogenesis o f superior limbic 
keratoconjunctivitis (SLK) seen in Graves’ ophthalmopathy . Alterations in lubricity 
and blinking result in a spiral o f changes that damage tarsal and bulbar conjunctiva and 
comeal epithelium and in turn continue the tear film disruption and high blink rates. The 
volume o f tears in Graves’ ophthalmopathy has been shown recently to be decreased and
o i 7
correlates with an increase in ocular surface damage
 ^I o
Lacnmal gland involvement in Graves’ ophthalmopathy was first reported in 1935 and
1 1 Q
radiological evidence came with advances in CT imaging in the early 1980’s . Increased
activity within the lacrimal gland has also been highlighted by radiolabelled gallium and
1 1 A A
somatostatin ’ . Interestingly the gallium scan detected increased uptake in thyroid,
thymus and lacrimal gland, all o f which express TSHR and can be enlarged in Graves’ 
ophthalmopathy ’ . Examining the products of lacrimal secretion would therefore
seem worthwhile, however, conjunctival vessel transudate, goblet cells and mucosal 
associated lymphoid tissue also contribute to tears. Protein analysis of tears using PAGE 
has shown reductions in lysozyme, lactoferrin and lipocalin in patients with longstanding 
severe infiltrative ophthalmopathy and attributed to lacrimal gland dysfunction 322. Using 
HPLC separation o f tear proteins, 5 peaks were observed, increases in IgA or protein G 
peak were obtained in 28% of Graves’ ophthalmopathy samples 323. IgA antibodies have 
been shown in Graves’ disease directed towards thyroglobulin, microsomes and TSH R 34, 
324. The endomysium and perimysium of Graves’ ophthalmopathy ocular muscles (not 
orbital fat), in longstanding or severe disease, exhibits staining for IgAi .The unknown 
protein G eluted between lactoferrin (80kD) and lysozyme (14kD) and was elevated in 
20% of Graves’ ophthalmopathy patients . No link could be drawn between the 
NOSPECS classification o f the patients and their tear protein profile. The same group 
reported an increased IgA:lysozyme ratio in 33% of Graves’ ophthalmopathy patients, 
especially those with long-standing disease . Searching through a reference 2D gel map 
for a tear protein between 80-14kD identifies firstly; zinc-a2-glycoprotein (ZAG), 
several isoforms present between 44-50kD and secondly; an abundant n-terminal sequence 
blocked protein of 67kD (this most likely represents albumin, 66-69 kDa).
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Apart from the previously discussed causes o f tear film disturbance, two further radio­
iodine related causes are also noteworthy. An initial report showed radio-iodine is secreted 
in tears and subsequently a prospective study has demonstrated ocular dryness with a 
sicca like dry mouth in a quarter and ai third (respectively) o f patients receiving radio- 
iodine therapy . The effect is mostly transient but can persist past three years and is an 
additional factor that compounds Graves’ ophthalmopathy patients’ tear film problems. 
Conversely epiphora can occur due to radio-iodine induced naso-lacrimal obstruction
4.1.3 Tear thyrotropin stimulator in smokers and Graves’ patients
Availability of GO orbital adipose and connective tissues is restricted to that obtained from 
invasive surgery, often when disease is inactive. A non-invasive method to evaluate 
immune and endocrine mediators present in active disease was sought. TRAb activity has 
previously been demonstrated in saliva from patients with Graves’, Hashitoxicosis and 
Hashimoto’s thyroiditis and found to be higher than TRAB activity in serum 3 3 Given the 
above outlined changes in tear film proteins and lacrimal gland inflammation; tears were 
assessed for thyrotropin receptor stimulating activity (TSHR-SA) and protein changes that 
may occur in conjunctival/lacrimal secretion as a result o f orbital disease.
The principle o f using bioassays to detect TSAB by measuring cAMP is well established 
. Refining the assay demonstrated increased sensitivity for TSAB in lower salt assay 
conditions, loss of sensitivity in normal salt concentration did not occur with TSH 
While these low salt conditions are not physiological their use is widely accepted. Another 
variation on the TSAB bioassay was co-expressing the human TSHR and a cAMP 
responsive luciferase reporter in CHO cells that allowed the replacement of cAMP
1 fiQestimation with radioimmunoassay by light output in a luminometer . Previous work 
within the department (S. Gullu, B. Mazzi and S. Rajapaska) measured TSHR-SA in tears 
using the cAMP luciferase reporter based assay described in 2.2.17 . Results showed
that 9/25 (36%) smokers, 7/51 (14%) Graves’ disease patients and 13/47 (28%) Graves’
Aj.
ophthalmopathy patients had tear TSHR-SA above the 97 centile o f non-smokers tears.
To calculate specific TSHR-SA the stimulation index (S.I.) of'zulu' cells (not expressing 
TSHR) was subtracted from the S.I. of'lulu ' cells (expressing TSHR) and values obtained 
(mean ± S.D. o f each group) o f normal non smokers (NNS, 0.15±0.52), normal smokers 
(NS, 0.35±1.09), Graves’ disease (GD, 0.71±1.83) and Graves’ ophthalmopathy
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(0.73±1.29). The reference normal baseline group (NNS) had a 97th centile S.I. o f 0.85. 
From this data, ’specific' TSHR-SA was present in the tears from approximately 25% NS, 
32% GD and 41% GO patients.
TSHR-SA was assessed in the tears from 7 Hashimoto's thyroiditis patients (all female, 
age 28-62). A specific TSHR-SA was present in 2/7, both of whom were smokers.
Apart from tears, the luminescent assay was also applied to investigate the TSHR-SA of; 
Viscotears, a common ocular lubricant (carbomer, Novartis, 10% vol/vol in SFM), 
lysozyme (0.002 to 20pM), lactoferrin (recombinant and biochemically purified, Sigma,
0.001.to 10 pM), mast cell tryptase (0.002 to 20 pM ) and of trypsin (0.01% vol/vol in 
SFM). Neither Viscotears nor lysozyme caused any TSHR-SA luciferase activity.
TSHR can be activated by the proteolytic cleavage o f trypsin 334. Trypsin (0.01% vol/vol) 
caused a modest TSHR-SA response (4-fold increase) after 10 minutes incubation and this 
persisted at 30 minutes incubation. A smaller response (2-fold increase) was also obtained 
using the ‘zulu’ cell line indicating the presence o f receptors, which can be activated by 
proteolysis, endogenous to the parent CHO cell line. A second experiment demonstrated 
that the effects disappeared when the cells were incubated with trypsin for 60 or 120 
minutes.
To examine proteins present in tears, pools from the various patient groups were analysed 
using silver-stained gels. A consistent observation was an increased vol/vol protein content 
in the tears from GO patients and smokers. This was accompanied by the presence of 
additional bands in the 30 to 40kD molecular weight range.
4.1.4 Aims: Further characterisation of the alterations in tear composition in 
smokers and patients with Graves9 ophthalmopathy
1. To measure TSHR-SA in serum free and salt free conditions to determine whether
activity is enhanced as in the case for TSAB.
2. To determine if  a correlation exists between the TSHR-SA in tears, smoking,
circulating thyrotropin stimulating antibodies and Graves' ophthalmopathy disease activity.
3. To identify a group of 30-40kD proteins in the tears of smokers and Graves'
ophthalmopathy patients.
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4.2 Methods
4.2.1 Patient recruitment
Three groups o f individuals were recruited, these comprised 9 normal non-smokers (7 
female, 2 male, age range 24-50); 8 normal smokers (7 female, 1 male, age range 24-60) 
and a group o f 38 patients with Graves’ ophthalmopathy (32 female, 6 male, age range 18- 
73) with ophthalmopathy clinical activity scores (CAS ) ranging from (0-9). Clinical 
data, tears and serum were collected and informed consent obtained in accordance with 
local research ethic committee approval (Bro Taf). Clinical data included age, sex, CAS, 
sum of proptosis (exophthalmometry readings from both eyes), orbital radiotherapy, 
steroid treatment (current, previous, none), radio-iodine treatment, carbimazole therapy, 
TSH, T4, T3, serum TSAB and tear TSHR-SA (in serum free and salt free conditions).
4.2.2 Tear collection and storage
Reflex tears were collected from both eyes using Shirmer strips placed at the outer canthus 
o f un-anaesthetised eyes using gloved hands for 5 minutes. No prior administration of 
dilation or staining agents had occurred. Strips were removed using forceps and placed 
into 0.5ml Eppendorf tubes and caps sealed to prevent evaporation. To extract tears from 
the tubes, the base of the collecting tube was pierced with a 25G needle, the tube placed 
into a 1.5ml Eppendorf tube and then centrifuged at 3000g, 4 C for 5 minutes. Tubes were 
sealed, labelled and stored at -80 C until used.
4.2.3 Thyrotropin receptor stimulation assay
Both tear samples and serum were assayed using the TSHR luciferase assay as described 
in section 2.2.17 with the following modifications for the tear assay. 5 pi of tears were 
analysed in triplicate in 45pi o f both salt free and serum free buffer (app. A). Serum was 
assayed with lOpl serum in 90pl o f buffer (i.e. both 10%vol/vol). The stimulation index of
thnine normal patients’ tears and serum in the two buffers was used to generate a 97 centile 
cut-off, above which tear TSHR-SA and serum TSAB were considered positive. The assay
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sensitivities were monitored by running a TSH standard in serum free medium 
(0.1/1/1 OmU) and a TSAB standard in salt free buffer (0.025/0.25/1 U).
4.2.4 SDS-PAGE Analysis of Tear proteins
Tears from normal non-smokers (NNS), normal smokers (NS), GD patients (GD) and GO 
patients (GO) were pooled, usually in these four separate groups. Each sample of pooled 
tears was boiled with an equal volume o f 2 x loading buffer (10% p-mercaptoethanol; 4% 
SDS; 0.125M Tris; 20% glycerol; 10% bromophenol blue) and 50pl per lane loaded onto 
10% SDS-polyacrylamide gels. Electrophoresis was carried out as in section 2.2.4, 
followed by silver staining, according to the manufacturer's instructions (Biorad) or 
electroblotted to PVDF membranes for western analysis as in section 2.2.5. The blots were 
probed with a 1:500 dilution of rabbit polyclonal antibody to ZAG (H-123, Santa Cruz) for 
1 hour. Detection used an anti-rabbit IgG-horse radish peroxidase (HRP) conjugate 
(1:5000, room temperature for 1 hour Amersham Biosciences) and was visualised by 
enhanced chemiluminescence (ECL Plus, Amersham Biosciences).
Tear proteins have also been stained after electrophoresis using SYPRO Ruby (Invitrogen) 
by a collaborator (Dr Catherine Winder, Department o f Chemistry, UMIST). The 
following samples were examined; Graves’ ophthalmopathy smokers (TSHR-SA 
negative), smokers (TSHR-SA positive), Graves’ ophthalmopathy non-smokers (TSHR- 
SA negative), smokers (TSHR-SA negative), normal non-smokers and Graves’ 
ophthalmopathy smokers (same sample used in lane 4 o f Figure 4.3, TSHR-SA activity not 
assessed). The gel (Figure 4.5) was imaged using Gene tools analysis software (Syngene) 
to estimate molecular weight and optical density (OD). Four bands were measured roughly 
between 30-40kD to correspond with the four bands of similar molecular weight excised 
from the silver gel. The first two lanes 32kD bands were not measured by the software 
making comparison o f this band not possible in all samples. A simple ratio between the 
three bands was made by dividing the optical density of the band by the optical density of 
the 28kD band.
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4.2.5 MALDI-TOF Mass Spectrometry of Tear Proteins
Following silver staining, proteins of approximately 43, 41, 38 and 33kd were cut from the 
gel using a scalpel and stored at -80°C until analysis. The following steps were carried out 
by Dr Mike Morton (Department o f Medical Biochemistry, UWCM). Bands were cut into 
small pieces (~ lx lm m  cubes) with a clean scalpel. After 2-3 washes with water the silver- 
stained gels were destained with a freshly prepared, 50:50 mixture o f 30mM potassium 
ferricyanide and lOOmM sodium thiosulphate. The clear gels were incubated with 200mM 
ammonium bicarbonate (20min), washed with water, dehydrated with acetonitrile and 
dried in a vacuum centrifuge. The dried gel plugs were reduced in 1 OmM dithiothreitol 
(DTT) in lOOmM ammonium bicarbonate and incubated at 56°C for 45 minutes. The gel 
plugs were cooled to room temperature, the DTT removed and alkylated with 55mM 
iodoacetamide (IAA) inlOOmM ammonium bicarbonate at room temperature in the dark 
for 30 minutes. The IAA was removed; the gel plugs washed twice with 50:50 
acetonitrile/lOOmM ammonium bicarbonate and then dried in a vacuum centrifuge. The 
gel plugs were rehydrated in a freshly prepared and chilled digestion buffer containing 
50mM ammonium bicarbonate and 12.5ng/pl sequencing grade trypsin at 4°C. After 45 
minutes on ice any remaining digestion buffer was removed and replaced with sufficient 
50mM ammonium bicarbonate (~20pl) to keep the gel pieces wet during overnight 
incubation at 37°C. Peptides were extracted from the gel by incubation with 25mM 
ammonium bicarbonate (20pl) for 10 minutes, without removing the supernatant the same 
volume o f acetonitrile was added and incubation continued for a further 10 minutes. The 
supernatant was recovered and the peptides further extracted from the gels by two similar 
extractions with 5% formic acid and acetonitrile. All extracts were pooled, dried in a 
vacuum centrifuge and redissolved in 5% formic acid (10pl).
The peptide solutions were then purified and concentrated in U-C18 ZipTips (Millipore) 
using the manufacturers protocol for wetting, equilibration, bonding and washing and 
peptides eluted directly onto the MALDI target with the matrix solution (saturated solution 
o f a-cyano-4-hydroxycinnamic acid in 50:50 acetonitrile/0.2% triflouroacetic acid (TFA), 
diluted 1:5 with 60:40 acetonitrile/0.2%TFA).
Peptide mass fingerprinting was carried out using a Bruker Reflex III MALDI-TOF mass 
spectrometer in the reflectron mode. All mass spectra were externally calibrated with a 
peptide mixture containing Angiotensin I and II, Substance P, Bombesin, ACTH (1-17 and
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18-39) and Somatostatin. Mascot software (Matrix Science, London, UK) was used for 
searching the NCBInr database using monoisotopic mass values for each peptide mass 
spectrum. Protein identity was based on a MOWSE score with a p significant value of 
<0.05 within the Mascot software.
k
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4.3 Results
4.3.1 Tear TSHR-SA does not show increased stimulation in salt free buffer unlike 
serum TSAB
t hThe 97 centile for tear TSHRA stimulation index in salt free conditions was 1.14 and in 
serum free conditions 1.65. (All clinical and biochemical parameters are tabulated in 
appendix B “Clinical data Graves’ ophthalmopathy patients chapter 4”). There was 
sufficient tear sample to perform triplicates in serum free conditions on 38 patients and salt 
free in 30 patients, all patients were tested for TSAB in both conditions, stimulation 
indicies are illustrated in Figure 4.1 and Figure 4.2.
Tear TSHR-SA was present in 4/8 smokers and 13/38 Grave’s ophthalmopathy patients in 
serum free conditions, the difference in proportions was not statistically significant (Table 
4-1). In Graves’ ophthalmopathy, positive serum TSAB increased significantly from 8/38 
in serum free conditions to 32/38 in salt free buffer (McNemar p<0.001, Figure 4.2).
Serum TSAB was not detected in smokers in either condition. In contrast, rather than 
increasing in salt free buffer, positive tear TSHR-SA in smokers decreased from 4/8 to 1/8 
(p=0.2), and was not greatly altered in Graves’ ophthalmopathy patients from 13/38 to 
9/30 (p=0.7), when in serum free and salt free buffer, respectively (Table 4-1).
Table 4-1 Measurement of TSAB and TSHR-SA
Number o f patients detected to have TSHR stimulating activity in tears and serum in 
different assay conditions. (Serum free medium (SFM) and salt-free buffer (SFB) from 
normal non-smokers (NNS), normal smokers (NS) and patients with Graves' 
ophthalmopathy (GO)).
Tear TSHR-SA Serum TSAB
SFM SFB SFM SFB
NNS 0/9 (0%) 1/8 (12.5%) 0/9 (0%) 0/9 (0%)
NS 4/8 (50%) 1/7 (14%) 0/8 (0%) 0/8 (0%)
GO 13/38 (34%) 9/30 (30%) 8/38 (21%) 32/38 (84%)
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Figure 4.1 TSHR-SA (Tears) in salt free buffer and serum free medium
Representative samples o f  Sm okers and G raves’ ophthalm opathy patients tears show tear 
TSH R-SA  o f  com parable levels in salt free and serum free buffer. (S- smokers. G- G raves’ 
ophthalm opathy patients. Colour m atched dotted line represents normal cut o ff o f each 
assay).
2.5 i -------------------------------------------------------------------—--------------------------------------  ,
S1 S3 S5 G1 G3 G5 G7 G9 G12 G14 G16 G18 G20
Patients
□  sa lt free buffer 0  serum  free buffer
Figure 4.2 TSAB (Serum) in salt free buffer and serum free medium
G raves’ ophthalm opathy patients serum shows TSAB activity greater in salt free buffer 
com pared to serum  free. (Dotted line represents normal cut o ff o f  both assays).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
Patients
■  Salt free buffer □  Serum  free buffer
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Correlations between serum TSAB, tear TSHR-SA and other linear variables; CAS, TSH, 
T4, T3, proptosis and age were tested (Spearman). Tear TSHR-SA tested in both buffers 
did not correlate with each other or with serum TSAB activity. Serum TSAB in serum free 
medium correlated with salt free buffer (rho=0.61, p<0.0001). CAS showed a positive 
correlation with serum TSAB in salt free buffer (rho=0.41, p=0.01) but not in serum free 
media. CAS did not correlate with tear TSHR-SA in either buffer. However, some would 
consider the CAS not to be a truly linear variable. We therefore grouped patients into those 
with active ophthalmopathy (CAS>3) and inactive (CAS<3) and compared mean tear 
TSHR-SA with smokers and non-smokers, both assay conditions were examined 
statistically (ANOVA) and no differences were found. Serum TSAB when grouped in this 
manner showed no significant difference between active and inactive Graves’ 
ophthalmopathy but both were significantly higher than smokers (active p=0.018, inactive 
pO.OOOl) and non-smokers (active p=0.016, inactive pO.OOOl) in salt free buffer. Serum 
TSAB in serum free medium showed no difference between groups. The apparent 
aberration between the positive correlation of CAS and serum TSAB and the failure of 
patients with active disease to have higher serum TSAB, may be caused by uneven 
sampling skewing distributions. The most frequent CAS was 3 (n=l 1), just below the 
threshold for active disease and only 7 out of the 38 patients had CAS greater than 3.
Mean tear TSHR-SA and serum TSAB showed no significant differences in either buffer 
when the Graves’ ophthalmopathy patients were grouped into; smokers/ non-smokers and 
patients with and without the following treatments; carbimazole, radio-iodine, orbital 
radiotherapy, thyroidectomy, steroids.
TSH was negatively correlated with tear TSHR-SA in salt free buffer (rho=-0.36, p=0.048) 
but not in serum free medium. However given TSHR-SA in salt free buffer had a very 
narrow range (SI.0.7-1.6) the strength of this correlation is questionable. TSH was not 
correlated with serum TSAB in either buffer. As expected, TSH levels had negative 
correlation with serum T4 (rho=-0.64, pO.OOOl) and T3 (rho=-0.51, p=0.04). Similarly,
T4 and T3 correlated positively (rho=0.61, p=0.012). Age and proptosis did not correlate 
with any other variables.
Further experiments were performed by Dr Marian Ludgate using 5 pooled TSHR-SA 
positive Graves’ ophthalmopathy tear samples in SFM and in the presence o f a thyrotropin 
receptor blocking antibody (TBAB) or normal human serum (both at 5, 10 and 20%
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vol/vol). There was no difference in activity in the pooled tears in the presence o f the 
TBAB compared with the normal human serum.
4.3.2 Tear zinc-ct2-glycoproteins are present in different proportions from Graves’ 
ophthalmopathy patients but does not show tear TSHR-SA
Increased banding was demonstrated on silver gels in the 30-40kD range along with 
increased vol/vol protein content in smokers and Graves’ ophthalmopathy patients (Figure 
4.3). Given the tear 2D reference map suggested ZAG is around this size, western blotting 
was used to detect ZAG in pooled normal and Graves’ ophthalmopathy patients. ZAG 
appears to be a highly abundant protein with nearly equal densitometry in normal non- 
smokers and Graves’ ophthalmopathy patients (Figure 4.4). However this is a sensitive 
technique and titration experiments using lower concentrations of primary antibody were 
not carried out.
SYPRO-Ruby staining o f tear proteins was performed by a collaborator (Dr Catherine 
Winder, Department o f Chemistry, UMIST). The following samples were examined; 
Graves’ ophthalmopathy smokers (TSHR-SA negative), smokers (TSHR-SA positive), 
Graves’ ophthalmopathy non-smokers (TSHR-SA negative), smokers (TSHR-SA 
negative), normal non-smokers and Graves’ ophthalmopathy smokers (same sample used 
in lane 4 o f Figure 4.3). The gel (Figure 4.5) was imaged using Gene tools analysis 
software (Syngene) to estimate molecular weight and optical density (OD). Four bands 
were measured roughly between 30-40kD to correspond with the four bands of similar 
molecular weight excised from the silver gel (Table 4-2). The 32kD bands of the first two 
lanes were not measured by the software so comparisons were not possible. Graves’ 
ophthalmopathy patients (lane 1&3) have similar ODs for, 42, 39 and 28kD proteins and 
the average ratio was 2.7:2.7:1 (42:39:28 kD). The total protein in these two samples is 
greater than a sample collected by previous investigators of Graves’ ophthalmopathy tears 
(lane 6) and differs also in the ratio 2.1:1.1:1. The smokers (lane 2&4) have differences 
between all three bands and the average ratio of the two groups was 3.7:2.1:1. The normal 
non-smoker tears had very similar OD readings to the previously collected GO tear sample 
and identical ratios 2.1:1.1:1. Whereas most samples show a reduction in OD from the 
42kD to the 39kD band, the more recent Graves’ ophthalmopathy samples did not.
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Figure 4.3 Silver stained gel of tear proteins
Increased banding in 30-40kD region o f  Graves ophthalm opathy and sm okers tears is 
shown. Gel bands excised for M ALD I-TO F protein analysis.
L a d d e r  N o rm a l G O  G O  s m o k e r
n o n - s m o k e r s  n o n - s m o k e r s  a n d  n o rm a l
s m o k e r s
4 3  kD (1)
41 kD (2
3 8  kD (3)
3 3  kD (4)
T  ry p ta se
ly so z y m e
Figure 4.4 W estern blot for tear ZAG
The W estern blot is overlaid onto gel w ith m olecular weight markers. Lane; 1, normal 
non-sm okers, 2, m olecular w eight m arkers, 3, G raves’ patients, 4, rainbow  m olecular 
w eight m arkers.
Normal
te a r s
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Figure 4.5 SYPRO Ruby stained tear proteins
L ane l, G raves’ ophthalm opathy smokers (TSHR-SA negative). Lane 2, smokers (TSHR- 
SA positive). Lane 3, G raves’ ophthalm opathy non-sm okers (TSHR-SA negative). Lane 4, 
smokers (TSH R -SA  negative). Lane 5, norm al non-sm okers. Lane 6, G raves’ 
ophthalm opathy smokers (same sample as lane 4 Figure 4.3).
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Table 4-2 Tear proteins stained with SYPRO-Ruby
Data from gel in Figure 4.5 showing molecular weight and optical density. In brackets is 
the ratio o f optical density relative to that o f the 28kD protein. Negative and positive refer 
to TSHR-SA. Sample six was included to compare staining in the previous silver stained 
gel and TSHR-SA was not measured in this sample.
kD
GO
smoker
negative
1
Smoker
positive
2
GO non 
smoker 
negative 
3
Smoker
negative
4
Normal
non
smoker
5
GO
smoker
6
42 60.5 (2.9) 50.8 (3.1) 56.9 (2.5) 69.5 (4.3) 48.4 (2.1) 44.1 (2.1)
39 56.7 (2.8) 28.9(1.8) 59.5 (2.6) 38.1 (2.4) 25.0(1.1) 22.0(1.1)
32 nr nr 9.7 (0.4) 7.6 (0.5) 11.2 (0.5) 11.4 (0.6)
28 20.6 (1) 16.4 (1) 23.0(1) 16.1 (1) 23.5 (1) 20.5 (1)
Table 4-3 MALDI-TOF peptide analysis of tears
Protein bands (30-40kD) excised following SDS-PAGE of tears from normal non- 
smokers, patients with GO and a pool of GO smokers and normal smokers were analysed 
by MALDI-TOF. (ZAG, zinc-a-2-glycoprotein; numbers indicate probability (p<0.05) 
based on Mowse score; Neb, nebulin; Hypothet. protein, hypothetical protein KIAA0542. 
In addition, the mast cell tryptase band was recognised with a significant Mowse score of 
101).
Normal non-smokers GO GO smokers and smokers
1 Nothing detected ZAG, 129 ZAG, 164
2 Neb, 76 Hypothet. protein, Nothing detected ZAG, 84
3 Lactoferrin, 84 Lactoferrin, 78 Lactoferrin, 93
4 Nothing detected Lactoferrin, 70 Lactoferrin, 86
The four bands excised in the 30 to 40kD region from each of the 3 tear-containing lanes 
and a band containing mast cell tryptase from the adjacent lane were analysed by MALDI- 
TOF (Figure 4.3). The 4 bands were zinc-a-2-glycoprotein (the two at higher Mr) and 
lactoferrin (the two lower Mr bands). The results o f the analysis are summarised in Table 
4-3. The results suggest the proteins in Graves’ ophthalmopathy patients present in similar 
proportions (2.7:2.7:1) are ZAG:ZAG:lactoferrin.
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In order to test ZAG for TSHR-SA, a colleague, Martin Bullock (Department of 
Endocrinology, UWCM) purified his-tagged human ZAG from A293 cells provided by 
Dr. Laura Hale (Duke University). The purified ZAG and the conditioned medium of the 
A293 cells were tested in the luciferase assay but neither displayed TSHR-SA.
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4.4 Discussion
To summarise work carried out previously and in this study; we have identified differences 
in the bioactivity and composition o f Graves’ ophthalmopathy patients' tears, which are 
similar to those observed in normal smokers, when compared with non-smokers.
There are several indications to suggest that tear TSHR-SA is not an antibody. The activity 
was detected in almost one third of 'healthy' smokers, yet in the small group (n=8) 
examined, none had serum TSAB. TSHR-SA was not affected by the presence of human 
serum containing TBAB. Furthermore the optimal conditions for the tear stimulating 
activity are physiological, unlike the salt-free assay buffer preferred by TSAB. If not an 
antibody, could it be a protease? The bioassay we have used is able to demonstrate TSHR 
activation by trypsin. However the kinetics of this response, which peaks at 30 minutes, 
differs from those o f TSHR-SA. This may be due to differences in concentration. A 
proportion o f the activity we have detected in tears is due to activation of Gsa coupled 
receptors, other than the TSHR, which are endogenously expressed by the parent CHO cell 
line. The maximum stimulation index obtained using the zulu cell line was 4.5 (range 1.1 
to 4.5), contrasting with the lulu cells expressing the TSHR, which produced stimulation 
indices ranging from 1.1 to 21.1 (Additional experiments by Dr Ludgate).
The tear gels stained by SYPRO-ruby (Dr Catherine Winder) show variation in protein 
content o f pooled samples from Graves’ ophthalmopathy patients, smokers and normals
T 1 7and in general protein content would seem higher in keeping with other studies 
Extrapolating protein quantity by gel densitometry is an in-exact process and the need for 
confirmation with other quantitative tests is clear but only possible after identification of 
the exact proteins has been made. The results hint at the differences present in the ratios of 
the various proteins that may underlie disease processes rather than simply tear osmolarity 
changes. Proteins present in tears are extensively modified; fragmentation, truncation, 
glycosylation, phosphorylation, are all changes that alter protein function. Subtle changes 
in the isoforms o f the proteins may underlie the pathological processes and resolution of 
such changes might only be possible with narrow pH gradients on 2D gels or other 
techniques such as combined HPLC/electrospray ionisation/mass spectrometry where both 
peptide types and quantification are possible 335.
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While total protein content of tears in normal individuals does not alter much day to day, 
serum albumin and immunoglobulin levels can fluctuate whereas regulated tear proteins 
(lysozyme, lactoferrin) seem fairly constant 336. In dry eye lactoferrin levels are reduced 
. By optical densitometry, levels o f the 28kD lactoferrin fragment were similar in our 
samples. Lactoferrin is an iron binding protein having pleiotropic effects, including anti- 
inflammatory and anti-microbial . Lactoferrin is able to bind glycosaminoglycans 
and has been found to have both protease 340 and protease inhibitor activities341. Apart 
from preventing infection o f the ocular surface, lactoferrin in tears has been suggested to 
have a role in reducing the formation of free radicals 342. Tear lactoferrin has been reported 
previously at 83 and 78kD, major and minor forms, but others were also present; 64, 60,
57 and 52kD, the shift to smaller isoforms was repeated when iron ions were added to 
tears 343. We have detected the protein at considerably lower molecular weight but 
consistent with fragments o f the larger forms. Elsewhere, nasal lavage fluid of normal 
subjects contains a 39kD fragment o f lactoferrin 344. Components of cigarette smoke have 
been shown to increase proteolysis o f lactoferrin 345, which can also be cleaved by 
cathepsins, a process that reduces its anti-microbial activity 346. Neutrophil elastase has 
also been shown to cleave lactoferrin in the lungs o f cystic fibrosis patients 347.
Neutrophils and their elastase are commonly found in conjunctiva, particularly at night 348. 
Proteolytic cleavage o f major forms o f lactoferrin seems the most likely source o f our 
fragment and could explain the reduced lactoferrin reported previously 322. Measurement 
o f all forms o f lactoferrin and their biological activity would be required to understand 
whether smoking or Graves’ ophthalmopathy has an effect.
Our initial tear gels suggested normals contained lower total proteins and the bands 30- 
40kD were virtually absent. This contrasts with the later samples visualised by SYPRO- 
Ruby stained gels and the western showing abundant ZAG (~40kD) in normal tears. 
Similarly elsewhere, tear gels from normals show prominent Coomasie blue stained 
proteins in the 30-40kD region . The apparent disparity between the protein contents of 
our early and late sampling could be due to a number of factors including sampling 
methods by different investigators and protein degradation in the older samples.
We have identified by MALDI-TOF (Dr Mike Morton) and western, the higher molecular 
weight bands as ZAG. It is therefore a common tear protein but receives little interest, 
searching PubMed for the two terms (zinc-alpha-2 glycoprotein, tears) returns only two 
articles 327;349. The purification of human ZAG was described in 1961 35°. ZAG is a 41kD
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protein present in plasma, saliva and tears with a high similarity to the extra-cellular 
domain o f the MHC class I a  chain, its natural ligand may be a polyunsaturated fatty acid 
and it possibly has a role in lipid homeostasis ’ . ZAG has an identical amino acid
sequence to lipid mobilising factor, responsible for the cachexia seen in some cancers and 
produces lipolysis in-vitro and in-vivo via a p3 -adrenoreceptor cAMP dependent 
mechanism 353’354. MALDI-MS has detected 5-7 ZAG isoforms 35-40.5kD in mass due to 
variable glycosylation and differences in scialic acid content 354. Tear sialic acid has been
-iff
detected previously and its presence attributed to an unknown glycoprotein, that we 
would now suggest to be ZAG. This number of ZAG isoforms detected in tears by 2DGE
977is similar to another study , our 1DGE could only resolve 2 bands of ZAG from Graves’ 
ophthalmopathy patients and smokers. A recent study found that the plasma of smokers 
contains a higher proportion of aberrantly glycated proteins compared with non-smokers 
due to nomicoteine . The precise function o f ZAG in tears and other biological fluids is 
unclear but it has recently been shown to be expressed by adipocytes . Whether the 
increased ZAG in Graves’ ophthalmopathy tears is derived from lacrimal gland secretion 
or possibly related to vascular leakage from congested orbits with fat hypertrophy is not 
known.
We have, in line with our specified aims, identified the proteins present in tears between 
30-40kD, however, studying the SYPRO-ruby gel shows numerous proteins below lOkD 
in size and initial MALDI-TOF characterisation o f these low molecular weight proteins
0^7
has been partially examined elsewhere . There are no correlations between serum 
TSAB, tear TSHR-SA and smoking in Graves’ ophthalmopathy. Serum TSAB in salt free
ICO
buffer correlates with CAS as shown previously but our sample sets are too uneven to 
support this fully. Graves’ ophthalmopathy tears contain a unique ZAG protein profile of 
unknown significance.
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§ In vivo and ex vivo investigation of a possible role for adiponectin in orbital 
adipogenesis 
5.1 Introduction
5.1.1 Adiponectin, an insulin sensitising adipokine
As discussed in the introduction appreciation of the active metabolic role adipose tissue 
plays, particularly in obesity and diabetes, has become of great interest given the increased
ICQ
incidence o f these two diseases . Insulin signalling is central to lipid homeostasis with 
resistin having a negative effect and adiponectin having a positive effect on insulin 
sensitivity ’ . Adiponectin has become the accepted name for a protein previously
identified by several terms including: adipocyte complement-related protein 30kD 
(ACRP30), adipoQ (murine form), adipose most abundant gene transcript 1 (apM l) and
o n
gelatine-binding protein 28kd (GBP28) (reviewed ). Sequence homology and a C- 
terminal complement factor Clq-like globular domain add adiponectin to a family of 
proteins including human type VIII and X collagens, precerebellin and hibernation- 
regulated proteins (hib 20, 25 and 27) . The locus for adiponectin is 3q27 and produces a
protein containing 247 amino acids (aa); signal peptide (17aa), highly conserved N 
terminus (l-44aa), remaining collagen domain (45-109aa) and a globular domain (110- 
247aa). Secreted protein is present as low molecular weight trimer dimers and high 
molecular forms such as hexamers, dodecamers and 18 mers. Adiponectin is present in 
human plasma between 5-30nM and therefore with such high levels present receptors were 
predicted to have low affinity binding. The adiponectin receptors have recently been 
cloned and two main isoforms characterised, adipoRl (widely expressed but mainly 
skeletal muscle) and adipoR2 (mainly liver), whose actions are mediated via AMP kinase 
and PPA Ra ligands 364. The receptors have seven transmembrane segments but are not G- 
protein receptors and are orientated oppositely with the C terminus externally and the N 
terminus internally. AdipoR2 is the receptor for full length adiponectin while adipoRl has 
high affinity for a globular domain fragment that may be produced in small amounts by
o z c ,  T Z Z
complement cascade activation or leukocyte elastase ’ . Adipocyte adiponectin gene
expression has sterol regulatory sites within its promoter for the transcription factor 
ADD/SREBP, an important factor during the initiation of adipogenesis 367.
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Recombinant adiponectin has been shown in vivo to decrease glucose production by 
increasing hepatic sensitivity and is mirrored in vitro by hepatocyte culture results 
In humans, dietary restriction of calories elevated adiponectin and type 2 diabetic patients 
(insulin insensitive) have lower adiponectin levels than non-diabetic controls . Elevation 
o f circulating adiponectin can be achieved by thiazolidinedione treatment which improves
70insulin sensitivity . Adiponectin knockout mice showed increasing insulin resistance 
from heterozygous to homozygous forms and were more susceptible to atherogenic insult 
. The globular head domain o f adiponectin, when cleaved, caused glucose lowering by 
increased muscle fatty acid oxidation but this form is present in small amounts in human 
plasma . However, the globular domain has been shown to improve insulin resistance
*377more effectively than full length adiponectin . Murine transgenics expressing the 
globular domain o f adiponectin when crossed with leptin deficient ob/ob mice showed 
increased insulin responses to glucose and improved insulin resistance but did not improve 
obesity . The same adiponectin transgenic mice when crossed with atherosclerosis 
model, apoE-deficient mice, produced an improvement in atherosclerosis. Adiponectin 
may reduce inflammation in endothelial cells by disruption of cAMP-PKA, NF-kB 
pathways 374.
5.1.2 Transgenic elevation of full length adiponectin improves insulin sensitivity
A group at the Albert Einstein College o f Medicine (AECOM) showed that secretion of 
adiponectin could be enhanced by the expression of a truncated form of adiponectin
775lacking Gly-X-Y repeats in the collagenous domain . Adiponectin initially formed as 
trimers, then pairs o f trimers and finally the tertiary protein structure contained 12-18 
subunits. The effect o f the truncated adiponectin was thought to be post-transcriptional, 
with a maximal effect around three hours, increasing secretion by reducing a normal 
process o f internal degradation. Conversely, adding Gly-X-Y repeats to the collagenous 
domain decreased adiponectin secretion. A transgenic model based on the truncated 
adiponectin developed serum levels of normal oligomeric adiponectin three times that of 
its wild type controls and was secreted from fat pads, none of the truncated form was 
secreted. The most successful transgene promoter was the fat specific aP2, the more 
ubiquitously expressed CMV promoter founder lines were difficult to propagate due to 
infertility. The pre-existing sexual dimorphism of females having 2-3 times the circulating 
adiponectin compared to males was conserved in the transgenic mice. Transgenic elevation
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of adiponectin did not alter levels of; TNFa, glucocorticoids, growth hormone or leptin, 
but prolactin levels were doubled in the transgenic mice. In wild type mice prolactin 
decreases adiponectin levels and might represent a counter regulatory mechanism to lower 
adiponectin in the transgenic mice. Female transgenic mice displayed higher rates of 
triglyceride and fatty acid clearance with increased lipoprotein lipase activity. Increased 
hepatic insulin sensitivity was found in transgenic mice prior to and after, increases in fat 
mass. Similarly, glucose clearance was achieved at lower levels o f insulin in transgenic 
mice.
5.1.3 Elevated adiponectin causes selective fat pad proliferation
A characteristic phenotype developed midlife in the transgenic mice with large 
interscapular and intraconal orbital fat pads but was only present when circulating 
adiponectin had been elevated by transgene expression. Percentage fat mass determined by 
tritiated water distribution showed increases in females but not males relative to wild type. 
The changes in fat mass were not obviously due to changes in food intake, 24hr energy 
expenditure or respiratory quotients. Macroscopic and microscopic appearances o f the 
interscapular fat pads were in keeping with brown fat but the transgenic adipocytes tended 
to contain less lipid vacuoles. Brown fat is known to secrete adiponectin and resistin 376. 
The proptotic changes within the orbits of the mice were investigated as part of this thesis 
and are described in the results (5.3.2).
Proptosis caused by fat expansion and de novo adipogenesis is, in part, a pathology we see 
in Graves’ ophthalmopathy. We hypothesized, given preadipocyte differentiation increases 
TSHR expression, the profound increases in fat pads of the adiponectin transgenic mice 
might lead to a break in tolerance to TSHR and the transgenic mice may have developed 
an inflammatory eye disease akin to Graves’ ophthalmopathy. Furthermore in humans the
07A
elevation o f circulating adiponectin by thiazolidinediones has been implicated in the
relapse o f a patient with Graves’ ophthalmopathy commenced on pioglitazone 377 and also 
has also been reported to cause proptosis in a patient without Graves’ disease or 
ophthalmopathy on roziglitazone . Consequently adiponectin levels may influence 
Graves’ ophthalmopathy activity.
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5.1.4 Aims:
1. To investigate whether the proptosis of the transgenic mice is caused by expansion of 
the orbital fat, ocular muscles and oedema. (A macroscopic, microscopic and MRI study).
2. To determine whether the transgenic mice have developed a Graves’-like disease by 
measuring antibodies to the TSHR
3. To measure adiponectin levels in patients with Graves’ disease and ophthalmopathy 
with varying severity to establish if  any correlations exist.
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5.2 Methods
5.2.1 Thyroxine and thyrotropin receptor antibody determination
Serum from FVB mice was collected and frozen by our collaborators at AECOM and 
transported to the UK; wild-type females (n=10), transgenic females (n=8), over-ovulated 
wild-type females (n=3), over-ovulated transgenic females (n=3), wild-type males (n=9) 
and one transgenic male. Serum was assayed for thyroxine, TSAB and TBII as in sections 
2.2.16-18. Serum assay for TSHR antibodies by flow was carried out as in 2.2.15, with the 
modification o f using CHO cells with and without the human TSHR. We then compared 
the histograms using Kolmogorov Smimof statistics to obtain a ‘d’ value. TSH was 
measured by our collaborators.
5.2.2 Histology and electron microscopy
Orbital samples were set in fixation fluid after excision of the entire orbit and eyelid skin 
(exenteration) prior to transportation to Cardiff. On arrival, samples were further dissected 
to remove the skin and Harderian gland before macroscopic photography. Samples were 
then mounted in plastic for light microscopy as in section 2.2.22. Electron microscopy was 
carried out on some specimens by Dr Chris von Rhuland, Department o f Medical 
Microscopy.
5.2.3 Orbital MRI
The MRI facility is a purely experimental setup for imaging and spectroscopy and has not 
been used previously for murine imaging, to gain experience of the equipment we used 
BALB/c mice to develop the following methods and sequence protocols. Imaging was 
carried out under the supervision o f Dr Bill Stewart (Medical Physics, UWCM).
A 1.2 Tesla, 17cm bore, superconducting magnet, associated imaging electronics, radio 
frequency generator and detectors (Surrey Medical Imaging Systems) were integrated at 
the system level by the Department o f Medical Physics, UWCM. A miniature 2.5cm radio­
frequency (RF) coil was designed in-house. T1 weighted images were generated on a 32
163
row greyscale matrix o f 256x256 with a slice thickness of 1.5mm but some 0.75mm 
images were also acquired. Switching between X, Y and Z detectors required additional 
scan sequences for axial, coronal and saggital images. The miniaturisation o f the RF coil 
resulted in each sequence of images generating four slices for analysis. Mice were 
sacrificed by CO2 (cervical dislocation was avoided to prevent orbital haemorrhage) and 
transferred to the MRI lab. Positioning within the coil was aided by wrapping the mice in 
cling film, a brief sequence, 4-8 minutes duration, was then run to confirm correct 
positioning within the field and adjusted as necessary to reduce artefacts of rotation and 
poor symmetry. Each adjustment required disconnection of the RF cables and extracting 
the RF coil from the centre of the magnet bore. Departmental guidelines regarding the 
safety o f high magnetic fields were observed. The full imaging sequence acquisition was 
25-45 minutes. Two wild-type FVB and two age matched transgenic mice were transferred 
from AECOM and studied by MRI. Fat explants were taken from the mice after MRI and 
cultured as in chapter 3.
5.2.4 Plasma adiponectin measurement
A small sample of patients with Graves’ disease, Hashimoto’s and controls were tested for 
adiponectin in a pilot study. Plasma was transferred at -80C to Dr Terry Combs (AECOM) 
for the Western blot assay. Briefly, 3 pi o f serum was separated by SDS-PAGE (12%), 
transferred to nitrocellulose, blots exposed to I-labelled rabbit antibody against murine 
adiponectin and analysed by densitometry against standards of known adiponectin
370concentration
Initial results suggesting an elevation in circulating adiponectin lead us to examine levels 
in Graves’ ophthalmopathy patients (n=36) and compare them to a group of thyrotoxic 
patients with toxic multinodular goitre (TMNG, n=13). Data and serum gathered from the 
ophthalmopathy patients was in accordance with local research ethic committee approval 
(Bro Taf). Clinical data included age, sex, CAS, body mass index, sum of proptosis 
(exophthalmometry readings from both eyes), orbital radiotherapy, orbital decompression 
surgery, steroid treatment (current, previous, none), radio-iodine treatment, carbimazole 
therapy, TSH, T4, T3 and serum TSAB. Statistical analysis was carried out as in 2.2.23.
164
5.3 Results
5.3.1 TSHR antibodies are not induced by adiponectin over-expression. FVB mice 
hypothyroidism is not altered by adiponectin over-expression
From ten female and nine male wild type mice centiles were established for normal ranges 
o f the antibody and thyroxine assays. TSHR by flow had a 97th centile “d” cutoff value of 
0.34, TBII had a 3rd centile value o f 69%, TSAB had a stimulation index 97th centile of
1.15 and thyroxine had a 97th centile of 3.3pg/dl and a third centile of 1.9jug/dl.
No TSHR antibodies were detected by flow cytometry or inhibition of TSH binding (Table 
5-1). Low level increases in TSAB were only present in some older mice; 2/3 16 month 
female transgenic (SI=1.5 and 1.28), 1/3 11 month female over-ovulated (SI=1.27) and the 
one male 16 month transgenic (SI=1.27). None of these mice had a reciprocal elevation in 
thyroxine. Thyroxine levels were normal, all between the 97th and 3rd centiles, in all FVB 
mice tested, irrespective o f transgene presence. The average thyroxine levels o f FVB was 
nearly half that o f B ALB/c tested in chapter 2. No significant differences in TSHR 
antibodies or thyrotropin were detected between the groups (ANOVA).
Table 5-1 TRAbs, Thyroxine and TSH results from FVB mice
Thyrotropin receptor antibodies (IgG by flow, TBII and TSAB), thyroxine and TSH results 
from FVB; wild type, transgenic and over-ovulated (OV) female and male mice (mean in 
bold, standard deviation or standard error o f the mean (sem) in faint).
TSHR IgG
m TBII (%) TSAB (SI) T4 (pg/dl)
TSH
(mU/ml)
Wild type
female
n=10
0.23 0.05 99.3 13.1 1.0 o i 2.4 0.47 4.3 0.4 sem
Transgenic 
female n=8 0.28 0.09 104 9.04 1.07 0.34 2.36 0.5 4.5 0.5 sem
Wild type 
female OV 
n=3
0.24 0.14 91.3 1.53 1.11 0.15 2.16 0.15 -
Transgenic 
female OV 
n=3
0.29 0.08 91 2.65 0.98 0.04 2.47 0.16 -
Wild type 
male n=9 0.29 0.04 79 7.35 0.91 0.18 2.69 0.44 -
Transgenic 
male n=l 0.24 91 1.87 2.4 -
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5.3.2 Elevated adiponectin induces intraconal fat pad proliferation causing 
proptosis and phthisis
The phenotype o f middle aged (8 months) wild type and transgenic FVB mice are shown 
in Figure 5.1.1. The hypertrophied interscapular fat pad gave a rounded, hunched 
appearance in the transgenic and the apparently larger eye is caused by the proptosis, the 
globe sizes are not altered. The wild type eye (8 months) in Figure 5.1.2 shows the normal 
macroscopic appearance after exenteration: the globe and muscles are shrouded by 
Harderian gland, ocular muscles taper away from the globe meeting at the peak of the cone 
with the optic nerve, the uvea is unpigmented in these albino mice giving the translucent 
appearance. Incising the muscle cone and removing the fat showed the retracted bundles of 
severed ocular muscles and the remaining stump of optic nerve (Figure 5.1.3). The 8 
month transgenic globe in Figure 5.1.4 has the harderian gland reflected to the right. The 
muscle cone was unopened and the muscle fibres were distended by fat from within, an 
individual muscle was separated into multiple fibres by the expansion of fat, adjacent to it 
an unsplit ocular muscle was spread broadly without splitting. The cornea remained clear. 
At the orbital apex the tendinous ring insertion of the ocular muscles was dilated with fat 
prolapsing through it. The entry point for the central retinal artery was through the 
tendinous ring. Chronic exposure keratopathy due to proptosis ultimately ulcerated the 
corneas o f older mice as illustrated by Figure 5.1.5 (20 months, transgenic). Globe 
perforation would follow but sight loss would probably already have occurred due to 
retinal artery occlusion. The intraconal fat would continue to prolapse between the straps 
o f ocular muscles. Once perforated, end stage phthisical shrinkage of the globe developed 
(Figure 5.1.6), and the intraconal fat advanced over the scarred remnant. The microscopic 
appearance of phthsis; globe contraction, corneal and retinal disruption with a central 
fibrotic process is shown in Figure 5.1.7. F. These disfiguring changes resulted in a 
decision by the vets to sacrifice the mice at 12 months before the onset of corneal 
ulceration, treatment by tarsorrhaphy or enucleation was not thought to be viable.
Histological preparation required chloroform extraction to remove the large amount of 
saturated lipid present. Two main morphologies were seen in the orbital fat although a 
spectrum between the two was present. The type most commonly found in transgenic mice 
had adipocytes composed of large single lipid spaces remaining with a few unsaturated 
lipid droplets (Figure 5.1.7. A). Cytoplasm was diminished to a thin tracing around the cell 
wall and nuclei. The appearances were in keeping with white adipose tissue with a storage
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function but electron microscopy from AECOM showed the presence of mitochondria in 
keeping with brown fat. The other fat morphology differed clearly (Figure 5.1.7. B), 
adipocytes had larger areas of cytoplasm, the nuclei had more densely stained 
heterochromatin. The lipid vacuoles were smaller and multiple and unsaturated lipid 
droplets formed in the cytoplasm. More blood vessels were scattered throughout the tissue. 
These appearances were interpreted to be consistent with either brown fat or sites of active 
adipogenesis. No inflammatory cellular infiltrates were present in any fat samples 
examined.
Ocular muscles were neatly organised in wild type and transgenic animals (Figure 5.1.7. 
A-B). Muscle fibres contained numerous pale staining mitochondria similar to those seen 
in chapter 2. In ocular muscles split by intraconal fat expansion the myofibrils were 
distended and vacuolated (Figure 5.1.7. C). Using electron microscopy the vacuolations 
were identified as swollen mitochondria with disruption of internal cristae (Figure 5.1.8. 
A-B). Degeneration o f light and dark bands was widespread and sarcomere length was 
increased (Figure 5.1.8. C). In the connective tissue between the muscles, no normal blood 
vessels were demonstrated and nerve tissue showed degeneration (Figure 5.1.8. D-F). 
These changes most likely represent an ischaemic process resulting from mechanical 
distension and compression caused by the fat volume expansion.
A small number of thyroids were examined and both wild type thyroids and transgenic 
thyroids contained a normal range of thyroid follicular heterogeneity (Figure 5.1.9. A-B). 
The older o f the two transgenic mice had a focal small mononuclear cell infiltrate present 
between the follicles (Figure 5.1.9. C-D). There were no signs of follicular destruction or 
hypertrophy. Further sectioning did not identify any associated ectopic thymus attached to 
the infiltrate. While dissecting out thyroids it was apparent there was an increase in fat 
throughout the head and necks o f the transgenic mice indicating fat hypertrophy was not 
just confined to the orbit and interscapular pads.
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Figure legends
Figure 5.1 Macroscopy and histology of adiponectin transgenic mice
5.1.1. Phenotype o f female wild type and transgenic FVB mice aged 8 months. Large 
interscapular fat pad developing in transgenic animal.
5.1.2-3. Exenteration specimens from female 8 month FVB showing normal anatomy of 
globe, ocular muscles, harderian gland and intraconal fat.
5.1.4. Female 8 month transgenic animal with intraconal fat hypertrophy and splitting of 
ocular muscles.
5.1.5. Female 20 month transgenic, proptosis had resulted in corneal exposure and 
ulceration.
5.1.6. Female 20 month transgenic, following on from corneal ulceration, globe 
perforation concludes with phthisis.
5.1.7. A-B. Orbital fat pads from both wild type and transgenic animals comprised two 
main morphologies: A, large adipocytes with minimal cytoplasm and a solitary lipid 
vacuolated area and B, cells with greater cytoplasmic content and multiple lipid vacuoles. 
No inflammatory cell clusters were noted. [8 month transgenic, LR white, tol. Blue, x40].
5.1.7. C-E. Ocular muscles were normal in wild type (C, x40) and transgenic mice (D, 
x40), containing the normal appearance of multiple pale areas of mitochondria. 
Abnormalities were seen in the mitochondria of muscles split by fat proliferation (E, 
xlOO).
5.1.7. F. A phthisical eye with highly disorganised cornea, retina and a central fibrotic 
process (xlO).
5.1.8. A-C. Mitochondria from mechanically distorted ocular muscles (5.1.4) show 
swelling and degeneration of cristae (A,B). In some muscle fibres the dark and light bands 
degenerated and sarcomere length had increased. [Transmission EM, x500-1000].
5.1.8. D-F Connective tissue between muscle fibres (5.1.4) is similarly disorganised 
and no blood vessels could be identified (D). Degenerative nerves could be detected by the 
preservation of external myelin structure (E-F). [Transmission EM, x 1000-2000].
5.1.9 Normal thyroid follicular heterogeneity was present in transgenic (A) and wild type 
(B) mice. In a 20 month female transgenic mouse a mononuclear cell infiltrate was present 
but no signs o f follicular destruction were evident (C, D). [x 10-40].
Figure 5.2 Magnetic resonance imaging of murine orbits
5.2.1. A-B MRI machine (A) and surface coil (B), department o f medical physics 
UHW.
5.2.1. C-E T1 weighted images of BALB/c heads, section showing coronal (A), 
saggital (B) and axial (C) 1.5mm slices through globes.
5.2.1. F-H Increasing resolution by decreasing thickness to 0.75mm slice could define 
retro-orbital structures o f muscles and optic nerve. Scan duration improved signal to noise 
ratio and image quality; 16 minutes (F), 32 minutes (G) and 44 minutes (H).
5 .2 .1 .1-K For orientation, normal sequence progression demonstrated in BALB/c,
starting with the lowest on left (I) to highest on right (K). BALB/c mice orbits contained 
minimal retro-orbital fat irrespective o f age.
5.2.2. A-B Age matched, 8 months, orbital MRI o f wild type FVB (A) and transgenic 
(B) mice showing high signal (white) retro-orbital tissue on T1 in keeping with fat present 
in transgenic but not wild type FVB.
5.2.2. C-D 20 month wild type (C) mice accumulate considerable retro-orbital fat with 
age. 20 month transgenic (D) mice develop phthisis and the orbits are filled with fat.
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5.3.3 Orbital fat pads can be imaged using MRI and demonstrates differences 
between adiponectin transgenic, wild-type FVB and BALB/c
The experimental MRI facility did not have an established protocol for scanning small 
animals but did have some miniature surface coils that could be adapted for such usage 
(Figure 5.2.1. A-B). Initial imaging experience used BALB/c mice to determine a working 
protocol. Images could be acquired in axial, transverse and coronal planes and once 
positioned correctly, retro-orbital contents could be demonstrated most effectively using 
coronal slices (Figure 5.2.1. C-E). A slice thickness of 1.5mm was routinely used but by 
altering RF gain it was possible to increase resolution down to 0.75mm slices giving 
detailed images o f ocular muscles and optic nerves. Decreasing the slice thickness greatly 
diminished the signal:noise ratio and very long imaging times (45 minutes to get sufficient 
signal) were required as the magnetic field could not be increased above 1.2 Tesla (Figure
5.1.9. F-H). During this time the temperature within the bore of the MRI would rise 
considerably, this along with the inaccessible nature of the long bore made initial plans of 
performing imaging on live anaesthetized mice not feasible. Additionally, even small 
respiratory movements of anaesthetized mice over a prolonged period of scanning could 
induce a movement artifact that might render the image useless. Attempts to generate a fat 
suppression sequence like the STIR useful in Graves’ ophthalmopathy produced images 
with distorted anatomy despite scan times in excess of 55minutes. High field experimental 
MRIs with magnets up to 9-10 Tesla might reduce scan times but can induce tissue 
changes at high field strengths.
At the outset, the high resolution imaging (0.75mm slice) was planned to examine the 
Graves’ ophthalmopathy model using gadolinium tagged antibodies but in the absence of 
any orbital pathology we gathered images of normal BALB/c orbits that contain little or no 
retro-orbital fat irrespective of age (Figure 5.2.1.1-K). The large orbital fat pads in the 
transgenic FVB mice could be imaged with 1.5mm slices and an image time of around 25 
minutes. However, allowing for between 2 and 4 positioning scans with adjustment it 
could take 90 minutes to achieve satisfactory scans. Images from an 8 month old 
transgenic mouse showed the high signal (white=fat) tissue accumulating in the retro- 
orbital space contrasting with minimal fat in the wild type (Figure 5.2.2. A-B). With 
advancing age (20 months) the transgenic mouse had bilateral phthisis and became 
enveloped by the proliferating fat pad. Its 20 month wild type counterpart had a normal
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globe but did accumulate orbital fat similar in volume to the 8 month transgenic mouse 
and much greater than that seen in BALB/c.
After imaging, orbital fat pads were excised and explant cultures attempted as in section
3.2.1. Only one o f the transgenic samples developed any adherent cells. These cells 
initially had a fibroblastic appearance but rapidly developed multiple lipid droplets, similar 
to cells in a differentiation protocol and in less than three weeks the cells gradually all lost 
contact and no further cells attached to the surface.
5.3.4 Wide individual ranges of circulating adiponectin exist in Graves’
ophthalmopathy patients and are inversely correlated with body mass index 
but not other clinical indices
In the small pilot experiment adiponectin levels in the Graves’ group averaged 65.9pg/ml 
(sem=5.9, n=14), Hashimoto’s 39.4 pg/ml (sem=3.93, n=5) and controls 35.4pg/ml 
(sem=3.53, n=5). Differences between the groups were significant (Kruskall Wallis 
p=0.0022) and post hoc testing showed significance only between Graves’ and normals 
(D unnpO .O l).
In the second larger group, Graves’ ophthalmopathy patients had mean adiponectin levels 
of 118.4pg/ml (sem 11.3, n=37) compared to 127.6pg/ml (sem= 6.7, n=13) in the TMNG 
group. The difference was not significant (unpaired t test p=0.464). For reference we had 
samples from another study used in the same assay comprising 10 females in early 
pregnancy that had mean adiponectin of 109.4pg/ml (sem=7.4), no significant difference 
was present between the three groups (ANOVA). The difference in values between the 
pilot study and the second cohort are large and possibly due to inter-assay variation as a 
result o f having to use densitometry as an end point of the western. Out of age, CAS, 
proptosis, TSH, T4, T3, TSAB, BMI, the only factors to be correlated with adiponectin 
were BMI (Spearman rho=-0.51, p=0.005) and TSAB (rho=0.33, p=0.045). When 
adiponectin levels are adjusted for BMI no new correlations were revealed. Comparing 
mean adiponectin in smokers/non smokers and patients with and without the following 
treatments; carbimazole, radio-iodine, orbital radiotherapy, thyroidectomy, steroid 
treatment, did not show any significant differences. As expected there is a slight sexual 
dimorphism present, with female Graves’ ophthalmopathy patients having higher mean
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adiponectin 126.3pg/ml (n=27) compared to men 97.3pg/ml (n=10) (unpaired t, p=0.08). 
Repeating the correlations excluding males only alters the adiponectin/BMI correlation 
slightly (rho= -0.492, p=0.011) and revealed no new correlations. Considering the females 
that underwent orbital decompression, as a marker of severity of disfigurement and 
dysfunction, they had a higher mean adiponectin o f 144.4pg/ml (n=7, median=173) 
compared to those not requiring surgery 119.5pg/ml (n=20, median=122). The difference 
was not significant (Welch’s, p=0.21). The numbers of males undergoing decompression 
was too small for meaningful analysis. Three patients had adiponectin sampled twice; the 
first had adiponectin measured 10 months apart (134 and 133pg/ml), the second 3 months 
apart (28 and 47pg/ml) and the third four months apart (118 andl 14pg/ml), suggesting 
from this small sample that adiponectin levels do not fluctuate much.
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5.4 Discussion
Transgenic elevation of adiponectin in FVB mice induced orbital adipocyte fat pads to 
enlarge. The cells contained within were larger, with single lipid vacuoles more like white 
adipose tissue, but contained increased mitochondria, in comparison to the more mixed 
appearance o f the smaller wild type fat pads. These in vivo changes are in agreement with
'X 7Qin vitro work using lentivirus driven adiponectin over-expression in 3T3-L1 cells 
Adiponectin over-expression lead to more rapid cellular lipid accumulation with larger 
lipid droplets, increased mRNA expression of C/EBPa and PPARy and decreased levels of 
adiponectin receptor mRNA. Adiponectin over-expression accelerated growth by 
increasing cell numbers entering G l/S  transition.
Attempting to culture preadipocytes from orbital fat pads of adiponectin transgenic mice 
was largely unsuccessful, this is disappointing given brown fat explants are thought to 
maintain a more normal phenotype o f the cells mitochondria 38°. The single plate that did 
attach may have similarities to the 3T3-L1 with adiponectin over-expression. Ex vivo 
adiponectin transgenic cells rapidly transformed from fibroblast like cells to lipid 
containing cells and then detached from the plates. Mature adipocytes are known to be 
poorly adherent. A feature o f some human fat explants is the accumulation of lipid in the 
cells that have attached to the culture plates adjacent to and maintained by the explants as 
described in section 3.3.1. The adiponectin explants may represent an extreme form of that 
seen in human explants. Given the behaviour of the transgenic explant preadipocytes and 
the adiponectin over-expressing 3T3-L1 it is tempting to speculate that endogenously 
produced adiponectin may be an autocrine factor in the lipid accumulation in human 
explants.
Our initial pilot data on circulating adiponectin suggested Graves’ patients had 
significantly higher levels than normal subjects. This may simply relate to the lower BMI 
induced by thyrotoxicosis but adiponectin levels generally fluctuate only slightly381 and 
levels may be set by adiponectin polymorphisms or mutations as seen in some patients 
with the metabolic syndrome . One study is in agreement with our findings of thyrotoxic 
patients adiponectin levels being elevated, but curiously the negative correlation with BMI 
was lost in thyrotoxics but remained negatively correlated in control patients 383. 
Additionally T3, T4 and TRAb correlated with adiponectin. Given the small sample size of 
both our Hashimoto’s and normals our result would need to be validated with a larger
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sample and otherwise should be considered as open to bias. However it interested us 
sufficiently to study adiponectin levels in Graves’ ophthalmopathy patients in which we 
found no difference between patients with a non-autoimmune cause of thyrotoxicosis, 
TMNG. Both groups had large ranges; Graves’ ophthalmopathy (28-180pg/ml) and 
TMNG (51-192pg/ml). Adiponectin does not correlate with factors routinely measured in 
assessing Graves’ ophthalmopathy but this may be due to our inability to estimate the 
parameter it may influence, orbital fat volumes. Given proptosis correlates more closely to 
orbital fat volumes than muscle changes 384 more attention could be made of this when 
orbital imaging is performed. Our cohort’s showed a low level correlation between TSAB 
and adiponectin in keeping with the above study . It is interesting that female patients 
undergoing orbital decompression had slightly higher mean adiponectin levels than those 
not requiring surgery, median values were very different but sample sizes were not equal. 
We found adiponectin levels did not greatly alter in patients over time periods as long as a 
year, this is in agreement with other work demonstrating this once changes in BMI had 
been taken into consideration38 ]. Improved understanding of receptors and the various 
circulating forms of adiponectin along with more accurate adiponectin ELISA/RIA’s, 
combined with orbital volumetric imaging may help to determine if adiponectin levels 
skew the degree o f muscle or fat hypertrophy in Graves’ ophthalmopathy.
In a small study examining several adipocytokines, thyrotoxic patients with lower body 
mass index had lower adiponectin levels than the higher body mass index hypothyroid 
patients 385. This is opposite to the negative correlation of BMI and adiponectin seen in 
weight loss 369 and in our cohort o f Graves’ ophthalmopathy patients. There also existed a 
sexual dimorphism with females having higher adiponectin than males seen in our cohort
“I O C
and by other investigators . The seemingly paradoxical situation of hypothyroid patients 
(higher body mass/higher TSH/lower T4/higher adiponectin/female biased sexual 
dimorphism) is reminiscent of some of the changes in the adiponectin transgenic mice. 
How much o f the changes in the transgenic mice that are solely due to adiponectin 
elevation is unknown. As mentioned in the introduction, transgenic mice had elevation of 
prolactin, a hormone primarily known for its role in the proliferation of glandular and 
adipose breast tissue in lactation. Prolactin receptor knockout mice, particulary females, 
have lower fat mass than their wild type counterparts 386. In FVB wild type mice prolactin 
decreases adiponectin levels and may represent a counter regulatory mechanism to lower 
adiponectin in the transgenic mice. Alternatively, murine breast adipocytes secrete extra- 
pituitary prolactin38?, in the adiponectin transgenics, breast tissue might be the source of
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the increased circulating prolactin and it would be worthwhile determining if either 
interscapular or orbital fat expressed the prolactin receptor.
Another factor that may be contributing to the changes seen in the FVB transgenics is their 
thyroid status. The two different mouse strains, FVB 375 and C57BL/6 373, in which 
adiponectin has been elevated by transgenic modification have resulted in different 
phenotypes in terms o f fat proliferation but similar capacity to improve insulin resistance. 
Is this difference due to the former having the natural adiponectin molecule and the latter 
the globular domain? As shown by the orbital MRI wild type FVB mice spontaneously 
accumulate orbital fat with age unlike BALB\c. The FVB phenotype would thus seem to 
be accentuated by the adiponectin transgene. Average T4 concentrations were lower in 
FVB (2.36pg/dl) than in C57BL/6 (4.6pg/dl) and while average TSH levels were similar, a 
very wide range was present in the FVB strain 388. Out o f all mice tested 388; CD-I, 
C57BL/6, SWR/J, NOD SCID, the FVB had the lowest T4 and highest TSH and could be 
considered as a hypothyroid strain relative to most other mice. As mentioned in the 
introduction, CD-I mice given a short course of TZDs accumulate interscapular brown fat
198 . It would be interesting to examine the effects on fat mass a prolonged course would 
have on both CD-I and FVB strains in terms of their contrasting thyroid status. Similarly 
the C57BL/6 adiponectin transgenics were only examined between 2 and 5 months and 
might also develop fat mass alteration in later life. Profound changes in body mass 
associated with congenital hypothyroidism are now largely confined to ancient literature 
since routine infant hypothyroid screening was introduced. “Fat masses in the necks of 
cretins” were identified as similar in phenotype to the hibernating glands of hedgehogs in
“l O Q
1909 by Shattock . The infant fat pads were seen to occupy the posterior triangle o f the 
neck, dip beneath the clavicles and could be traced extending over the infraspinal muscles 
and to the lowest angle o f the scapula. Treatment with thyroid extract lead to 
disappearance o f the fat pads. These observations were describing brown fat and the 
supraclavicular pad can also swell slightly in adults with hypothyroidism, these facts lead 
Doniach to hypothesize that TSH stimulated brown fat in 197 5 390. Initially detected in 
guinea pig brown fat, the role of TSHR was unclear391. Hypothyroidism was shown to 
selectively elevate adenyl cyclase type III indirectly via adrenergic stimulation 392. When 
later studied in rat brown adipocytes TSH was found to stimulate cAMP in a dose 
dependent fashion and TSHR mRNA was inhibited by TSH stimulation, similar to the 
situation seen in thyrocyte cell lines 393. TSH stimulation lead to increased type II 
iodothyronine deiodinase and uncoupling protein (UCP)-l mRNA. T3 is required for
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optimal expression o f UCP-1 and this is achieved by conversion of T4 by locally 
transcribed type II iodothyronine deiodinase. UCP-1 is responsible for thermogenesis and 
is located on the inner mitochondrial membrane. However the levels of TSH required to 
achieve this were 10 times that required to stimulate thyroid cells. We performed a 
pioglitazone induced differentiation experiment on 9 patients orbital preadipocytes, 
extracted RNA and attempted to measure UCP-1 levels after 7 and 14 days but only 
detected house-keeper and no UCP-1 (data not shown). The experiment was hampered by 
the lack o f a positive UCP-1 control. Dr Ludgate has subsequently demonstrated UCP-1 394
•  • • ^  TQSpresent in differentiated orbital preadipocytes in keeping with others findings . White 
adipose tissue is known to contain small amounts of brown adipose specific UCP-1 
Whether the fat proliferation in Graves’ ophthalmopathy contains alterations in brown and 
white cell number is not known but understanding the biology might offer more selective
TQ7therapy as our current treatment, steroids, can cause orbital fat proliferation 
Differences in fat accumulation are illustrated by our MRI findings both between strains 
and between transgenically modified animals. Newer scanners offer increased resolution, 
shorter scan times and software to measure volume, all features that would allow in vivo 
detection of changes in fat.
In summary, the fat mass increase o f the adiponectin transgenic mouse is in keeping with 
in vitro changes seen in 3T3-L1 cells, but additional factors including TSH and prolactin 
may also have effects that are specific to the FVB strain. In particular, wild type FVB 
appear to spontaneously accumulate orbital fat with advancing age in excess of age 
matched o f BALB/c. Generalised orbital, interscapular and neck fat proliferation does not 
in turn lead to a widespread break in tolerance to TSHR. Although some low level TSAB 
activity was detected, this was only present in older animals and did not alter thyroxine 
levels. Advances in understanding adiponectin biology are ongoing, it probably has effects 
on fat directly and indirectly by altering muscle and liver function where its’ receptors are 
highly expressed. Adiponectin is demonstrated to be a robust pro-adipogenic adipokine 
with transgenic over-expression, this would seem at odds with higher levels of adiponectin 
seen in people with lower BMI’s. However, in the physiological setting of lower BMI, 
adipose tissue probably aims to restore fat mass by increased adiponectin secretion and 
conversely decrease fat mass with low level secretion in obesity. Patients seem to have 
relatively constant levels of adiponectin and whether this alters fat proliferation in Graves’ 
ophthalmopathy remains unanswered but given the multifactoral nature of the disease is 
worthy o f further investigation.
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6 General discussion
This thesis reports a series of in vivo and in vitro models used to examine tissue 
remodeling in Graves’ ophthalmopathy. The first model demonstrates a recurring problem 
of reproducibility and re-evaluates findings present in terms of thyroiditis and 
ophthalmopathy. The presence o f a focal thyroiditis needs to be distinguished from the 
frequent developmental anomaly o f ectopic thymic tissue, but is interesting in itself, given 
that thymic enlargement is seen in Graves’ disease. The normal contraction artefacts in 
muscle histology require considerable experience to distinguish them from pathological 
changes and would be best avoided entirely by the outlined dissection and fixation 
techniques. From this work, there has been a re-evaluation of previously proposed models 
of Graves’ ophthalmopathy in BALB/c and NMRI mice. It remains that we are without a 
reproducible model for Graves’ ophthalmopathy.
In chapter three a moderate reduction in cell proliferation, following a moderate rise in 
basal cAMP, results in enhanced adipogenesis. Higher levels of cAMP prevented any lipid 
accumulation, but morphological changes o f rounding were not affected. Work by other 
groups suggests this is due to reduced expression of lipogenic enzymes, rather than 
inducing lipolysis . Our model fails to follow the temporal pattern o f TSHR expression 
in adipogenesis because it is driven by a viral promoter and cAMP signalling is 
continuous. Normally, lipid is already accumulating by the time TSHR expression is 
peaking in 3T3-L1 cells (7 days) and TSHR mRNA was not present before day 5 264. We 
need to characterise the pattern o f TSHR expression in human primaries fully (and in any 
other cell line used) and then reproduce this using inducible vectors controlling the 
activating TSHR mutants. TSAB or TSH would seem to have a relatively brief period to 
affect adipogenesis given TSHR expression in mature adipocytes is low. TSHR on 
preadipocytes are possibly non-functional in a normal physiological range, they require 
high TSH concentrations (10-100mU) for cAMP signalling. However, TSAB might have 
higher binding affinities, above the level of TSH, for TSHR on differentiating 
preadipocytes. If TSHR activation has a direct effect on adipocyte differentiation we 
would expect it to be in the middle or late stages and this is what this work has guided us 
to. TSHR activation might act in tandem with other recently identified factors such as 
antibodies that stimulate IGF-1 receptor 42. We find no clear evidence to support a role for 
TSHR stimulation in adipogenesis from our study.
183
We have further characterised a TSHR stimulating factor present in tears and concluded its 
behaviour does not follow that o f TSAB. While examining the tears of smokers and 
Graves’ ophthalmopathy patients we were able to identify a prominent protein that had 
initially appeared to present in lower concentrations in non-smokers. This was not evident 
in later samples but a profile of ZAG expression was present that seemed to be different in 
smokers compared with Graves’ ophthalmopathy patients and non-smokers. This agrees 
with a recent publication demonstrating increased proteins in smokers tears, with the
TQO
region between 25 and 40kD being most discriminatory . The full complexity of the 
protein profiles would require considerable further work using 2DGE or other techniques 
that allow peptides to be identified and quantified. The role of ZAG in the tear film is not 
known and its’ role in lipid mobilisation in cachexia is all that is currently understood. 
Future studies might also investigate the time course e.g. tear composition whilst smoking 
at varying intervals and passive smoking. From our studies we cannot identify a specific 
protein to cause TSHR stimulation in tears and cannot rule out a non-specific ionic effect 
caused by an increased protein concentration in tears.
The final experimental chapter hints at a possible synergistic effect of an abundant 
adipocytokine, adiponectin and TSH in the proliferation of fat. Adiponectin transgenic
o'yc T7Q
elevation resulted in profound fat accumulation in vivo and similar in vitro changes 
have been demonstrated by others. What this probably tells us is adiponectin gene 
expression is lipogenic but might also suggest that the secreted protein may also be 
lipogenic or adipogenic. The FVB mice stand apart from other strains of mice in terms of 
their relatively hypothyroid status and accumulation of orbital fat, even in wild type mice. 
Transgenic adiponectin elevation in another more euthyroid strain did not induce fat
' l H ' i  TRQ
proliferation at the ages studied . Fat proliferation seen in congenital hypothyroidism 
has some similarities with that of the transgenic FVB mice, again hinting at a 
proadipogenic effect of elevated TSH. However these effects seem very different to those 
of activating TSHR mutants that appear to reduce fat mass, but the kinetics of cAMP 
signalling is presumably very different in ligand/receptor interactions compared to a 
constitutively active receptor as seen in our in vitro model. While we found wide ranges of 
circulating adiponectin in Graves’ ophthalmopathy, levels within the orbit may be more 
important and others have shown increases in adiponectin mRNA in Graves’ 
ophthalmopathy adipose tissue 399,40°. If adiponectin has an autocrine proadipogenic effect, 
heightened by orbital congestion, it could be a key step in the perpetuation of a chronic 
disease process triggered by TSHR activation by either TSAB or TSH.
Future work on modelled ophthalmopathy may require heightened antigenicity; techniques 
utilizing adjuvants and apoptosis have been discussed in chapter 2. More recently, 
activation o f Toll-like receptors, either with direct agonists or heat killed gram positive and 
negative bacteria, have been shown to be effective in increasing virally induced type-1 
diabetes 401. However, no similar virally or bacterial induced in vivo model is available for 
Graves’ disease but this would be another method to increase immune responses and add 
support to the importance o f infection and the innate immune system. In this context, a 
recent abstract reported higher and more persistent induced TSAB in mice housed in a 
conventional animal unit compared with a pathogen free facility 402. As reviewed in 
chapter 2, there are several reproducible models of Graves’ disease whereby TSAB are 
induced in which it would also be interesting to increase immune responses 173, l75. Low 
level and sporadic lymphocytic infiltration is already present in these models. The roles of 
these infiltrates is unknown, are they simply non-specific responses of thyrocytes and local 
dendritic cells (both expressing TSHR) that are relentlessly stimulated by TSAB, a type of 
wound response, rather than a TCR/TSHR specific interaction? Our interpretation and 
further investigation o f animal models are important tools in understanding Graves’ 
disease and ophthalmopathy.
If TSHR is not proadipogenic then we possibly need to explore how preadipocytes could 
act as APCs, does differentiation induce co-stimulatory signals such as CD-40 or HLA IIc'y
? Understanding the basic models is necessary before we can add into the equation the 
full range of orbital cells and cytokines present in Graves’ ophthalmopathy. This in vitro 
model needs to replicate the pattern o f TSHR expression and this might more faithfully 
test over-stimulation that mimics the action of TSAB. From our findings of reduced lipid 
accumulation in cells transduced with activating mutations that cause greatest inhibition of 
proliferation we investigated for possible similar effects on body composition of germline 
TSHR mutations. One patient has been examined in preliminary work, a euthyroid 8-year- 
old girl harbouring the activating TSHR V597L. She had weight and height below the 0.4th 
centile compared with 3 siblings and parents who were between the 9-25th centiles. 
Measurement o f body composition using dual energy X-ray absorptiometry demonstrated 
that she had reduced body fat (19.1% of total body weight) compared to her unaffected 11- 
year-old twin sisters (22.1 & 25.4%) and 13-year-old sister (23.3%). The reduced height 
and fat mass observed could possibly be attributed to prolonged thyrotoxicosis. Graves’ 
thyrotoxicosis can cause significant lowering of body cell mass while increasing
185
extracellular water content, changes that normalise after euthyroidism is established 403.
Fat mass is reduced in males with Graves’ disease but is not significantly altered in women 
404. Not only fat mass is affected but bone density is also reduced in thyrotoxic Graves’ 
patients and this improves with normalised thyroid function but might not reach levels of 
unaffected control patients 405,406. Improvement in bone density correlates with reduced 
TSAB levels but whether this is an epiphenomenon or a TSHR mediated effect on bone is 
unclear. As demonstrated by us and others previously 294, MG63 osteoblastic cells express 
TSHR but the importance of TSHR has only recently been demonstrated in bone 
metabolism 407. Halving TSHR expression impaired osteoblast and osteoclast formation 
resulting in osteoporosis and localised osteosclerosis.
Clinical outcomes in Graves’ ophthalmopathy have improved considerably in the fifty 
years intervening since Duke-Elder’s 1952 text book in which patients were still being 
enucleated due to lack o f understanding of the condition. Improvements have come mainly 
from re-establishing euthyroidism, immunosuppression and surgery. Further understanding 
the underlying pathogenesis requires ongoing co-operation and funding between clinicians 
and scientists.
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8 Appendicies
8.1 Appendix A 
Agarose gel electrophoresis
TAE buffer x l  Tris base 40mM  ph7.6
EDTA ImM
Glacial acetic acid 20mM
Culture Media
GPI D M E M x l 177ml
DM EM / 10%FCS FCS 20ml
PS x 100 2ml
Fungizone x 100 1ml
LULU* Hams F I2 177ml
Hams F12 complete FCS 20ml
PS x 100 2ml
Fungizone x  100 1ml
Hams F12 complete (charcoal stripped) as above but substitute FCS for charcoal stripped FCS.
Hams F12 (serum free) as above but omit FCS and use 197ml HamsF12.
Splenocytes RPMIxlO 10ml
RPMI 1640 Dist. water 85ml
N aH C 03 (7.5% ) 2.7m l
P S G x  100 2ml
Fungizone x  100 1ml
NaOH 10N 200|ul
100ml
RF10 RPMI 1640 (above) 89ml
FCS 10ml
p-mercaptoethanol (5mM ) 1ml
100ml
ECD/M BP protein production and purification
Column Buffer Sodium Phosphate 0.5M 10ml
Sodium chloride 14.6g
Dist. water 490ml
500ml
Luria Broth LB medium 1.8g
Dist. water 500ml
Autoclaved, cooled and stored at 4 C.
Luria rich broth LB 11
G lucose (20m m ol) 3.6g
205
Lysis buffer Tris 20mM , pH 7.4 2m ls 1M stock
EDTA ImM 200pl 0.5M  stock
Sodium chloride 200mM  20ml 1M stock
(3-mercaptoethanol 1ml 1M stock
Lysozym e 1 mg/ml 23m g
Sodium Phosphate 0.5M
solution A  11.7ml
solution B 38.3m l
50ml
where: solution A 6.9g NaH 2P0 4  in 100ml dH20
solution B 13.4g N a2HPC>4 in 100ml dH20
ELISA reagents and buffers
1. ECD/M BP
Wash
Coating buffer
Diluent
Conjugate
Substrate
NaCl 
Tris base 
Tween
Dist. Water 61
NaHCOs 
N aN 3 
Dist. water
NaH 2P 0 4 
NaCl 
N aN 3 
Tween  
Dist. water
NaCl 0.9%
Anti mouse IgG HRP 
Sheep serum
ABTS* 0.0 lg
Citrate phos buffer
H20 2
(* 2-2azino-bis(3-ehtylbenzthiazolin 6-sulfonic acid))
Citrate phosphate 
Buffer
2. IFN-y and II 4 
Wash buffer
Citric acid 
N a2H P 0 4 
Dist. water
PBS
Tween 20 0.05%
87.66g
24.23g
5ml
adjust to pH 7.4 and then 
make up to 101.
4.2g
0.2g
800ml
pH to 9.3 and make up to 11
1.56g
9g
0.2g
0.5ml
800ml
pH to 7.4 and make up to 11
3ml
1.5pl
60pl
25ml
lOpl
5.106g  
7.31 g
800ml pH to 5 and make up to 11
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Blocking buffer
Reagent diluent 
IFN-y
Reagent diluent 
114
PBS
Sucrose 5%
N aN 3 0.5%
PBS
BSA 1%
Tris buffered saline (Tris base 20mM  and N aCl 150m M ) 
PBS 0.1%
Tw een 20 0.05%
D eveloping buffer
T etram ethy lbenzid ine 
(TM B) stock
Citric acid 
Dist. W ater
TM B
D M SO
Ethanol
8.4g
160ml pH to 3.95 with 4M KOH 
and m ake up to 200ml
240m g
5ml
5ml store protected from light 
4 C
Substrate soulution D eveloping buffer 
TM B  stock 
H20 2 (30% )
1 5 m l 
1 5 0 jll1 
15 p i
Stop solution H2S 0 4 2N
ELISA sam ple standard curve IL4 and IFN gam m a
IL4 ELISA plate 2
1.2
0.8
E
J; q g II4 standard plate 1
•Linear (II4 standard plate 1)
o
0.4
0.2
y = 0.0011 x + 0.021
0 100 200 300 400 500 600 700 800 900 1000
114 pg/ml
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IFN gamma ELISA plate 2
1.2
1
0.8
E1
“ » 0.6 <§)TJo
0.4
400 600
IFN gamma pg/ml
■ IFN gamma standards 
■Linear (IFN gamma standards)
G eneral Buffers
Phosphate buffered 
saline (PBS)
Dist. W ater
N aC l
N a2H P 0 4
N aH 2P 0 4
KC1
20g
3.6g
0.6g
0.5g
2.51 pH to 7.2 w ith N aO H  1 ON 
and autoclave.
H istology Processing
Paraffin processing schedule (26 hour)
A lcohol 50% 1 hr
A lcohol 70%  2 hr
A lcohol 80% 2 hr
A lcohol 90%  2 hr
A lcohol 100% 1 hr
A lcohol 100% . 2 hr
A lcohol 100% 3 hr
C edar w ood oil 2 hr
C edar w ood oil 4 hr
W ax 2 hr All w ax processing at 60C
W ax 3 hr
W ax 2hr
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Partial dehydration in LR white for ultrastructure and immunoelectron microscopy
Embedding in LR white
Dist. water x  3 10 min
Uranyl acetate 2% 2 hr
Dist. water x  3 10 min
Alcohol 50% 10 min
Alcohol 70% x 3 10 min
2:1 LR white monomer: 30 min
Alcohol 70%
LR white monomer x 4 20 min
LR white monomer (at 0 C) 10ml
LR white catalyst 15pl
Stir 30 seconds, place 0.65m l in gelatine capsules in an aluminum heat sink on ice, insert 
specimens, seal capsules, store overnight at 0 C and finally cure in an oven at 50 C for 1 hour.
Maxiprep buffers 
Resuspension buffer
Lysis buffer
Tris-Cl 50mM ph8 
EDTA lOmM 
RNase A  100|ng/ml
NaOH 200mM  
SDS 1%
store 2-8 C
Neutralisation buffer Potassium acetate 3M pH5.5 store 2-8 C
QIAfilter wash
Equilibration buffer
Wash buffer
Elution buffer
TE
NaCl 750mM  
MOPS 50mM pH7 
Isopropanol 15%
NaCl 750mM  
MOPS 50mM pH7 
Isopropanol 15% 
Triton X -100 0.15%
NaCl 1M
MOPS 50mM pH7 
Isopropanol 15%
NaCl 1.25M  
MOPS 50mM pH8.5 
Isopropanol 15%
Tris-Cl lOmM pH8 
EDTA ImM
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SD SPA G E
R esolving Gel (12%) Acrylamide 30%  
Dist. water 
Tris-Cl 1M ph 8.8 
SDS 10%
APS 10%
4ml (1 :29, bis:acrylamide)
2.25m l
3.75m l
lOOpl
lOOjul
Degas under vacuum then add: 
TEMED 3 jll1
Load between gel plates 3ml below  level o f  stacking gel comb 
and seal with N-butanol. Set for 30-40m ins.
Stacking Gel (4%) Acrylamide 30% 1.3ml
Dist. water 6.1ml
Tris-HCl 0.5M  ph 6.8 2.5ml
SDS 10% lOOpl
APS 10% lOOpl
D egas under vacuum then add:
TEMED lOpl
Rem ove N-butanol from resolving gel, rinse, add stacking gel, in
Loading buffer SDS 20% 2ml
(Laemlli 1.8X) Glycerol 2ml
Tris-HCl 0.5M  ph 6.8 2ml
P mercaptoethanol 200pl
Pyronin Y 200ju.l
6.4ml
Running buffer 5X Tris base 9g
Glycine 43.2g
SDS 3g
C oom assie Blue stain Coomassie blue 250m g
Methanol 1ml
Glacial acetic acid 10ml
Propan-2-ol 25ml
Dist. water 64ml
100ml
C oom assie wash Methanol 20%
A cetic acid 10%
Dist. water 70%
Coom assie drying Methanol 50%
Glycerol 5%
Dist. water 45%
Make up to 600m ls with 
Dist.water.
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TBII and TSAB buffers
HANKS balanced 
solution salt free 
buffer (SFB) 4X
KC1
KH2HPO4
M g S 0 4
NaHCOs
N a2H P 0 4
CaCl2 stock CaCl2 
Dist. water
Working buffer
distilled water.
SFB 4X  
Glucose  
Sucrose 
BSA
H EPES1M  
CaCl2
0.4g
0.06g
O.lg
0.35g
0.48g Make up to 250m ls with 
distilled water.
1.85g
1 0 ml
25m ls
O.lg
9.6g
l-5g
2 ml
lOOpl Make up to 1 OOmls with
Thyrotropin Receptor Peptides
TSHR residue Amino Acid Sequence
Functional 34-53 EEDFRVTCKDIQRIPSLPPS
Receptor 48-67 PSLPPSTQTLKLIETHLRTI
90-109 QQLESHSFYNLSKVTHIEIR
104-123 THIEIRNTRNLTYIDPDALK
118-137 DPDALKELPLLKFLGIFNTG
132-151 GIFNTGLKMFPDLTKV Y STD
146-165 KVY STDIFFILEITDNPYMT
188-207 GFTSVQGYAFNGTKLDAVYL
216-235 IDKDAFGGVY SGPSLLD V SQ
230-249 LLD V SQTS VT ALPSKGLEHL
286-305 FKNQKKIRGILESLMCNESS
300-319 M CNESSM QSLRQRKSVNALN
306-325 M QSLRQRKSVNALNSPLHQE
356-375 FEEQEDEIIGFGQELKNPQE
Restriction endonuclease buffer
Buffer K Tris-Cl 200mM  pH8.5
M gCl2 lOOmM 
Dithiothreitol lOmM 
KC1 1M
Western blotting
13.7gm  
3.02gm  
800ml
2 0 0 ml
24.2g
80g
1000ml Adjust to pH 7.6, store at 4 C.
Blotting buffer G lycine
Tris base 
Dist. water
D issolve fully before adding methanol.
Methanol
T B S -T 10X  Tris base
Sodium chloride 
Dist. water
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For IX  solution dilute 1:10, then to 999m l add 1ml o f  Tween to give 0.1%.
Blocking buffer TBS-T 100ml
Marvel 5g
Blotting cassette Open cassette black side down in blotting buffer, then lay on in turn: fibre
pad, filter paper x3, gel, membrane, filter paper x3 and fibre pad. (Ensuring all bubbles removed 
between gel and membrane). C lose cassette and load into blotting tank “black to black”.
8.2 Appendix B
Culture Media
3T3-L1 DM EM  x l
DMEM/10%  CS C alf serum
Pen/strep xlOO 
Fungizone xlOO
Human Preadipocytes 
DM EM /H AM S/
10% FCS
HC C l
MEM/10% FCSFCS
DMEM x l 
HamsF12 x l 
FCS
Pen/strep xlOO 
Fungizone xlOO
MEM x l
Pen/strep xlOO 
Fungizone xlOO
177ml
20ml
2ml
lml
200ml
88.5ml
88.5ml
20ml
2ml
lm l
200ml
177ml
20ml
2ml
lm l
200ml
MG 63
DMEM/10% FCS
H BSS
see app.A
HBSS xlO  
N aH C 03 (7.5% ) 
Dist. water
10ml
470pl
89.5ml
FCS Heat inactivated30 minutes at 56 C
HEPES x  2 NaCl
N a2H P 04
HEPES
1.64g
0.054g
4.99m l (1M stock)
1 OOmls made up with dist. water 
pH to 7.1 and filter through 0.2pm
Red blood cell 
lysis solution
M ix then autoclave.
Ammonium chloride (0 .154M ) 
Potassium hydrocarbonate (lOmM) 
EDTA (0.1 mM)
Dist. water
0.822g
O. lg
20pl (0.5M  stock) 
100ml
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Immunocytochemistry
PGT
PBS 500ml
Gelatine (dissolved @  50C) lOOmg 
Tween 20 250pl
Periodic acid 0.025%  PGT 10ml
Periodic acid 50% 50pl
Ligation reaction
BstEII (N ew  England Biolabs) has endonuclease activity in the follow ing region:
5 . . . G AG T N A C C . . . 3 '
3 . . . C C A N T G AG. . . 5 '
BstEII 
Buffer NE3
Plasmid D N A  (2-3 jug) 
Dist. water
0.5 jli1  
2 |li1 
5 pi 
12.5|ul 
2 0 jli1 2 hours at 60C.
PCR reaction
cD N A  (from RT step) 
Taq polymerase 
M g xlO buffer 
dNTP lOmM 
forward primer 
reverse primer 
Dist.water
2.5jul 
0.5pl 
5 pi 
2 pi 
lpl 
lpl
39.5pl
PCR program (Thermal cycler Genius Techne) 
Initially denature 1 minute @95 C
follow ed by 35 cycles o f : 1 minute @ 95 C
1 minute @55 C
2 minutes @ 72 C
final elongation 10 minutes @ 72 C (then hold at 4C)
Retroviral handling considerations
If possible learn safe handling techniques from som eone experienced in Level 2 conditions. In 
brief the guidelines are as follow s.
1. Work in a biosafety level 2 tissue culture facility, clearly labeled with biohazard warning 
signs and use a system o f  un-recirculated exhaust air.
2. U se a regularly serviced and maintained biological safety cabinet (Class II laminar flow  
hood with HEP A filter).
3. Perform work behind closed doors and restrict access when working with virus particles.
4. U se gloves, a lab coat and do not use sharps. Use quills and syringes and avoid forming 
aerosols, i f  unavoidable use eye and face protection.
213
5. A ll virus contaminated waste, medium/plasticware should be soaked in concentrated 
bleach overnight before autoclaving and disposal.
6. A ll spills to be washed exhaustively with bleach.
Further information can be found at: http://bmbl.od.nih.gov 
RNA reverse transcription
RT master m ix RT buffer x5 4pl
DEPC water 0.5pl
R N A se inhibitor (25u) 0.5pl
O ligo(dt) 2 jli1
dNTPs 2 pi
M M LV RT (200u) l p l
lOpl
A ll reagents from Promega.
Sequencing reaction
B ig dye 2pl
Primer (lO pM /pl) lp l
PCR product 3 pi
Dist. water 4ul
lOpl
Vortex then pulse centrifuge.
Sequencing program (Thermal cycler Genius Techne)
Initially denature 3 minute @ 96 C
follow ed by 30 cycles o f : 0.5 minute @ 96 C
4 minutes @ 60 C
0 minutes @ 70 C (then hold at 4C)
Transformation o f  competent cells and small scale plasmid preparation
SOC Luria broth (appA) 96ml
M gCl2 (lOmM ) lm l (1M  stock)
M g S 0 4 (1 OmM) 1 ml (1M stock)
G lucose (20m M ) 2ml (1M  stock)
LB agar LB agar 7.4g
Dist. water 200ml
Autoclave, allow  to cool, melt gently in a microwave, add 
ampicillin lOOpg/ml, plate and store at 4C until use.
SET Sucrose 20% 5g
Tris HC1 50mM 1.25ml (1M  stock pH 7.5)
EDTA 5OmM 5ml (25OmM stock)
25m l made up with sterile 
dist. water.
D N A se free 
R NAse A
R NAse A  lOmg/ml in lOmM Tris HC1 (pH 7.5) and 
15mM NaCl. D issolved at 100 C for 15 mins, cooled to RT, 
aliquoted and stored at -20 C.
Sodium acetate 
3M  pH4.8
CH3COONa
H20
24.61g
45ml
Lysis solution NaOH 0.2N  
SDS 1% 
Dist. water
1 ml (2N stock)
1 ml (10% stock) 
8ml
Sample information sheet 
Adipogenesis in Thyroid Eve Disease
Thyroid eye disease (TED) develops in some patients with an overactive thyroid gland, 
some with an under-active thyroid gland and a few with a normally functioning gland. It is 
important that the disease is recognised and treated early in order to reduce the risk of 
double vision or visual loss. Even more vital is the search for effective treatment. We 
currently believe that this may be due to an abnormality in the fat tissue of the eye sockets 
in these patients. To investigate this we would like to test fat samples from patients with 
and without TED.
You are currently about to undergo surgery and tissue that is normally discarded can be 
useful in furthering research. We would like to ask for your consent to retain a small piece 
of fat tissue so that we can use it in our studies to help investigate TED and its potential 
cause. There will be no other incision made, only the one your surgeon has to make for 
your particular operation and there will be no other scarring or post-operative effects from 
removing this tissue.
You are not obliged to take part in this study. Participating or declining to participate will 
have no effect on the treatment you receive.
Thank you for taking time to read this and please ask your surgeon if you have any further 
questions about participating in this study.
Sample consent
Adipogenesis in Thyroid Eve Disease
I consent to the removal of a small piece of fat tissue whilst undergoing my prearranged 
operation, to be sent to the laboratory for testing and storage in relation to thyroid eye 
disease. I have read and understood the attached information sheet.
Signed_________________________________________
Date
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Preadipocyte cultures
Sample M/F Age Diagnosis History Summary
l.G H
lidbx
F 49 TED Euthyroid initially then thyrotoxic, smoker, 
on prednisolone
2. CH 
decomp
M 49 TED Thyrotoxic now euthyroid, radio-iodine 
1988, ex smoker
3.D J
decomp
F 38 TED Thyrotoxic now hypothyroid, radio-iodine 
1994, smoker, previous immunosuppression 
therapy
4. PSN 
lid bx
M 64 TED Euthyroid, non smoker, high TSAB.
5.HM
decomp
M 69 TED Thyrotoxic relapse, smoker, on carbimazole, 
previous radio-iodine and orbital 
radiotherapy.
6. PSM 
decomp
F 59 TED Thyrotoxic now euthyroid, non smoker, 
previous orbital radiotherapy, on 
immunosuppression.
7. NF 
decomp
F 44 TED Thyrotoxic now euthyroid, smoker, previous 
thyroidectomy, on immunosuppression.
8. ED
decomp
right
F 22 TED Prolonged thyrotoxicosis, smoker.
9. DR 
decomp
M 50 TED Thyrotoxic now euthyroid, smoker, previous 
radio-iodine.
10. ED
decomp
left
F 22 TED Prolonged thyrotoxicosis, smoker.
11. GC 
decomp
F 73 TED Thyrotoxic now hypothyroid, previous 
orbital radiotherapy, on immunosuppression.
12. AJ 
bleph bx
F 62 Dermatochalasis No thyroid history and euthyroid.
13.X 
bleph bx
F 70 Dermatochalasis No thyroid history and euthyroid.
14. JU 
bleph bx
F 78 Ptosis Right No thyroid history and euthyroid.
15. RT 
bleph bx
M 43 Dermatochalasis No thyroid history and euthyroid.
16. JU 
bleph bx
F 78 Ptosis Left No thyroid history and euthyroid.
17. WH 
bleph bx
F 38 Ptosis No thyroid history and euthyroid.
18. IL 
bleph bx
F 65 Dermatochalasis No thyroid history and euthyroid.
19. PSB 
bleph bx
M 58 Dermatochalasis No thyroid history and euthyroid.
20. MS 
LCSbx
F 73 Ectropion No thyroid history and euthyroid.
21. TT 
bleph bx
F 44 Dermatochalasis No thyroid history and euthyroid.
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patient Age sex CAS propt sum cigs cbz 1131 dxt thy Steroid TSH T4 T3 spegTSAB sfmTSAB tsfinTSAB tpegtsab
1 39 0 0 38 0 0 0 0 1 0 6.31 15 4.9 7.7 1.02 1.74 0.96
2 62 1 3 43 1 0 0 0 0 0 0.02 22.1 8.3 2.6 1.17 1.74 1.03
3 63 0 3 31 0 0 0 1 0 0 0.02 31.4 13.8 6.2 1.61 1.2
4 62 0 1 49 1 0 1 0 0 0 2.28 17.4 5.2 1.03 1.36 1.1
5 59 0 1 46 1 0 0 0 1 1 1.27 16.5 1.1 0.72 1.81 1.11
6 32 0 0 39 0 0 0 0 0 0 1.6 13.6 1 0.86 1.38 0.8
7 66 0 1 38 1 1 0 0 0 0 0.02 12.3 4.5 7.7 0.93 1.33 1.37
8 49 0 3 44 0 0 0 0 1 0 0.02 24.6 4.4 6.7 1.02 1.76 1.21
9 18 0 2 50 1 0 0 0 1 0 0.39 29.7 4.6 2.7 0.64 1.5 0.74
10 57 0 3 43 1 0 1 0 1 0 0.02 27.5 5.1 13.9 11.4 1.69 2.61
11 73 0 5 42 0 0 0 1 0 1 0.02 30.8 9.9 5.07 1.8 1.42
12a 41 1 4 50 0 0 1 0 0 0 0.14 21.1 5.2 6.1 0.94 1.39 1.09
12b 41 1 2 53 0 0 1 0 0 0 0.06 24.2 5.6 1 0.97 1.26
13 22 0 3 56 1 1 0 0 0 0 0.02 46.9 16 7.2 1.97 1.66 0.83
14 56 0 3 50 0 1 0 0 0 0 0.02 23.9 6.9 9.7 5.39 1.91 0.89
15 51 0 0 46 0 0 0 0 1 0 0.02 21 7.6 2.7 0.66 1.02
. 16 66 0 2 44 0 0 0 .1 0 0 0.02 19.4 4.4 15.5 2.8 1.79
17 53 0 3 42 1 0 0 0 1 0 1.54 18.5 3.5 0.86 1.84
18 49 0 4 34 1 0 0 0 0 1 0.08 20.1 6.6 0.88 1.77 1.04
19 19 0 1 36 1 0 1 0 0 0 3.17 19 6.6 0.86 1.61 0.92
20 48 1 2 55 1 0 0 0 1 0 9.8 11.5 0.8 1.71 1.13
21 38 0 3 42 1 0 1 0 0 0 3.54 17 5.1 1.09 1.67 0.68
22 32 0 0 43 0 0 0 0 0 0 0.62 15.3 1.2 0.82 1.36 0.85
23a 69 1 9 48 1 1 1 1 0 1 0.61 9.5 13.6 1.43 1.61 0.93
23b 69 1 7 49 1 0 1 1 0 1 0.69 11.9 5.8 1.19 1.46
24 39 0 2 51 0 0 1 0 0 0 0.04 23.9 4.4 1.06 1.46 0.99
25 49 0 2 37 1 0 0 0 0 0 1.4 19.8 1.7 1.12 1.49 1.06
26 48 0 3 43 0 0 0 0 0 1 1.34 14.6 2.7 0.92 1.96 1.07
Clinical data Graves’ ophthalmopathy patients chapter 4 (0=yes, l=no)
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patient Age sex CAS propt sum cigs cbz 1131 dxt thy Steroid TSH T4 T3 spegTSAB sfmTSAB tsfmTSAB tpegtsab
27 43 0 3 34 0 0 1 0 0 0 0.26 20.7 4.2 1.9 0.72 1.26 0.72
28 54 0 3 47 1 0 0 0 1 0 6.76 17.4 13 16.5 1.48 1
29 57 0 7 49 0 0 1 0 0 1 0.91 16.8 7.8 3.93 2.23 1.35
30 63 0 2 41 0 0 0 0 0 1 1.13 15 1.2 0.62 1.22
31 59 0 1 46 0 0 1 0 0 0 1.44 20.2 3.7 0.7 0.84 1.74
32 45 0 9 44 0 0 0 0 0 0 0.02 42.7 5.9 1.08 1.69
33 45 0 1 38 0 0 0 0 0 0 0.81 12.1 9.1 0.99 1.4 1.17
34 59 0 6 59 0 0 0 1 0 1 0.26 28.3 7.5 0.88 1.59
35 60 0 3 49 1 0 0 0 0 0 0.02 28.1 8.8 3.7 0.97 1.35 1.46
36 48 1 0 45 0 1 0 1 0 0 1.02 15.6 2.4 0.93 1.73
37 64 0 0 37 0 0 1 0 0 0 0.02 22.2 5.2 0.9 1.1 2.26 1.62
38 27 1 4 37 1 0 0 0 0 0 0.67 13.6 2.5 1.65 0.83 0.78
Clinical data Graves’ ophthalmopathy patients chapter 4
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